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ABSTRACT 
PO-HUNG HSIEH:  Structural characterization of oligosaccharides and understanding heparan 
sulfate-protein interactions 
(Under the direction of Jian Liu) 
 
 Heparin is known as a widely used anticoagulant drug since the 1930s.   Heparin and 
heparan sulfate (HS) are highly sulfated polysaccharides that consist of a repeating disaccharide 
unit of glucosamine and glucuronic (GlcA) or iduronic acid (IdoA).  The polydispersity of the 
saccharide sequence as well as the polyheterogeneity of the sulfation pattern make the study of 
this type of carbohydrate a formidable task.  Instead of traditional extraction from animal mucus, 
we use the chemoenzymatic approach to synthesize homogeneous heparin oligosaccharides.  The 
synthetic low molecular weight heparin was proven anti-FXa activity with reversible 
anticoagulant activity.  In addition to secure the supply chain, the extra benefits aid future 
clinical usage of synthetic heparin drug.  On the other side, the availability of synthetic pure 
common and less abundant HS oligosaccharides can serve as heparin component standards to 
secure the drug safety. 
Take the advantage of chemoenzymatic synthesis, the sufficient amount of structurally 
tailored oligosaccharide reagents are accessible.  To investigate the interaction between HS and 
proteins, several oligosaccharide probes were successfully developed.  Firstly, a synthesized 
heptasaccharide was used to co-crystalize with 2-O-sulfotransferase (2-OST) and probe the 
molecular basis of specificity.  2-OST was found to recognize N-sulfo and exclude 6-O-sulfo 
group of substrates, supporting the biosynthetic hypothesis 2-O-sulfation occurs after N-sulfation 
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and prior to 6-O-sulfation.  Secondly, we designed and synthesized the active heparan sulfate 
oligosaccharide probe carrying a diazoacetyl group.  The resultant oligosaccharides demonstrate 
inhibitory activity and structural selectivity toward HS biosynthetic enzyme 2-OST and 3-OST, 
respectively.  Thirdly, 
13
C-labeled saccharide was introduced at the desired site of the 
oligosaccharide to enhance the intensity of NMR signals.  The labeled reagents facilitate directly 
analysis the binding between specific saccharide and protein.  Finally, nuclear magnetic 
resonance analyses were performed to obtain coupling constants and full chemical shift 
assignments of all synthetic oligosaccharides. Comparing to relatively rigid GlcA, IdoA shows 
structural plasticity and diverse conformational preference in response to different sulfation 
patterns, which may be critical for various protein specific binding.  The success of these 
projects assists the fundamental understand of HS-protein interaction as well as the design of 
next generation heparin-based therapeutics. 
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Chapter I 
  Introduction 
 
Proteoglycans 
 Carbohydrates, in addition to nucleic acids and proteins, dominate critical and diverse 
biological roles in living organism. Many physiological processes and protein functions 
including cell development, differentiation, inflammation, bacteria and virus infection, 
metastasis and cancer are mediated by proteoglycans, macromolecules composed of 
carbohydrates [2].  Proteoglycans are ranging from 32 to 500 kDa.  The proteoglycans consist of 
core protein and various glycosaminoglycan (GAG) side chains.  The types of core protein 
include syndecans, glypicans, agrin, perlecans, and serglycin (Figure 1) [3].  Syndecans and 
glypicans are membrane bound via transmembrane domain and glycosylphosphatidylinositol 
anchor, respectively [4, 5].  Agrin and perlecans are non-membrane bound and found in the 
extracellular matrix.  Serglycin is the only intracellular proteoglycan and carrying heparin as side 
chain [6].  The heparin proteoglycan is majorly found in connective tissue mast cell which 
belongs to secretory granule of hematopoietic cell type [7]. 
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Main glycosaminoglycan types are hyaluronan, chondroitin sulfate, dermatan sulfate, 
heparan sulfate (HS) and heparin (Figure 2) [8].  Unlike protein translated from template DNA, 
the GAGs are generated by non-template enzymatic process as well as the array of various 
saccharide building blocks [9].  However, each type of GAG is made by specific repeated 
disaccharide and inherited manner of glycosidic linkage with specific anomeric configuration 
[9].  The usage of designated saccharide and glycosidic linkage render the distinct roles.  Heparin 
and HS are the most widely investigated ones due to capable binding to antithrombin to 
contribute to clinic antithrombotic application [10].   
Figure 1.  Representation of heparan sulfate proteoglycans.  The syndecans and glypicans are 
membrane bound via transmembrane domain and glycosylphosphatidylinositol anchor, respectively.  
Agrin and perlecans are non-membrane bound and found in the extracellular matrix.  Serglycin is the 
only intracellular proteoglycan and carrying heparin as side chain.  The heparin proteoglycan is majorly 
found in connective tissue mast cell.   
 
3 
 
 
 
Chemical Structure of Heparin 
 Heparin, a widely used clinical anticoagulant since the 1930’s, was the first biopolymeric 
drug and is one of the few carbohydrate based drugs [11, 12]. Because of the heterogeneity of 
heparin, structural characterization remains challenging.  Heparin is a mixture of polysaccharides 
and has high polydispersity and polyheterogeneity [12] as well as flexible structural 
characteristics [11]. In addition, heparin is a negatively charged polysaccharide under 
physiological pH.  This charged character originates from carboxylate and sulfo groups on the 
Figure 2.  Structure of main type of glycosaminoglycans (GAGs).  GAGs are the components of 
proteoglycans in the extracellular matrix and cell surface.  Main GAG types are hyaluronan, 
chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin.  The structure of common 
disaccharide repeating units are shown here.  The possible sulfation or acetylation/sulfation are 
indicated as X or Y. 
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saccharides.  The average molecular weight of heparin is ~17 kDa [13] with a range of chain 
lengths from 5,000 to 50,000 Da [14].  Heparin has repeating disaccharide units consisting of 
uronic acid (90% L-iduronic acid, IdoA, and 10% D-glucuronic acid, GlcA) linked 1 → 4 to D-
glucosamine (GlcN) [15], where the glucosamine residues can be either N-acetylated (GlcNAc) 
or sulfated (GlcNS). The GlcN monosaccharide can also contain O-sulfo groups, including 6-O- 
and 3-O-sulfation, while the GlcA and IdoA residues can be 2-O-sulfated. 
Chemical Structure of Heparan Sulfate 
 Heparan sulfate (HS) is structurally analogous to heparin.  HS has a similar disaccharide 
repeating structure to heparin with some noticeable differences.  Generally, the size of the HS 
chains is longer with an average MW of 30 kDa [16], and HS has lesser IdoA (< 20%) content 
and lesser sulfation than heparin [12].  On average, HS contains around 0.6 sulfo group for each 
disaccharide, and heparin contains 2.6 sulfo groups per disaccharide [4].  In addition, HS has 
more diverse sulfated saccharide sequences and domain structures compared with heparin 
(Figure 3).  The domain structures can be roughly categorized into NAc domain, NAc/NS 
domain, and NS domain based on sulfation density.   
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Biosynthesis of Heparan Sulfate 
Biosynthesis Scheme 
 The biosynthesis of HS mainly happens in Golgi apparatus.  The participating enzymes 
cooperately work in the lumen.  The biosynthetic processes of heparan sulfate can be categorized 
into three major steps: initiation, polymerization, and modification.  Each step requires specific 
enzyme for reaction.   
Figure 3.  Chemical structure difference between heparin and heparan sulfate.  Heparin contains 
repeating disaccharide units consisting of 90% 2-O-sulfated iduronic acid linked 1 → 4 to glucosamine.  
The glucosamine residues are mainly N-sulfated and 6-O-sulfated.  Heparan sulfate contains lesser 
IdoA (< 20%) content and lesser sulfation than heparin.  HS has more diverse sulfated saccharide 
sequences and domain structures comparing to heparin, such as NAc domain, NS/NAc domain, and NS 
domain. 
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 Initiation starts from attachment of tetrasaccharide linkage to the core protein (Figure 4).  
The core protein with the sequence of Ser-Gly/Ala-X(any)-Gly is recognized by enzyme for 
tetrasaccharide linkage [17].  The tetrasaccharide is common in all kinds of glycosaminoglycan 
with the sequence of –GlcAβ1,3Galβ1,3Galβ1,4Xylβ1-O-[Serine] [18].  Each monosaccharide is 
transferred from respective UDP-sugar sequentially.  Firstly, xylose is transferred from UDP-
xylose to serine by xylosyltransferase [19].  Secondly, two galactose residues are subsequently 
added by β1,4-galactosyltransferase-I and β1,3-galactosyltransferase-II [20, 21].  Finally, the 
glucuronic acid is attached by β1,3-glucuronyltransferase-I [22].  Some modification, including 
4-O-, 6-O-sulfation on galactose as well as 2-O-phosphorylation on xylose, were reported relate 
to selectively regulation of different GAG biosynthesis [23].   
 
 
 
Polymerization of backbone chain happens after attachment of the first tetrasaccharide at 
initiation phase.  The monosaccharide GlcNAc and GlcA is alternatively transferred by 
Figure 4.  Glycosaminoglycan tetrasaccharide linkage to core protein.  The tetrasaccharide with the 
sequence of GlcAβ1,3Galβ1,3Galβ1,4Xylβ1-O-[Serine] is attached to the core protein. Each 
monosaccharide is transferred from respective UDP-sugar.  Xylose is transferred from UDP-xylose to 
serine by xylosyltransferase.  Two galactose residues are subsequently added by β1,4-
galactosyltransferase-I and β1,3-galactosyltransferase-II.  The final glucuronic acid is attached by β1,3-
glucuronyltransferase-I. 
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exostosin-like and exostosin family of glycosyltransferase including EXTL1, EXTL2, EXTL3, 
EXT1 and EXT2 (Figure 5) [24, 25].  The first saccharide attachment to the linkage region 
tetrasaccharide is the divergent point for biosynthesis of CS or HS.  Attachment of GalNAc by 
GalNAcT enzyme results in CS; attachment of GlcNAc leads synthesis of HS.  EXTL2 and 
EXTL3 transfer the first GlcNAc to the GlcA-end of tetrasaccharide linkage [24, 26].  These 
EXTL enzymes were reported capable of recognizing and interacting with specific sequence of 
core protein to selectively polymerize HS chain [17, 27].   After the polymerization of GlcA and 
GlcNAc are performed by EXT1 and EXT2 [25].  Both EXT1 and EXT2 may be able to form a 
complex and cooperate with other biosynthetic enzymes to regulate the HS biosynthetic 
machinery [28].     
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 HS backbone modification includes deacetylation, epimerization, and 4 types of 
sulfation.  Each reaction requires unique enzyme with different substrate specificity.  The feature 
of substrate recognition leads each enzyme able to perform modification on modified HS 
backbone sequentially.  The HS backbone modification is generally known in the order of 
deacetylation, N-sulfation, epimerization, 2-O-sulfation, 6-O-sulfation and 3-O-sulfation (Figure 
6).  The sulfotransferases utilize 3’-phosphoadenosine 5’-phosphosulfate (PAPS) as a sulfo 
Figure 5. Polymerization of the heparan sulfate backbone. Polymerization starts after attachment of 
the first tetrasaccharide at initiation phase.  EXTL2 and EXTL3 transfer the first GlcNAc to the GlcA-
end of tetrasaccharide linkage.  The adding of repeating units of GlcA and GlcNAc are performed by 
EXT1 and EXT2. 
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group donor to introduce sulfation to HS backbone.  However, incompletion at each modification 
step leads great structural heterogeneity of HS.   
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Glucosaminyl Deacetylation/N-sulfation 
Deacetylation and N-sulfation of GlcN residue is performed by glucosaminyl N-
deacetylase/N-sulfotransferase (NDST) (Figure 7).  NDST contains two domains for 
deacetylation and N-sulfation, respectively.  There are four isoforms of NDST with different 
substrate preference providing different modified HS backbones, which can be selectively 
recognized by the other cooperative enzymes [29, 30].  NDST-1 and NDST-2 were reportedly 
critical for HS and heparin biosynthesis.  NDST-1 is found in most of the cell.  On the contrary, 
NDST-2 is mainly found in connective tissue mast cell associated with heparin synthesis [31, 
32].  On the other hand, the biological significance of NDST-3 and NDST-4 are not well 
understood [33]. 
 
 
C5-epimerization 
 Epimerization of D-GlcA to L-IdoA provides HS with greater heterogeneity in addition to 
different size and sulfation level of backbone.  C5-epimerase was found only single isoform in 
Figure 6. Heparan sulfate backbone modifications.  After heparan sulfate backbone polymerization, 
the biosynthetic modifications are in the order of deacetylation, N-sulfation, epimerization, 2-O-
sulfation, 6-O-sulfation and 3-O-sulfation.  Each reaction requires unique enzyme with different 
substrate specificity.  The modification parts are highlighted in red color. 
Figure 7.  N-deacetylation and N-sulfation by NDSTs.  NDST contains two domains: N-deacetylase 
and N-sulfotransferase for glucosamine deacetylation and sulfation, respectively.  PAPS is the sulfo 
donor of the reaction.  The four isoforms carry different substrate preference. 
. 
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human genome with 70 kDa molecular weight [34].  The gene knockout mice were neo-natal 
lethal, proving the essential role of C5-epimerase [35].  The epimerization is happened at the C5-
position of GlcA via putative carbanion intermediate [36].  The original 
4
C1 conformation of 
GlcA is transformed to relatively stable 
1
C4 or 
2
So conformation of IdoA (Figure 8).  This 
conformational change further increases the structural diversity of HS for various proteins 
selectively binding.  Epimerization is reversible between GlcA and IdoA and preferably having a 
non-O-sulfated GlcNS at adjacent nonreducing-end [36, 37].  However, a recent report found 
GlcNAc at nonreducing-end 3 residues away from epimerization site can lock epimerization and 
relatively irreversible forward to IdoA [38].  The phenomenon suggests the substrate structure or 
sulfation state is critical for the subsequent biosynthetic enzymes to synthesize HS.     
 
 
 
2-O-sulfation 
 Uronosyl-2-O-sulfotransferase (2-OST) is used to transfer the sulfo group to uronic acid 
including GlcA and IdoA (Figure 9).  2-OST
-/-
 gene knockout mice led neonatal death supporting 
Figure 8.  C5-epimerization by C5-epimerase.  The epimerization is happened at the C5-position of 
GlcA via putative carbanion intermediate.  A proton is abstracted and added back at C5 position.  The 
original 
4
C1 conformation of GlcA is transformed to relatively stable 
1
C4 or 
2
So conformation of IdoA. 
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2-OST is essential in sustaining life [39].  Similar to C5-epimerase, there is only one isoform of 
2-OST in human genome with 43 kDa molecular weight [40].  C5-epimerase and 2-OST were 
also been proven highly cooperate with each other, including stability, localization, and function 
[41].  2-OST prefers to sulfate IdoA than GlcA [42].  The preference substrate is that an IdoA 
flanked by two non-6-O-sulfated GlcNS residues, suggesting that HS biosynthesis follow an 
order of reaction steps [43].  N-sulfated substrate makes the HS backbone subsequently 
recognized by epimerase, 2-OST, and finally 6-OST. 
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6-O-sulfation 
 6-O-sulfotransferase (6-OST) transfers the sulfo group to GlcNS residue at HS backbone 
(Figure 10).  There are three known isoforms of 6-OST, including 6-OST-1, 6-OST-2, and 6-
OST-3 with 50-57% homology and molecular weight 47kDa [44].  The expression of these 
isoforms may be regulated in tissue-specific manners [44].  These isoforms provide similar but 
subtly different substrate specificity resulting in structural heterogeneity of HS [44-47].  
However, these studies of substrate preference may be ambiguous because of using 
heterogeneous polysaccharide substrate.  The 6-O-sulfted HS were reported as prerequisite for 
different biological functions, such as signaling of FGF1 and FGF2 [44, 48].  The isoforms of 6-
OST maybe provide diverse modified structures for the specific downstream bioactivities.   
 
 
3-O-sulfation 
Figure 9.  2-O-sulfation by 2-OST.  Uronosyl-2-O-sulfotransferase (2-OST) is used to transfer the 
sulfo group to uronic acid including GlcA and IdoA.  PAPS is utilized as sulfo donor.  IdoA is the 
preferred substrate than GlcA. 
 
Figure 10.  6-O-sulfation by 6-OSTs.  6-O-sulfotransferase (6-OST) transfers the sulfo from donor 
PAPS to GlcNS residue at HS backbone.  The isoforms provide the different substrate specificity 
resulting in highly structural heterogeneity of HS.   
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 The final sulfation modification is performed by 3-O-sulfotransferase (3-OST) adding 
sulfo group to the 3-O-hydroxyl of unsubstituted or N-/6-O-sulfated glucosamine (Figure 11).  
So far there are 7 isoforms of 3-OST discovered, which are ubiquitously or specifically residing 
in certain tissues [49, 50].  Although only around 0.5% of total sulfate happened in HS, 3-O-
sulfation is considered the most critical modification for bioactivities.  3-OST-1 is reported 
correlate with HS binding to antithrombin to contribute anticoagulant activity; however, 3-OST-
3A/B is highly associated with binding of gD-envelope protein of HSV-I to initial the viral entry 
[51-53].  These isoforms of 3-OST also equip with different substrate specificities.  For example, 
3-OST-1 prefers binding to GlcNS/6S with non-2-O-sulfated GlcA/IdoA at nonreducing-end [50, 
54].  The bound IdoA2S, at reducing-end of modified GlcN, adopt the 
1
C4 conformation in 3-
OST-1 crystal structure complex.  On the contrary, 3-OST-3A/B prefers binding to GlcNS/6S 
with IdoA2S at nonreducing-end.  The bound IdoA2S, at reducing-end of modified GlcN, adopt 
2
So conformation is 3-OST-3 complex instead [55, 56].  Regarding to the rest of isoforms, 3-
OST-2 prefers binding to GlcNS [57].  The substrate specificity of 3-OST-4 and 3-OST-6 are not 
well understood yet [58-60].  The substrate recognition was reported associated with the 
saccharide at the nonreducing-end of the modified GlcN as well as likely related to the 
conformation flexibility coming from IdoA entity[61].  These various isoforms of 3-OST greatly 
enlarge the structural heterogeneity of HS and the corresponding biological functions.   
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Heparin Pharmaceutical Production 
 Heparin is a widely used anticoagulant.  Based on molecular weight difference, heparin 
related drugs can generally be categorized into three types: unfractionated heparin (UFH), low 
molecular weight heparin (LMWH), and synthetic pentasaccharide fondaparinux (Arixtra) (Table 
1) [62].  Fondaparinux is purely chemical synthesized with molecular weight of 1508 Da.  
However, UFH and LMWH are heterogeneous polysaccharide mixture extracted from animal 
source.  The averaged molecular weight of UFH and LMWH is around 14 kDa and 4.5~6.5 kDa, 
respectively.  Different types of heparin drug provide different pharmacokinetic profiles [63].  
Healthcare workers can choose the best suitable form of heparin based on clinical needs.   
 
Figure 11.  3-O-sulfation by 3-OSTs.  3-O-sulfotransferase (3-OST) adds sulfo group to the 3-O-
hydroxyl of unsubstituted or N-/6-O-sulfated glucosamine.  The isoforms of 3-OST equips with 
different substrate specificities.  The substrate recognition was reported associated with the saccharide 
at the nonreducing-end of the modified GlcN as well as likely related to the conformation flexibility 
coming from reducing-end IdoA entity. 
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Traditional Extraction and Depolymerization 
 Unfractionated heparin (UFH) is isolated from animal source including bovine lung and 
porcine intestine.  Generally, these animal tissues are firstly boiled before collecting the mucosa.  
The dried mucosa then requires very complicated processes of purification and formulation to 
obtain the final commercial product for human usage.  Low molecular weight heparin (LMWH) 
is derived from partially chemical or enzymatic digestion of UFH [64].  Based on different 
manufacturing approaches, there are three common commercialized LMWH products: 
enoxaparin (averaged MW: 4.5 kDa), dalteparin (averaged MW: 6 kDa), and tinzaparin (6.5 
kDa) [65].  Enoxaparin is manufactured from alkaline hydrolysis of UFH and followed by 
chemical benzylation.  Dalteparin is made by nitrous acid depolymerization of UF.  Tinzaparin is 
obtained by heparinase digestion.  However, FDA indicates that these LMWH drugs are not 
interchangeable due to different range of molecular weights and pharmacological profiles [66, 
67].  The complicate manufacturing processes from original animal source to final drug also 
make supply chain relatively vulnerable and insecure.   
Heparin Safety Crisis 
 In 2007-2008, batches of contaminated heparin were discovered in US, which drew 
significant public attention because the contaminated drug killed 94 patients in US [68].  
Hundreds of people got severe allergic effects [69].  Afterwards, nuclear magnetic resonance 
(NMR) techniques were employed, and rapidly identified the nature of the contaminant to be 
Table 1.  Heparin drugs and pharmacokinetic properties.  Heparin related drugs can generally be 
categorized into three types: unfractionated heparin (UFH), low molecular weight heparin (LMWH), 
and synthetic pentasaccharide fondaparinux (Arixtra).  Different types of heparin drug provide different 
pharmacokinetic profiles.  * Heparin-induced thrombocytopenia (HIT), deep vein thrombosis (DVT), 
pulmonary embolism (PE). 
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over sulfated chondroitin sulfate (OSCS) [70].  OSCS was reported intentionally added for cost 
reduction reason by manufacturer [71].  Due to OSCS structural similar to heparin, the quality 
control failed to screen this adulterant out and made the crisis happened [72].  The long process 
and vulnerable supply chain make the chance of contamination and adulteration.  Therefore, the 
government and regulatory agency are eagerly looking for the alternative production approach to 
secure the heparin supply.   
Chemical Synthesis of Heparin 
 Synthesis of heparin using a purely chemical approach was considered.  However, the 
method is proved to be difficult to synthesize the homogeneous compound with the size of 
LMWH ranging from 4.5-6.5 kDa.  Instead, scientists have found the pentasaccharide with the 
sequence of GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S is sufficient enough for AT binding 
to contribute anticoagulant activity (Figure 12) [10].  The total synthesis method to synthesize 
this sequence of oligosaccharide was developed in 1989 with US Patent 4,818,816, 1989.  The 
synthesis scheme takes overall around 50 steps with only 0.1% yield [73].  Fondaparinux 
(Arixtra) is the licensed drug.  However, this size of pentasaccharide is not long enough to be 
neutralized by antidote protamine [74].  Furthermore, fondaparinux cannot be used for renal-
impaired patient due to the compound requires kidney for clearance [75, 76].  Due to the lengthy 
chemical scheme and relative low yield, the chemical synthesis is unable to deliver large size 
oligosaccharides.  A high efficient approach capable to synthesize homogeneous larger 
oligosaccharide resembling LMWH is urgently needed.   
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Chemoenzymatic Synthesis 
 Recently, a new method using recombinant HS biosynthetic enzymes to prepare 
structurally homogeneous HS oligosaccharides was developed (Figure 13) [1].  This method 
allows the synthesis of a series of structurally homogeneous heparin or HS oligosaccharides at 
the scale up to gram level with high yield.  The size of synthetic oligosaccharide more than 
twenty residues is feasible.  Access to highly purified HS oligosaccharides allows for full-scale 
analyses of these complex molecules by NMR.  
Notably this synthetic approach enables the analysis of structurally “rare” 
oligosaccharides which are difficult to isolate in sufficient quantity for extended biological and 
structural analysis. For example, the -GlcA2S- residue represents only 1-5% of total uronic acid 
in heparin isolated from natural sources [77].  The –IdoA- entity without 2-O-sulfation is even 
less abundant within heparan sulfate.  To address the knowledge gap of these potentially 
biological important species, chemoenzymatic approach is capable to synthesize a library of 
standards efficiently.  This approach is also possible to secure the future heparin and heparan 
sulfate supply chain. 
Figure 12.  Anticoagulant pentasaccharide structure.  The pentasaccharide with the sequence of 
GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S can activate antithrombin to contribute anticoagulant 
activity. 
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Structural Analysis of Heparan Sulfate 
 Accurate structural characterization of heparan sulfate is remaining challenging for 
decades.  The polydispersity of the sequence as well as the polyheterogeneity of the sulfation 
pattern are formidable issues for structural analysis.  The access of sufficient structural defined 
samples for study is also a big problem.  However, it is extremely important to accurately 
characterize the heparan sulfate structure.  The study of structure-activity relationship requires 
comprehensive understanding the molecular properties.  Nowadays there are several of methods 
used for identifying heparan sulfate structures including disaccharide analysis, Mass 
spectrometry, and NMR spectroscopy.    
Enzymatic or Chemical Degradation for Disaccharide and Mass Analysis 
 Since heparan sulfate is heterogeneous and ranging from 100 to 400 units of saccharides, 
depolymerization followed by compositional analysis is an alternative approach to characterize 
Figure 13.  Chemoenzymatic synthesis of oligosaccharide.  The recombinant HS biosynthetic 
enzymes are used to prepare structurally homogeneous HS oligosaccharides with high yield.  
Rearrangement of the reaction steps can synthesize diverse desired structures.  The reactions can be 
simply repeated to synthesize larger size of oligosaccharides.  The structurally rare oligosaccharides, 
which are difficult to isolate in sufficient quantity, can also be acquired by chemoenzymatic approach. 
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the structure.  Two commonly used degradation methods are enzymatic and chemical 
degradation.  The degraded components are afterward analyzed by reverse phase ion pairing-
high performance liquid chromatography (RPIP-HPLC) [78, 79].  The chromatography condition 
is altered by ion pairing reagent, such as tributylamine or tetrabutylammonium phosphate.  This 
system can well resolve the epimers as well as the degraded disaccharides with different 
sulfation patterns.  The reference standards are co-eluted to identify the components of heparan 
sulfate.  There are overall 22 various disaccharides reported from heparan sulfate compositional 
analysis [5].  The mass spectrometry is utilized to confirm the molecular weight of degraded 
fragments.  Electrospray ionization mass spectrometry (ESI-MS) is useful to determine the 
sequence and length of fragments.  Tandem mass spectrometry (MS/MS) can further investigate 
the type and number of modifications based on fragmentation patterns.   
 Heparin lyase is used for enzymatic degradation.  There are three isoforms heparin lyase 
I~III found from Flavobacterium heparinum.  Different isoform brings different substrate 
specificity to depolymerize heparan sulfate [5, 80].  Heparin lyase I prefers the cleavage site with 
the sequence GlcNS-IdoA2S.  Heparin lyase II and III have relative promiscuous substrate 
preference.  Heparin lyase II cleaves the glycosidic linkage with GlcNAc/NS-GlcA/IdoA/2S, and 
heparin lyase III can degrade the linkage of GlcNAc/NS-GlcA.  The β-elimination reaction is 
performed by heparin lyase to cleave the glycosidic linkage (Figure 14).  The degraded 
fragments carrying the Δ4,5–unsaturated uronic acid with UV 232nm absorbance greatly makes 
the observation easy.  The identities and relative abundance of observed fragments are used to 
deduce the structure of parent molecule.  However, the degraded fragments lose the C5 
configuration due to forming of double bond.  This disadvantage makes enzymatic degradation 
approach unable to understand the property of GlcA/IdoA epimer in the parent molecule.  
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Additionally, the incompletion of enzymatic degradation results in misleading or 
underestimating of the amount of monitored disaccharide fragments.   
 
 
 Chemical degradation by nitrous acid is another approach to depolymerize the heparan 
sulfate (Figure 15) [81].  The glycosidic linkage between glucosamine and uronic acid can be 
degraded.  The glycosidic linkage of GlcNH2-GlcA/IdoA is the favored substrate at elevated pH 
4.5; on the other hand, at pH 1.5 the sequence of GlcNS-GlcA/IdoA is the preferred one.  The 
GlcNAc residue requires using hydrazine to remove acetyl group before nitrous acid treatment.  
The chemically degraded fragments are followed by reduction utilizing sodium borohydride.  
The final reduced disaccharide fragments, carrying modified residue 2,5-anhydromannitol, are 
Figure 14.  Enzymatic degradation of heparan sulfate by heparin lyase.  Heparin lyase isoforms 
show different substrate specificity to depolymerize heparan sulfate.  Heparin lyase I prefers the 
cleavage site with the sequence GlcNS-IdoA2S.  Heparin lyase II and III have relative promiscuous 
substrate preference.  The β-elimination reaction is performed at glycosidic linkage to produce the Δ4,5–
unsaturated uronic.  The C5 configuration of parent molecule is lost due to forming of double bond.   
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co-eluted with standards during RPIP-HLPC analysis.  The advantage of this approach is the 
configuration of uronic acid still remained for inferring the parent structure [5].  However, the 
radio-labelled sample needs to be provided before degradation since there is no UV absorbance 
for degraded fragments.  Combining use both enzymatic and chemical degradation approach give 
people good understanding of the identity and relative abundance of components of heparan 
sulfate.   
 
 
Figure 15.  Chemical degradation of heparan sulfate by nitrous acid.  The glycosidic linkage between 
glucosamine and uronic acid can be degraded by nitrous acid.  The glycosidic linkage of GlcNH2-GlcA/IdoA is 
the favored substrate at elevated pH 4.5; on the other hand, at pH 1.5 the sequence of GlcNS-GlcA/IdoA is the 
preferred one.  The GlcNAc residue requires using hydrazine (H2NNH2) to remove acetyl group before nitrous 
acid treatment. The chemically degraded fragments are followed by reduction utilizing sodium borohydride to 
obtain 2,5-anhydromannitol.  the configuration of uronic acid still remained by this chemical degradation 
approach. 
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Nuclear Magnetic Resonance (NMR) Measurement 
Reliable structural characterization techniques are critically important to safeguard the 
quality of heparin drugs.  In 2008, batches of contaminated heparin were discovered in US, 
which drew significant public attention because the contaminated drug killed 94 patients in US 
[68].  Nuclear Magnetic Resonance (NMR) techniques were employed, and rapidly identified the 
nature of the contaminant to be over sulfated chondroitin sulfate (OSCS), demonstrating the 
important role of NMR measurements in heparin quality control (Figure 16) [11].  
NMR data provides structural information that cannot be obtained by other methods, 
specifically; epimer recognition, anomeric configuration identification, sulfated position 
determination, and conformation and secondary structure determination.  One limitation in 
utilizing NMR to analyze the structure of heparin or HS is that these species are a mixture of 
compounds and pure oligosaccharide standards have not been available.  Although certain 
oligosaccharides have been isolated from partially depolymerized heparin or HS, obtaining 
sufficient amounts of those highly purified oligosaccharides is a difficult and time consuming 
process.  
The chemoenzymatic approach makes the synthesis of sufficient amount of 
oligosaccharide constructs possible.  Structural characterization by NMR experiments becomes 
much easier by virtue of better signal intensity.  
1
H NMR was used to test the purity of constructs 
as well as to measure the 
3
JH-H coupling constants.  To fully assign the chemical shifts of all the 
proton and carbon signals, multidimensional homonuclear (COSY, NOESY) and heteronuclear 
(HSQC, HMBC, HSQC-TOCSY) NMR experiments were used to resolve the overlapped 
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signals.  The chemical shift assignments of constructs were acquired by dissecting the individual 
residue coupling system, one-bond and three-bond correlation based on NMR spectra. 
Since the 2008 contaminated heparin crisis, NMR analysis of heparin drug has become 
part of the heparin sodium US Pharmacopeia monograph.  Because heparin is a heterogeneous 
polysaccharide mixture, the assignment of all of the signals is difficult.  To this end, acquiring 
the NMR spectra of highly purified heparin oligosaccharide standards provides a map for 
assigning highly complex heparin spectra, especially those signals from rare components.  
Chemoenzymatic synthesis used to produce structures for NMR.  
 
Molecular Dynamics (MD) Simulation 
 In addition to the length of saccharide chain, diversity of sulfation patterns and plasticity 
of iduronic acid (IdoA) are known correlated to HS biological importance [8, 82].  The flexible 
glycosidic linkages and IdoA could facilitate heparan sulfate conformational rearrangement.  The 
same structure of HS oligosaccharide may dynamically populate at several conformations [43, 
83].  The preference of conformation could attribute to comparable energy states established by 
local environment.  Highly heterogeneous sulfations of heparan sulfate provide the local 
environment diversity.  NMR used to be the best way to accurately identify the molecular 
Figure 16.  Structural comparison between over sulfated chondroitin sulfate (OSCS) and heparin.  
Over sulfated chondroitin sulfate was identified as contaminant in heparin drug.  The main disaccharide 
repeating unit is shown here. 
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structure of protein.  Unfortunately due to highly flexible character, carbohydrate is difficult for 
NMR analyzed [84].  The rapid dynamically exchange between conformations makes NMR only 
observe the signals averaged from individual conformations [85].  Alternatively, molecular 
dynamics (MD) simulation could identify the list of possible low energy conformations.   
However, simulation is unable to accurately calculate the equilibrium population of each 
conformation [86].  Take the advantage of both NMR and simulation analysis, the best manner to 
calculate the realistic equilibrium population of conformations is to deconvolute the NMR 
measured parameters into simulated parameters for each conformation with corresponding 
populations.  The measurement of spin-spin coupling constant (
3
JH-H) and intensity of nuclear 
overhauser effects (NOE) are the appropriate parameters representing saccharide conformation 
[82].  The change of conformation altering the dihedral between vicinal protons as well as the 
spatial distance between ring protons which are reflecting on shift of 
3
JH-H coupling constant and 
NOE, respectively.  The 
3
JH-H coupling constants are obtained by direct 
1
H-NMR experiment or 
calculated from simulated dihedral using Karplus equation [87, 88].  Intensity of NOE signals are 
acquired from 2D-NOESY NMR experiment or calculated from simulated proton distance.  Both 
3
JH-H coupling constant and NOE are used as constraints to monitor the conformational change 
and corresponding population.  Parallel using both NMR and simulation approach enable to 
capture the structural and dynamic properties of carbohydrate conformation ensembles [85].   
 
Biological Functions of Heparan Sulfate 
 Modification by sequential biosynthetic enzymes provides high structural diversity to HS.  
The isoform of enzymes with different substrate specificity further enlarge the array of possible 
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synthetic structures.  The diverse structures of HS associate with various physiological functions.  
HS has been being reported relate to anticoagulation, cell proliferation, tumor progression, 
inflammation, viral and bacterial infection.  The structure-activity relationship between HS and 
anticoagulation was well known.  However, the studies understanding the role of HS play to the 
other physiological or pathophysiological functions is still limited or ongoing.  The 
homogeneous HS oligosaccharide is required for detail ligand-protein interaction studies.   
Anticoagulation 
 Blood flow is highly regulated and finely tuned in living organism.  The coagulation and 
anticoagulation require under strictly control and balance.  Series of serine protease are lined in a 
cascade involved in activation or regulation downstream enzymes to achieve final blood clotting 
(Figure 17) [89].  For example Factor IIa, commonly called thrombin, is the key protease cleaves 
and activates the fibrinogen to fibrin to form clot.  Coagulation cascade can initiate from either 
intrinsic or extrinsic pathway [90].  The intrinsic pathway is induced by damaged vasculature 
surface; on the other hand, extrinsic pathway is happened upon body injury.  To balance the 
coagulation cascade, several anticoagulation factors are critical to maintain blood flowing if 
there is no vasculature damage or body trauma.  These anticoagulation factors, also called 
serpins, are serine protease inhibitors.  Serine protease inhibitors include heparin cofactor II [91, 
92], protein C inhibitor [93, 94], tissue factor pathway inhibitor [95], and the most essential one 
– antithrombin-III (AT) [10].  AT is the key regulator of blood coagulation cascade, which gene 
knockout is lethal to mice model [96, 97]. 
27 
 
 
 
 The interaction mechanism of serpin and the corresponding protease is exquisitely 
regulated.  Generally these serpins consist of a reactive center loop which can be specific 
recognized by the corresponding protease [98-100].  For example, antithrombin (AT) can inhibit 
factor-IIa or Xa using reactive center loop extended into the catalytic site of protease.  This AT-
protease recognition is further regulated by binding to heparan sulfate or heparin.  Heparin 
binding to AT induces conformational change of AT and outward reactive center loop.  This 
conformational change of AT significantly increase the affinity and inhibitory effect to factor-IIa 
or Xa [98, 101, 102].      
Figure 17.  Blood coagulation cascade.  Series of serine protease are line in a cascade involved in 
activation or regulation downstream enzymes to achieve final blood clotting.  Coagulation cascade can 
be initiated from either intrinsic or extrinsic pathway.  The intrinsic pathway is induced by damaged 
vasculature surface; on the other hand, extrinsic pathway is happened upon body injury.  Factor Xa is 
the convergent point of both pathways.  Antithrombin is the key regulator of blood coagulation cascade 
via interaction with heparin. 
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 Upon the heterogeneous structure of heparin, the pentasaccharide with the sequence of 
GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S was reported able to bind and activate AT to 
inhibit the downstream protease in coagulation cascade (Figure 12) [103].  Unless under high 
concentration, heparin or heparan sulfate without this pentasaccharide sequence weakly binds to 
AT [104].  AT binding to pentasaccharide is mainly due to electrostatic interactions between 
basic amino acid residues and acidic sulfate and carboxylate groups [10].  The structure-activity 
study shows that the 3-O-sulfate and nonreducing-end 6-O-sulfate are especially essential for AT 
binding affinity [105, 106].  Additionally, different sulfation also associates with the 
conformational shift of the saccharide.  Within the oligosaccharide fragment the 
2
So 
conformation of IdoA residue, rather than 
1
C4 form, is critical for AT binding (Figure 19).  
However, except AT, the mechanism and specific oligosaccharide structure requirement binding 
to the other serpins is still unclear.    
Figure 18.  Anticoagulation mechanism that heparin activates antithrombin to inhibit Xa.  Heparin binding 
to AT induces conformational change of AT and outward reactive center loop.  This conformational change of 
AT significantly increase the affinity and inhibitory effect to factor-Xa.  The coagulation cascade is held by 
inhibition of the key protease regulator Xa. 
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 In addition to anticoagulant serpins, heparin binds to protease as well.  Heparin could 
serve as bridge bringing serpin and corresponding target protease tightly together (Figure 20).  
For example, in ternary structure the nonreducing-end of heparin can bind to factor-IIa with 
reducing-end pentasaccharide binding to AT [107].  Crystal structure elucidates that heparin 
binds the exosite of factor-IIa and orientates the catalytic site toward anticoagulant AT.  
Similarly, heparin also acts as bridge between AT and target protease factor-IXa demonstrated in 
another ternary crystal structure.  The role of heparin play is more complicate because of 
capability forming different ternary complex to mediate the protein-protein interaction at higher 
level of regulation.  On the other hand, smaller fragment of LMWH are not able to functional as 
Figure 19.  Key structural components of pentasaccharide for AT binding.  The pentasaccharide 
with the sequence of GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S was reported bind and activate AT 
to inhibit coagulation cascade.  The IdoA2S as well as 3-O-sulfate and nonreducing-end 6-O-sulfate, 
highlighted in red, are especially essential for AT binding.  The 
2
So conformation of IdoA residue, 
rather than 
1
C4 form, is observed in crystal structure of HS/AT complex. 
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bridge.  Simply, LMWH activate AT conformational change to directly bind and inhibit factor-
Xa to contribute anticoagulation [108].  The pentasaccharide drug fondaparinux is the factor-Xa 
inhibitor via this relatively simple mechanism [73].    
 
 
Cell Proliferation 
 Heparan sulfate play the important role mediating cellular proliferation.  Heparan sulfate 
and heparin can regulate the binding between fibroblast growth factor (FGF) and the receptor 
tyrosine kinase (FGFR) [109-112].  The binding of FGF to FGFR induces the receptor 
dimerization, autophosphorylation, and finally leads the downstream signaling for cell 
differentiation or proliferation [113-115].  Due to highly negatively charged entity, heparan 
sulfate can stabilize the FGF/HS/FGFR ternary complex via electrostatic interaction with 
positively charged amino acid residues [116].  The intervention of heparan sulfate greatly 
enhances the affinity between FGF and FGFR.  Nowadays, overall a family of 22 FGFs and 
Figure 20.  Anticoagulation mechanism that heparin activates antithrombin to inhibit IIa 
(thrombin).  Heparin binding to AT induces conformational change of AT and outward reactive center 
loop.  Heparin also acts as bridge bringing AT and IIa tightly together.  In ternary structure the 
nonreducing-end of heparin can bind to factor-IIa with reducing-end pentasaccharide binding to AT.  
The inhibition of IXa possibly takes similar mechanism.  However, smaller fragment such as 
fondaparinux or LMWH are not able to functional as bridge to exhibit anti-IIa activity. 
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FGFR-1~4 are identified.  It’s been believed certain selectivity existed among the structure of 
heparan sulfate and FGF/FGFR.  Different set of complex may bring different signaling pathway 
for specific requested response. 
 The heparan sulfates binding to FGF1 or FGF2 are the most extensive studied 
interactions.  2-O-sulfated iduronic acid (IdoA2S) and N-sulfated glucosamine (GlcNS) are both 
required for binding to FGF1 or FGF2.  However, FGF1 shows different substrate preference 
versus FGF2 (Figure 21).  The repeated trisulfated disaccharide IdoA2S-GlcNS6S with the size 
larger than pentasaccharide is the preferred substrate for FGF1 [117].  On the other hand, FGF2 
prefer binds to non-6-O-sulfated HS to mediate the cellular proliferation [118].  The sequence of 
UA-GlcNS-UA-GlcNS-IdoA2S pentasaccharide was reported minimum HS fragment with high 
affinity to FGF2 [119].  The substrate specificity of different FGFs may involve multiple factors, 
such as length of HS, IdoA/GlcA ratio property, and the position of sulfo groups [120].  The 
comprehensive study of structure-activity relationship between HS and FGFs requires further 
investigation.  Understanding the mechanism of HS binding to FGFs and associated downstream 
signaling may help design of HS oligosaccharide for suppression of tumor cell proliferation and 
angiogenesis.   
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Tumor Progression 
 HS is known associated with several aspects of tumor progression including tumor 
growth, angiogenesis, invasiveness, and metastasis [121].  Different modification of HS may 
either enhance or inhibit tumor progression [122].  On the other hand, cancer cell can modify 
nearby HS sequence as well as mediate the expression level and distribution of HS-attached 
proteoglycan [123].  For example, syndecans-1 is down-regulated or absent in several of cancer 
Figure 21.  Minimum heparan sulfate structure for FGFs binding.  FGF1 shows different substrate 
preference versus FGF2.  The repeated trisulfated disaccharide IdoA2S-GlcNS6S with the size larger 
than pentasaccharide is the preferred substrate for FGF1.  FGF2 prefer binds to non-6-O-sulfated HS 
with the minimum sequence of UA-GlcNS-UA-GlcNS-IdoA2S.  The length of HS, IdoA/GlcA ratio 
property, and the position of sulfo groups may involve in substrate specificity of FGFs binding. 
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cell lines [124].  However, the detail HS proteoglycan (HSPG) structure-activity relationship 
needs further clarification.   
HSPG present on the cell surface and have the ability to interact with proangiogenic 
factors including fibroblast growth factors (FGFs) and vascular endothelium growth factors 
(VEGFs).  Some sequences of HS can bind to FGFs to mediate dimerization of FGFR and the 
following tyrosine kinase signaling (Figure 21).  The density of these sequences of HS was 
reported increased in some of cancer lines [125].  The increased abundance of certain HS 
fragments can enhance FGFs –mediated signaling and the consequent tumor cell proliferation.  
Similarly, vascular endothelium growth factor is also mediated by HSPG to influence the 
angiogenesis [126].  Additionally, HS also can modulate tumor metastasis.  Tumor cells utilize 
HS to adhere to the surface of endothelial cells via p-selectin (Figure 22).  Once tumor cells 
adhere and cross into blood stream the metastasis could happen elsewhere.  Interestingly, 
treatment of heparin could inhibit tumor metastasis.  Inhibition of tumor growth is possibly due 
to exogenous heparin competing to binding of p-selectin and epithelial cell [127].  Combined 
with other inhibitory effects, heparin was reported able to slow down the tumor progression 
clinically. 
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The expression of heparanase is upregulated in several tumor cells [128, 129].  HS within 
extracellular matrix is suggested capable to sequester FGFs to reduce tumor growth.  However, 
tumor cells upregulated secret heparanase to degrade the HS and to reduce the capability 
sequestering tumorigenic growth factors [130].  To counter the effect of heparanase, exogenous 
treatment of HS or heparin may be clinically used to inhibit the cancer growth by sequestering 
the growth factors.  The structural difference of HS sequence for stimulated or inhibitory effect 
on tumor growth still remains unclear.  Homogeneous HS is therefore urgently required to clarify 
this critical issue of structure-activity relationship.  Another promising direction of drug design is 
to develop anticancer HS-mimetic reagent without anticoagulation effect as concern of 
unexpected side effect.   
    
Figure 22.  Role of HS and heparin in mediating of tumor progression.  Tumor cells utilize HS to 
adhere to the surface of endothelial cells via p-selectin.  Once tumor cells adhere and cross into blood 
stream the metastasis could happen elsewhere.  Treatment of heparin may inhibit tumor adhesion and 
metastasis by competing binding of p-selectin. 
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Inflammation 
 Heparan sulfate is a key regulator during the process of inflammation.  Inflammation is a 
physiological response to some malicious scenarios including cancer, skin injury, infection, and 
so on [131, 132].  Similar to cancer progression, heparanase is upregulated during inflammation 
[133-135].  The upregulated heparanase degrade the heparin and result in the loss of ability 
sequestering the inflammatory factors.  To counter the heparanase effect, the treatment of 
exogenous heparin is postulated to attenuate the inflammation.   
Regarding to skin injury derived inflammation, HS is critical interacting with several 
chemoattractant such as chemokines and cytokine [136-138].  Chemokine and cytokine released 
by injury are bound by negatively charged HS, and subsequently attract neutrophil rolling along 
vessel (Figure 23) [139].  The L-selectin on the surface of neutrophil is attracted and slowed 
down the rolling by interaction with this chemoattractant-attached HS [140-142].  The trapped 
neutrophil further release chemoattractant and recruit more inflammatory responses.    
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HS polysaccharide chain containing several unsubstituted glucosamine residues 
(GlcNH2) was revealed may interact with L-selectin [143].  Unsubstituted glucosamine is 
relatively sparse saccharide among heparan sulfate.  Possibly this special saccharide play the role 
to distinguish various chemoattractant and achieve the desired inflammation response.  Heparin 
is potentially useful to control inflammation such as ulcerative colitis, bronchial asthma, and skin 
injury [144-147].  The explanation is exogenous heparin can compete endogenous HS binding to 
chemoattractant, and decrease neutrophil trafficking at the injury site bringing further 
inflammatory response.  Additionally, 6-O-sulfo group on HS is required for the inhibitory effect 
[140].  The electrostatic interaction between positively charged chemoattractant and highly 
negatively charged heparin may drive the binding.  However, to develop the anti-inflammatory 
reagent without anticoagulation effect demands more detail understanding of relation between 
structure and biofunction.   
Viral Infection 
 HS on cell surface play critical role in mediating multiple virus infection such as human 
immunodeficiency virus (HIV), hepatitis C, human papillomavirus (HPV), and herpes simplex 
virus-I (HSV-I) [148-150].  HS is essential to interact with several viral glycoproteins for 
internalization of the virus into the host cell [53, 151].   
Figure 23.  Role of HS and heparin in mediating of inflammation.  Chemoattractants including 
chemokine and cytokine released by injury are bound by negatively charged HS, and subsequently 
attract neutrophil rolling along vessel.  The L-selectin on the surface of neutrophil is attracted and 
slowed down the rolling by interaction with this chemoattractant-attached HS.  Heparin is potentially 
useful to control inflammation by competing endogenous HS binding to chemoattractant and reducing 
neutrophil trafficking at the injury site.   
37 
 
 The importance of HS for HSV-I infection is one of the most well-studied case [152, 
153].  HSV-I infection can generally separate to two phase: attach host cell, and entry host cell.  
Firstly, attachment of HSV-I requires viral envelop glycoprotein gB and gC to interact with HS-
attached host cell [154-156].  The HS responsible for HSV-I attachment is called binding 
receptor with the sequence of repeated IdoA2S-GlcNS6S more than decasaccharide [157].  
Secondly, 3-O-sulfate HS serve as entry receptor for viral entry [53, 158].  gB, gH, gL, and the 
most important gD are used to recognize entry receptors and fuse envelope into host membrane 
[159-161].  Instead of 3-OST-1 make the AT binding domain, 3-O-sulfation of this entry 
receptor HS was reported made by 3-OST-3 [53].  The implication of distinct 3-O-sulfation 
performed by isoforms suggests that different modified HS may be in charge of different 
biological functions.   
 Since 3-O-sulfated HS is principal for virus infection, design of 3-O-sulfated HS mimic is 
possibly a good candidate structure for development of anti-viral drug (Figure 24).  Accordingly, 
heparin, which contains scattered 3-O-sulfo group, is proven preventing HSV-I infection [151].  
An octasaccharide with the sequence of UA2S-GlcNS-IdoA2S-GlcNS6S-IdoA2S-GlcNS3S6S-
IdoA2S-GlcNS6S also shows IC50 as 40uM for inhibition of HSV-I infection [162].  The 
various 3-O-sulfated HS structure synthesized by 3-OST isoform may be another possible 
approach to develop new anti-viral therapy.   
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Figure 24.  Chemical structure of HSV-I binding and entry receptor as well as inhibitor.  The HS 
responsible for HSV-I attachment is called binding receptor with the sequence of repeated IdoA2S-
GlcNS6S more than decasaccharide.  3-O-sulfate HS was isolated as entry receptor for viral entry.  3-O-
sulfated HS mimic, an octasaccharide with the sequence of UA2S-GlcNS-IdoA2S-GlcNS6S-IdoA2S-
GlcNS3S6S-IdoA2S-GlcNS6S, shows IC50 as 40uM for inhibition of HSV-I infection.  
39 
 
Statement of Problem 
Heparin is a widely used clinical anticoagulant since the 1930s.  Heparin was the first 
biopolymeric drug and one of the few carbohydrate based drugs.  The polydispersity of the 
saccharide sequence as well as the polyheterogeneity of the sulfation pattern make study of 
heparin and heparan sulfate formidable tasks.  The access of sufficient structural defined samples 
for study is extremely difficult.  In this dissertation, we directly address three main issues of 
heparan sulfate: safeguard drug safety, probe interaction with proteins, and characterize the HS 
conformations.   
To safeguard heparin drug safety, reversible anticoagulant activity and secured heparin 
components are two important concerns.  Low-molecular-weight heparin (LMWH) is a mixture 
of oligosaccharides (MWavg 3500 to 6000 Da) and the most widely prescribed heparin in the US.  
However, LMWH is incompletely neutralized with antidote protamine, thereby increasing the 
risks of bleeding.  A structural defined homogeneous LMWH with reversible activity is highly 
expected in clinical usage.  Reliable structural characterization of heparin components is also 
critical to safeguard the quality of heparin drugs.  In 2008, batches of contaminated heparin 
killed 94 patients in US because adulteration of structurally similar carbohydrate was escaped 
from government supervision.  Therefore, a library of common and less abundant heparin 
oligosaccharides were synthesized for structural referencing to secure the components of heparin 
drug.    
HS achieves its functions by interacting with a variety of proteins.  There is strong a 
demand for probes to decipher different interactions of specific HS structures with their protein 
targets.  Several of problems are awaiting probes to deal with.  Firstly, heparan sulfate 
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sulfotransferase (2OST) is a key enzyme in the HS biosynthetic pathway; however, the cellular 
mechanism regulating HS biosynthesis is largely unknown.  Secondly, the positions of sulfo 
groups and the locations of the IdoA residues are critically important for the protein binding 
specificities, but lack of the probes to selectively target different HS biosynthetic enzymes.  
Thirdly, HS repeating saccharide or bound by large protein make the NMR signals overlapped 
and indistinguishable, therefore a tool able to study the specific saccharide and detail picture of 
HS-protein interaction is in demand.  In the dissertation, we developed different kinds of probes 
to solve these issues.  
It has been proposed that the conformation of HS plays a critical role in binding affinity 
and selectivity toward proteins.  In addition to the length of saccharide chain, diversity of 
sulfation patterns and plasticity of iduronic acid (IdoA) are known possibly associated to the HS 
conformational change.  The flexible glycosidic linkages and IdoA facilitate heparan sulfate 
conformational rearrangement to allow specific proteins binding.  Nevertheless, this hypothesis 
remains to be unproven due to the lack of a set of compounds that is able to systematically 
investigate the effect of different sulfation on HS conformation.  Unfortunately due to highly 
flexible character, carbohydrate is difficult to crystalized and NMR-analyzed.  Thus an array of 
various structural defined HS oligosaccharides as well as an innovative method capable to 
accurately quantitate the saccharide conformations is developed in this study. 
Last but not least, the efficient synthetic approach and accurate characterization of the HS 
oligosaccharide is crucial for all the studies.  Understanding the molecular mechanisms of HS 
biosynthetic enzymes and interaction proteins should greatly aid in the design and production of 
heparin-based molecules.  The success of these projects will assist the development of 
therapeutics tailored for specific disease targets.   
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Chapter II 
Materials and Methods 
 
Preparation of Heparan Sulfate Biosynthetic Cofactors 
Saccharide Donor  
 UDP-GlcA and UDP-GlcNAc are commercial available products from Sigma-Aldrich 
while UDP-GlcNTFA is made by chemoenzymatic approach.  The preparation of UDP-GlcNTFA 
was started from glucosamine (Sigma-Aldrich), which was first converted to GlcNTFA by reacting 
with S-ethyl trifluorothioacetate (Sigma-Aldrich) followed the protocol described previously [163]. 
The resultant GlcNTFA was converted to GlcNTFA-1-phosphate using N-acetylhexosamine 1-kinase 
[164]. The plasmid expressing N-acetylhexoamine 1-kinase was a generous gift from Prof. Peng 
Wang (Georgia State University), and the expression of the enzyme was carried out in E. coli as 
reported [164]. The UDP-GlcNTFA synthesis was completed by transforming GlcNTFA-1-
phosphate using glucosamine-1-phosphate acetyltransferase/N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) as described [163]. The resultant UDP-GlcNTFA was ready for the 
elongation reaction involved in using KfiA as described below. Because the impurities in the reaction 
mixture used to synthesize UDP-GlcNTFA do not interfere with the reactions involved in KfiA, 
purification of UDP-GlcNTFA was not conducted. The successful synthesis of UDP-GlcNTFA was 
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confirmed by PAMN-HPLC analysis as a distinct UV 260 nm peak. The intensity of the peak was 
also used to estimate the amount of UDP-GlcNTFA.   
 
Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides 
KfiA and pmHS2 for Backbone Elongation 
 The elongation starts from a commercial material, GlcA-pnp, followed by elongation of 
GlcNTFA and GlcA with number of desired repeating times.  Elongation of GlcA-pNP requires 
using two bacterial glycosyl transferases, N-acetyl glucosaminyl transferase of E. coli K5 (KfiA) 
and heparosan synthase-2 (PmHS2) from Pasteurella multocida.  To introduce a GlcNTFA 
residue, GlcA-pnp (1.2 mM) was incubated with KfiA (20 µg/ml) in a buffer containing Tris (25 
mM, pH 7.5), MnCl2 (15 mM) and UDP-GlcNTFA (1.5 mM), at room temperature overnight.  
To introduce a GlcA residue, disaccharide substrate, GlcNTFA-GlcA-pnp (1.2 mM), was 
incubated with pmHS2 (20 µg/ml) in a buffer containing Tris (25 mM, pH 7.5), MnCl2 (15 mM) 
and UDP-GlcA (1.5 mM), at room temperature overnight. C18 column (0.75 × 20 cm) was used 
for purification with gradient elution (0-100% acetonitrile in H2O, 0.1% TFA, 2 ml/min in 60 
min). The eluted products were monitored by UV absorbance at 310 nm and characterized by 
ESI-MS. The additional GlcNTFA and GlcA elongation was repeated under the same condition. 
 
GlcNTFA Deacetylation and Subsequent Modification with NST 
 Detrifluoroacetylation was completed using 0.1M LiOH at 0°C for two hours. The 
products were analysis by PAMN-HPLC (polyamine-based high performance liquid 
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chromatography) and electrospray ionization mass spectrometry (ESI-MS).  Upon the 
completion of detrifluoroacetylation, the pH of the reaction mixture was neutralized to pH 7.0.  
Afterwards, N-sulfation was performed within pH 7.0 MES (50 mM), N-sulfotransferase (10 
µg/ml), and PAPS (0.5 mM, 1.5 equivalent of substrate amount) at 37°C overnight. The sulfated 
products were purified by Q-Sepharose column (15 × 200 mm, GE Health Sciences) with linear 
gradient elution (20–100% 1 M NaCl in 20 mM NaOAc, pH 5.0, flow rate 2 ml/min) and 
followed by dialysis to obtain highly targeted oligosaccharides or intermediates. 
 
C5-Epi and 2-OST Modification 
 Epimerization and 2-O-sulfation were performed within the solution contained MES (50 
mM, pH 7.0), CaCl2 (2 mM), C5-epi (10 µg/ml), 2-OST (10 µg/ml), PAPS (0.2 mM), and 
oligosaccharide intermediate (0.13 mM) at 37
o
C overnight.  The products were analysis by 
PAMN-HPLC (polyamine-based high performance liquid chromatography) and electrospray 
ionization mass spectrometry (ESI-MS).  The sulfated products were purified by Q-Sepharose 
column (15 × 200 mm, GE Health Sciences) with linear gradient elution (20–100% 1 M NaCl in 
20 mM NaOAc, pH 5.0, flow rate 2 ml/min) and followed by dialysis to obtain highly targeted 
oligosaccharides or intermediates. 
 
6-OST-1, 6-OST-3 and 3-OST Modification 
 General 6-O-sulfation was performed using PAPS (400 µM), MES (50 mM, pH 7.0), 6-
OST-1 (0.1 mg/ml), 6-OST-3 (0.1 mg/ml) overnight at 37°C.  For some naturally rare structures, 
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sometimes 6-O-sulfation was pushed in higher concentration of PAPS (800 µM), MES (50 mM, 
pH 7.0), 6-OST-1 (0.6 mg/ml), 6-OST-3 (0.6 mg/ml) overnight at 37°C.  The reaction was 
monitored by DEAE-HPLC to ensure the desired product reached to the highest level and the 
substrate was consumed. The reaction mixture was purified by Q-Sepharose column and 
dialyzed. 
3-O-sulfation was performed to synthesize constructs under the condition of MES (50 
mM, pH 7.0), MnCl2 (10 mM), MgCl2 (5 mM),  3-OST-1 (10 µg/ml) or 3-OST-5 (10 µg/ml), 
PAPS (600 µM) at 37
o
C overnight.  The extent reaction was also monitored by DEAE-HPLC. 
The products were purified by Q-Sepharose column to obtain targeted oligosaccharides.   
 
Preparation of 
35
S-Labeled Heparan Sulfate 
 UFH (from US Pharmacopeia) and enoxaparin (from local pharmacy) were modified by 
NST.  Reaction consisted of MES (2-(N-morpholino)ethanesulfonic acid, Sigma) 50 mM pH 7.0, 
NST 0.1 mg ml
-1
 and 0.5 nmol [
35
S]PAPS (specificity activity of [
35
S]PAPS was 2.2 × 10
4
 cpm 
pmol
-1
), 50 µg of UFH or enoxaparin in total 500 µl at 37°C overnight.  The products were 
purified by a DEAE-column.   
35
S-labeled synthetic constructs were prepared from the synthetic LMWH constructs 
intermediates, which are followed by further any sulfation using [
35
S]PAPS.  Reaction consisted 
of MES 50 mM pH 7.0, 10 mM MnCl2, 5 mM MgCl2, any sulfotransferase 0.1 mg ml
-1
 and 0.5 
nmol [
35
S]PAPS and oligosaccharide (5 µg) in total 500 µl at 37°C overnight.  The 
35
S-labeled 
construct was purified by a DEAE-HPLC column. 
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Purification of Synthetic Heparan Sulfate 
C18 and Q Sepharose Fast Flow
TM
-HPLC Purification and Analysis  
 C18 column (0.75 × 20 cm; Biotage) was used for purification with gradient elution (0-
100% acetonitrile in H2O, 0.1% TFA, 2 ml/min in 60 min). The eluted products were monitored 
by UV absorbance at 310 nm and characterized by ESI-MS.  
 Purification of oligosaccharides as well as intermediates was conducted by a fast flow Q-
Sepharose column (15 × 300 mm; GE Health Care ), which was eluted with a linear gradient of 
20–100% 1M NaCl in 20 mM NaOAc at pH 5.0 in 2 h at a flow rate of 2 ml/min
-1
. Purification 
of those highly sulfated oligosaccharide, was eluted with a linear gradient of 30–100% 2M NaCl 
in 20 mM NaOAc at pH 5.0 in 2 h at a flow rate of 2 ml/min
-1
. 
 
HPLC Analysis 
Both DEAE-HPLC and polyamine-based anion exchange (PAMN)-HPLC were used to 
analyze the purity of the products.  The elution conditions for the HPLC analysis were described 
elsewhere [165].  Briefly, for DEAE-HPLC method, the DEAE-NPR column ((0.46 × 7.5 cm, 
Tosohaas) was eluted with a linear gradient of NaCl in 20 mM sodium acetate buffer (pH 5.0) 
from 0 to 1 M in 60 min at a flow rate of 0.4 ml/min. For PAMN-HPLC, the column (silica-
based polyamine column, 0.45 × 25 cm, YMC) was eluted with a linear gradient of KH2PO4 
from 0 to 1 M in 40 min at a flow rate of 0.5 ml/min.  GPC-HPLC was used to analyze and 
protein purify and protein-oligosaccharide conjugates. The GPC-HPLC conditions were as 
46 
 
follows: the column G3000SW from Tosoh Bioscience (7.8 mm × 300 mm, 5 μm) the elution 
was isocratic; the buffer consisted of 25 mM MOPS and 400 mM NaCl; the dual wavelengths 
were set as 280 nm and 310 nm respectively, the flow rate was 0.2 mL/min. 
 
Structural Characterization of Synthetic Heparan Sulfate 
NMR Parameter and Spectroscopy Analysis 
The structure of the oligosaccharides constructs and intermediates were analyzed by 
NMR experiments, including 1D- (“s2pul” pulse sequence 1H or 13C), 2D- (1H-1H “gCOSY” 
pulse sequence COSY, “TOCSY” pulse sequence TOCSY, 1H-13C “gHSQC” pulse sequence 
HSQC, “gHMBC” pulse sequence HMBC, and “gHSQCTOXY” pulse sequence HSQC-
TOCSY) NMR. NMR experiments were performed at 298 K on a Varian Inova 500 MHz 
spectrometer equipped with 5mm triple resonance XYZ or broadband PFG probe and processed 
by VnmrJ 2.2D software. Chemical shifts are referenced to external 2,2-dimethyl-2-silapentane-
5-sulfonate sodium salt (DSS, Sigma, Co.). Deuterated EDTA (Sigma, Co.) was added to resolve 
the coupling constants of IdoA2S signals. Samples (5.0 to 10.0 mg) were each dissolved in 0.5 
mL D2O (99.994%, Sigma, Co.) and lyophilized three times to remove the exchangeable protons. 
The samples were re-dissolved in 0.5 mL D2O and transferred to NMR microtubes (OD 5 mm, 
Norrell). 1D 
1
H-NMR experiments were performed with 256 scans and an acquisition time of 
768 msec. 1D 
13
C-NMR experiments were performed with 40000 scans, 1.0 sec relaxation delay, 
and an acquisition time of 1000 msec. 2D (
1
H-
1
H COSY, TOCSY,
 1
H-
13
C HSQC, HSQC-
TOCSY) spectra were recorded with GARP carbon decoupling, a 1.5 sec relaxation delay, a 204 
msec acquisition time with 500 increments for 48 scans. Forty eight steady state scans were used 
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prior to the start of acquisition. 2048 points were collected in f2. Gradients were used for 
coherence transfer selection with sensitivity enhancement in the HSQC experiment. 
13
C 
transmitter offset was set at 77.0 ppm. The echo-anti-echo phase cycling scheme was used. The 
polarization transfer delay was set with a 
1
JC-H coupling value of 147Hz. 2D 
1
H-
13
C HMBC 
experiments were performed with 72 scans, 1.5 sec relaxation delay, and a 204 msec acquisition 
time. The delay for evolution of long-range couplings was set with Jlr of 7.6 Hz. 
NMR experiments were also performed at 298 K on Bruker Avance II 800 MHz 
spectrometer with Topsin 2.1 software.  Samples (3.0 to 6.0 mg) were each dissolved in 0.5 ml 
D2O (99.996%, Sigma-Aldrich) and lyophilized three times to remove the exchangeable protons. 
The samples were re-dissolved in 0.4 ml D2O and transferred to NMR microtubes (O.D. 5 mm, 
Norrell). 1D 
1
H NMR experiments were performed with 256 scans and an acquisition time of 
850 msec. 2D 
1
H-
1
H COSY experiments were performed with 16 scans, 1.5 sec relaxation delay, 
and 500 msec acquisition time.  2D 
1
H-
13
C HMQC experiments were performed with 16 scans, 
1.5 sec relaxation delay, and 250 msec acquisition time.  
 
MS Spectrometry Analysis 
 The low-resolution MS analyses were performed at a Thermo LCQ-Deca.  A syringe 
pump (Harvard Apparatus) was used to introduce the sample by direct infusion (35 µl min
-1
).  
Experiments were carried out in negative ionization mode. Synthetic non-sulfated 
oligosaccharides were diluted in 200 µl of H2O, the electrospray source set is 5 KV and 275 °C.  
Sulfated LMWHs were diluted in 200 µl of 10 mM ammonium bicarbonate, the electrospray 
source set is 3 KV and 200 °C.  Sulfated oligosaccharide (1 µl) was diluted in a different 
working solution containing 200 µl of 10 mM ammonium bicarbonate.  Experiments for sulfated 
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oligosaccharides were carried out in negative ionization mode with the electrospray source set to 
2 KV and 200 °C.  The automatic gain control was set to 1 × 10
7
 for full scan MS.  The MS data 
were acquired and processed using Xcalibur 1.3. 
 High resolution ESI-MS analysis was conducted on Thermo LTQ XL Orbitrap (Breman, 
Germany) under the following conditions.  A Luna hydrophilic liquid interaction 
chromatography (HILIC) column (2.0 × 150 mm
2
, 200 Å, Phenomenex, Torrance, CA) was used 
to separate the oligosaccharide mixture.  Mobile phase A was 5 mM ammonium acetate prepared 
with high performance liquid chromatography (HPLC) grade water.  Mobile B was 5 mM 
ammonium acetate prepared in 98% HPLC grade acetonitrile with 2% of HPLC grade water.  
After injection of 8.0 µL oligosaccharide mixture (1.0 µg μl-1) through an Agilent 1200 
autosampler, HPLC binary pump was used to deliver the gradient from 10% A to 35% A over 40 
min at a flow rate of 150 μl min-1.  The LC column was directly connected online to the standard 
electrospray ionization source of LTQ-Orbitrap XL Fourier transform (FT) mass spectrometer 
(MS) (Thermo Fisher Scientific, San-Jose, CA).  The source parameters for FT-MS detection 
were optimized using fondaparinux to minimize the insource fragmentation and sulfate loss and 
maximize the signal/noise in the negative-ion mode.  The optimized parameters included a spray 
voltage of 4.2 kV, a capillary voltage of −40 V, a tube lens voltage of −50 V, a capillary 
temperature of 275° C, a sheath flow rate of 30, and an auxiliary gas flow rate of 6.  External 
calibration of mass spectra routinely produced a mass accuracy of better than 3 ppm.  All FT 
mass spectra were acquired at a resolution 60,000 with 300−2000 Da mass range. 
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Disaccharide Analysis 
 To determine the size of the [
35
S]sulfation, the sample was subjected to nitrous acid 
degradation at pH 1.5 to produce 
35
S-labeled disaccharide as described by Shively and Conrad 
[166].  The resultant 
35
S-labeled disaccharides were resolved using a C18 reverse-phase column 
(0.46 × 25 cm; Vydac) under reverse-phase ion-pairing HPLC conditions [167]. The identities of 
the disaccharides were determined by co-elution with the appropriate 
35
S-labeled standards. 
 
Molecular Modeling 
Oligosaccharide Pre-processing 
 The hexasaccharides were created with the GLYCAM06 (version j-1) parameter set 
[168], neutralized with NA
+
 ions, and solvated by the TIP5P water model in a truncated 
octahedral box 12 Å around the ligand [169]. Ensemble charges were developed for the 
Glucosamine (GlcNH2) residue according to the standard GLYCAM protocol [168]. Briefly, 
electrostatic potentials were calculated by GAUSSIAN09 at the HF/6-31G(*) level of theory for 
100 snapshots at 0.5 ns intervals (50 ns total). Partial atomic charges were computed using the 
RESP module of AMBER14 by fitting to these electrostatic potentials with a restraint weight of 
0.01 [170]. 
 
Energy Minimization 
Energy minimizations and MD simulations were performed using the pmemd.cuda 
module from AMBER14 [171]. The system was minimized using the steepest descent method for 
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the initial 1000 cycles before switching to conjugate gradient for the remaining 24,000 cycles. 
Three minimizations were performed with varying atomic restraints. Initially, cartesian restraints 
(10 kcal/mol Å2) were applied to each atom of the hexasaccharide.  The second stage involved 
restraining the ring atoms. All restraints were removed for the final minimization. During the 
remaining simulations, internal restraints were applied to the iduronic acid residue in order to 
maintain a 1C4, 
2So, or 4C1 conformation. Details of these restraints are provided in Table 2. 
 
 
Table 2. Internal restraints applied for iduronic acid during MD simulation.  The IdoA ring conformations 
were restrained by limiting the rotational freedom of each dihedral of the 6-membered ring. The restraint is 
imposed by an energy potential in the shape of a flat-welled parabola which becomes linear past specified 
torsion angles (R1 and R4). The R2 and R3 parameters define the points where the parabola flattens. The force 
constants (RK2 and RK3) were set at 300 kcal/mol for each ring conformation. 
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Molecular Dynamics Simulation 
MD simulations were performed with pmemd.cuda from AMBER14 [171]. Electrostatic 
interactions were treated with the Particle-Mesh Ewald algorithm [172]. An 8 Å cutoff for non-
bonded interactions.  The SHAKE algorithm was included in order to constrain hydrogen-
containing bonds, enabling an integration time step of 2 fs. The system was heated to 300 K 
under NVT conditions over 60 ps by employing the Berendsen thermostat with a coupling time 
constant of 1 ps, and allowed to equilibrate for a total of 1 ns under NPT conditions. A post-
equilibration data set was collected for 1 µs, also under NPT conditions. 
 
Simulation Data Analysis 
 Structural metrics (i.e. torsion angles, hydrogen bond properties, r.m.s.d. values, and 
coordinate averaging) were generated using the cpptraj module of AmberTools14 [173].  The Φ- 
and Ψ-glycosidic torsion angles were defined by the H1-C1-O4-C4 and C1-O4-C4-H4 atomic 
sequences, respectively.  Theoretical J-coupling values were calculated by collecting the H1-H2, 
H2-H3, H3-H4, and H4-H5 torsion angles for the Iduronic acid ring for the three ring 
conformations. An average torsion angle from 8 µs of data, one µs per compound, was 
transformed into a J-coupling value via the reparameterized Haasnoot Karplus equation-
14.63*cos2(φ)-0.78*cos(φ)+0.60+∑λi{0.34-2.31cos2[sin(φ)+18.4|λi|]} [174, 175].  
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Biological Activities of Synthetic Heparan Sulfate 
Activity Measurement for 2-O-Sulfotransferase 
 Activity measurement for 2-OST using the completely desulfated N-sulfated  heparin 
(CDSNS, purchased from Neoparin) substrate was determined by incubating 0.5 μg of 2-OST  
with 1 μL of CDSNS (10 mg/mL) and 1~5 ×105 cpm of [35S]PAPS in 200 μL of buffer 
containing 50 mM MES(2-(N-morpholino)ethanesulfonic acid) (pH 7.2), 10 mM CaCl2  at 37 
0
C 
for 1 h. Reactions were quenched by the addition of 6 M urea, 1mM EDTA 
(ethylenediaminetetraacetic acid), 0.01% Triton X-100, then subjected to 200-μL DEAE-
Sepharose (from Sigma) chromatography to purify the 
35
S-labeled polysaccharide product. The 
quantity of [
35
S]sulfated polysaccharide was determined by liquid scintillation counting. The 
negative control contained all of the components with the exception of 2-OST enzyme. 
 To analyze the inhibition effect of test compound on the activity of 2-OST enzyme, 1 μg 
of 2-OST was deactivated by incubating with various amount (0, 1, 2, 4, 6 and 10 μL) of test 
compound (5 μM) at pH 5.5 to initiate the inhibition (cross-linking) reaction in 100 μL of 25 mM 
MES buffer. After 1 h incubation,  the inhibition effect of compound on 2-OST was determined 
by incubating 10 μL of the deactivated 2-OST protein above, 10 μg of CDSNS heparin and 1~5 
× 10
5 
cpm of [
35
S]PAPS in 100  μL of a buffer containing 50 mM MES (pH 7.2), 10 mM CaCl2.  
All the reactions were incubated at 37 
0
C for 1h and quenched by the addition of a buffer 
containing  6 M urea, 1mM EDTA, and 0.01% Triton X-100. The samples were then loaded onto 
a 200-μL DEAE-Sepharose (Sigma-Aldrich) column to purify the [35S] CDSNS heparin, which 
were eluted with 1M NaCl and 0.01% Triton X-100. The quantity of [
35
S] HS was determined by 
liquid scintillation counting. The inhibition activity of test compound against 2-OST was showed 
53 
 
by IC50 (half maximal inhibitory concentration) value that was calculated by linear regression 
analysis of the concentration-response curves by means of Sigmaplot 12.5. 
 
Activity Measurement for 3-O-Sulfotransferase 
 Activity measurement for 3-OST using the heparan substrate (isolated from bovine 
kidney) was determined by incubating 0.5 μg of 3-OST with 1 μL of HS (10 mg/mL) and 1~5 
×10
5 
cpm of [
35
S]PAPS  in 200 μL of buffer containing 50 mM MES (pH 7.2), 10 mM MnCl2 
and 5 mM MgCl2 at 37 
0
C for 1 h. Work-up of reaction mixture and activity measurement 
followed essentially the same procedure as described for 2-OST. 
 To analyze the inhibition effect of test compound on the activity of 3-OST enzyme, 3-
OST (1 μg) was deactivated by incubating with various amount (0, 0.5, 1.0, 1.5 and 2.0 μL) of 
test compound (2.0 μM) at pH 5.5 to initiate the inhibition (cross-linking) reaction in 100 μL of 
25 mM MES buffer. After 1 h incubation, the inhibition effect of compound on 3-OST was 
determined by incubating 10 μL of the deactivated 3-OST protein above, 10 μg of HS and 
1~5×10
5 
cpm of [
35
S]PAPS in 100 μL of a buffer containing 50 mM MES (pH 7.2), 10 mM 
MnCl2, 5 mM MgCl2. All the reactions were incubated at 37 
0
C for 1h and quenched by the 
addition of a buffer containing  3 M urea, 1mM EDTA, and 0.01% Triton X-100. The samples 
were then loaded onto a 200-μL DEAE-Sepharose (Sigma-Aldrich) column to purify the [35S]HS, 
which were eluted with 1M NaCl and 0.01% Triton X-100. The quantity of [
35
S] HS was 
determined by liquid scintillation counting. The inhibition activity of test compound against 3-
OST was showed by IC50 value that was calculated by linear regression analysis of the 
concentration-response curves by means of Sigmaplot 12.5. 
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In vitro and ex vivo Anti-FXa Activity 
Assays were based on a previously published method [176, 177].  Briefly, human factor 
Xa (FXa) (Enzyme Research Laboratories, South Bend, IN) was diluted to 50 U ml
-1
 with PBS. 
The chromogenic substrates, S-2765 was from Diapharma (Westchester, OH) and made up at 1 
mg ml
-1
 in water.  UFH (from US Pharmacopea), enoxaparin (Lovenox
®
 from local pharmacy) 
and synthetic oligosaccharide was dissolved in PBS at various concentrations (3 to 600 µg ml
-1
).  
The reaction mixture, which consisted of 20 µl of human plasma (Sigma-Aldrich) and 8 µl of the 
solution containing the sample, was incubated at room temperature for 5 min.  Factor Xa (100 
µl) was then added.  After incubating at room temperature for 4 min, 30 µl of S-2765 substrate 
was added.  The absorbance of the reaction mixture was measured at 405 nm continuously for 5 
min using spectrophotometer.  The absorbance values were plotted against the reaction time to 
measure the reaction rate.  The initial reaction rates were used to measure the activity of FXa. 
 
Binding Affinity to Antithrombin 
 
35
S-labeled constructs were prepared via any sulfation as described previously, using 
[
35
S]PAPS (0.5 nmol, specific activity 2.2 × 10
4
 cpm/pmol) and oligosaccharide precursor (5 µg) 
in total 500 l at 37°C overnight. The products were purified by DEAE-HPLC column. Affinity 
co-electrophoresis [178] was used for measurement of dissociation constant (Kd) of 
oligosaccharides. 
35
S-labeled constructs (1500-2500 cpm) were loaded for lanes with AT 
concentration at 0, 8, 16, 32, 60, 120, 250, 500, and 1000 nM. The agarose gel was run with 300 
mA electrophoresis for two hours, and was dried at room temperature overnight. The dried gel 
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was analyzed by PhosphoImager (Amersham Biosciences, Storm 860). The retardation 
coefficient was calculated at R = (M0-M)/M0, where M0 is the mobility of the oligosaccharide 
flow through in the lane without AT, and M is the mobility of the sample in an individual lane. 
The retardation coefficient was then plotted against the retardation coefficient divided by its 
respective AT concentration. The constant -1/Kd is the slope of the trendline.  
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1Part of this chapter previously appeared as two articles in the Journal of Nature Chemical Biology and Glycobiology.  The original citations are 
as follows: Y. Xu, C. Cai, K. Chandarajoti, P. H. Hsieh, L. Li, T. Pham, E. Sparkenbaugh, J. Sheng, N. Key, R. Pawlinski, E. Harris, R. Linhardt, 
J. Liu, “Homogeneous low-molecular-weight heparins with reversible anticoagulant activity,” Nature Chemical Biology, 10, 2014, 248–250;  P. 
H. Hsieh, Y. Xu, D. A. Keire, J. Liu, “Chemoenzymatic synthesis and structural characterization of 2-O-sulfated glucuronic acid-containing 
heparan sulfate hexasaccharides,” Glycobiology, 24, 2014, 681–692 
 
 
Chapter III 
Safeguard Heparin Safety:  
Reversible Anticoagulant Activity and a Library of Standards
1
 
 
Synthesis of Low Molecular Weight Heparins (LMWH) 
Introduction 
Heparin is a widely used anticoagulant to prevent and treat arterial and venous 
thrombosis [179].  There are three approved forms of heparin: unfractionated heparin (UFH, 
average molecular weight (MWavg) ~14000), LMWH (MWavg 3500 to 6000) and fondaparinux 
(MW 1508).  UFH has a rapid onset action, is safe for renal-impaired patients, and is reversible 
using the cationic peptide drug, protamine[180], but shows a 1-6% incidence of heparin-induced 
thrombocytopenia (HIT), a life-threatening complication[181].  Introduced in the 1990’s[182], 
LMWHs are subcutaneously administered and have a longer half-life than UFH, permitting their 
outpatient use and/or self-administration.  Because of these advantages, LMWH is the most 
widely prescribed heparin in the US[183].  However, LMWH can only be used in renal-impaired 
patients at reduced doses[184] and is incompletely neutralized with protamine, thereby 
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increasing the risks of bleeding.  Fondaparinux, a synthetic pentasaccharide, is subcutaneously 
bioavailable and has reduced risks of HIT and osteoporosis[185].  However, it is primarily 
excreted through the kidney, and thus, is contraindicated in renal-impaired patients[184], and 
lacks an antidote.  The US Food and Drug Administration (FDA) recently approved generic 
forms of LMWH and fondaparinux, underscoring the rapid growth in the development of 
heparin-based drugs.   
Heparin consists of a disaccharide-repeating unit of either iduronic acid (IdoA) or 
glucuronic acid (GlcA) and glucosamine (GlcN) residues, each capable of carrying sulfate 
groups.  The locations of sulfate groups, IdoA and GlcA dictate the anticoagulant activity of 
heparin[186].  In vivo, heparin is synthesized by a series of heparan sulfate (HS) biosynthetic 
enzymes.  HS polymerase catalyzes the formation of the polysaccharide backbone, a repeating 
disaccharide of GlcA and N-acetylated glucosamine (GlcNAc).  This backbone is modified by N-
deacetylase/N-sulfotransferase (NDST), C5-epimerase (C5-epi), 2-O-sulfotransferase (2-OST), 6-
O-sulfotransferase (6-OST), and 3-O-sulfotransferase (3-OST). Recombinant HS biosynthetic 
enzymes, readily expressed in E. coli, display comparable substrate specificities to their 
mammalian counterparts[187].  These recombinant enzymes offer a new strategy to synthesize 
heparin oligosaccharides using a chemoenzymatic approach[188-190].   
LMWH is a depolymerized derivative of heparin, isolated from porcine intestine.  A 
worldwide contamination of heparin in 2007 impacted the purity and safety of LMWHs[191] and 
was associated with over 200 deaths in the US[192].  This crisis revealed the fragility of the 
LMWH supply chain.  The cost-effective preparation of a synthetic LMWH could improve drug 
safety and efficacy[193].  Currently available LMWHs are complex mixtures, having average 
molecular masses of 3500-6000 Daltons, corresponding to 12-20 saccharide units.  Until now the 
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preparation of a homogeneous LMWH has not been possible due to difficulties in the chemical 
synthesis.  Thus, we sought to design and synthesize a potential lead compound for a new 
generation of LMWH, particularly to explore reversibility of treatment.  
 
Targeted Structures and Schematic Synthesis of LMWHs 
 
 
Five synthetic LMWHs (Compound 1-5, Figure 25), ranging from hexasaccharide to 
dodecasaccharide, were synthesized. The structures of 1-4 contain a different number of –
Figure 25.  Targeted structures and schematic synthesis of synthetic LMWHs.  (a) The five synthetic 
LMWHs prepared in this study. (b) Hexasaccharide 6 (Figure 26) was converted to octasaccharide 7, 
decasaccharide 8 and dodecasaccharide 9 to synthesize 2, 3 and 4, respectively. The conversion of 4 to 5 was 
achieved by 3-OST-5 modification.  
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IdoA2S-GlcNS6S- (where S is sulfate) repeating units near their reducing ends.  5 differs from 4, 
as it has two 3-O-sulfate groups.  The synthesis of 1 was initiated from a commercially available 
monosaccharide, 1-O-(para-nitrophenyl) glucuronide (GlcA-pNP) (Figure 26).  Elongation of 
GlcA-pNP to a hexasaccharide was accomplished using two bacterial glycosyltransferases: KfiA 
(N-acetylglucosaminyl transferase from E. coli K5 strain) and heparosan synthase 2 (PmHS2) 
from Pasteurella multocida. N-sulfation, O-sulfation and epimerization afforded 1[190].  1 was 
expected to have a comparable pharmacological profile to that of fondaparinux as both have very 
similar structures.  The approach also afforded hexasaccharide 6 (461 mg), a key intermediate for 
subsequent syntheses. 
 
 
Figure 26.  Chemoenzymatic synthetic schemes of Compound 1 and Compound 6.  The synthesis started from 
monosaccharide 1-O-(para-nitrophenyl) glucuronide (GlcA-pNP), which is commercially available. The recovery 
yield at each synthetic step is indicated below the reaction arrow. 
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The syntheses of 2, 3, and 4 were initiated from hexasaccharide 6 through intermediates 
7, 8 and 9, respectively (Figure 25).  These intermediates contain multiple –IdoA2S-GlcNS- 
repeating units, posing a synthetic challenge due to the substrate specificity of C5-epi
25
.  A 
carefully designed sequence of enzymatic steps was employed for high purity and yields.  The 
conversion of GlcA to IdoA2S involves two steps: C5-epi catalyzes epimerization of a GlcA to 
an IdoA; and 2-OST transfers a sulfate group to IdoA.  C5-epi catalyzes both the forward and 
reverse reactions, leading to the incomplete conversion of GlcA to IdoA2S[194] and a complex 
mixture of products[195].  The placement of a pentasaccharide domain, GlcN-
trifluoroacetyl(TFA)-GlcA-GlcNS-GlcA-GlcNS-, into the substrate, directs C5-epi to relatively 
irreversible react only with one GlcA residue and avoids incomplete conversion.   
The conversion of 6 to 7, to construct the pentasaccharide domain recognized by C5-epi, 
was completed in four steps.  The GlcNTFA residue (Residue A) of hexasaccharide 6 was first 
converted to a GlcNS residue (Step a, Figure 25).  The resultant hexasaccharide was then 
elongated to an octasaccharide in two enzymatic steps (step b and c), to obtain the desired 
pentasaccharide domain (dashed box, Figure 25).  The conversion of GlcA (Residue E) to 
IdoA2S in 7 was achieved by C5-epi and 2-OST (step d).  The formation of IdoA2S residue 
removes its reactivity towards further C5-epi modification.  Repeating these steps (steps a to d) 
once or twice afforded 8 and 9, respectively.  The syntheses of 7, 8, and 9 were completed, and 
structural characterization and purity are shown in Appendix Supplementary Figure 1 – 12. The 
octasaccharide 7 and decasaccharide 8 were converted to 2 and 3 respectively after N-sulfation, 
6-O-sulfation and 3-O-sulfation; dodecasaccharide 9 was converted to 4 after 6-O-sulfation and 
3-O-sulfation.  The conversion of 4 to 5 was achieved by 3-OST-5 modification.  Final product 
purity was confirmed by high performance liquid chromatography (HPLC).  Structures were 
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determined by mass spectrometry (MS) and nuclear magnetic resonance (NMR) analysis 
(Appendix Supplementary Figure 13-28).  MS-assisted sequence analysis[196] was employed to 
further prove the structure of 5 (Appendix Supplementary Figure 29-30).   
 
Anticoagulant Activity and Protamine Reversibility of Synthetic LMWH 
 
 
The anticoagulant activities of synthetic LMWHs were determined.  All compounds (1-5) 
displayed strong antithrombin (AT)-binding affinity (Kd 5-30 nM) (Table 3).  Unlike UFH and 
enoxaparin, synthetic LMWHs have no detectable anti-FIIa activity, and thus, these compounds 
are FXa-specific inhibitors.  Our data also suggest that compounds larger than dodecasaccharides 
are required for anti-FIIa activity.  Bemiparin, a “second-generation” LMWH, was recently 
Table 3.  Summary of the properties of synthetic LMWHs [1].   
62 
 
approved by the European Medicines Agency (EMA).  It has significantly lower anti-FIIa 
activity than other LMWH drugs, but has very similar clinical utility, suggesting that LMWH 
anti-FIIa activity is not critical[197]. 
 
 
We next determined the protamine reversibility of the anticoagulant activity of five 
synthetic LMWHs (Figure 27a).  In contrast to the activities of 1–3, the activity of 4 was 
partially reversed by protamine and the activity of 5 was more reversible than enoxaparin and 
showed the same protamine reversibility as UFH activity (Figure 27a). Using an ex vivo mouse 
model, we confirmed that 5 has similar sensitivity to protamine neutralization as UFH. As 
expected, enoxaparin was only partially neutralized by protamine (Figure 27b). Finally, using a 
mouse-tail-clip bleeding model, we demonstrated that protamine shortened the prolongation of 
bleeding time induced by 5 (Figure 27c), confirming the sensitivity of 5 to protamine 
neutralization in vivo. The US FDA has recently approved three new anticoagulants—dabigatran 
Figure 27.  Determination of the anti-FXa activity and sensitivity to protamine neutralization of synthetic 
LMWHs.  (a) FXa activity of synthetic LMWHs in the presence of different concentrations of protamine under 
in vitro conditions. (b) Ex vivo reversibility of anti-FXa activity by protamine. The inhibition of FXa activity by 
the test compounds was significantly affected in the presence of protamine (*P < 0.05 and ****P < 0.0001). 
Data presented in a–b are the average of three to five determinations ± s.d. (c) Effect of 5 and protamine on tail-
bleeding time after tail transection. Protamine significantly shortened the primary bleeding time (**P < 0.01) 
that was induced by 5. Each data point represents the measured value from an individual mouse in the test 
group. Data are presented as mean ± s.d.  
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etexilate, rivaroxaban and apixaban—however, none of these drugs has an antidote. Although 
other strategies to inhibit anticoagulant drugs using an engineered FXa-like protein[198] or 
antithrombin mutant[199] have been reported, these methods remain to be approved by a regu-
latory agency. Synthetic LMWH 5 can be neutralized by protamine, an FDA-approved antidote 
for UFH. 
Superb sensitivity toward protamine neutralization displayed by synthetic 5 suggests that 
both sulfation pattern and size contribute to its sensitivity to neutralization.  Currently marketed 
LMWHs, e.g. enoxaparin, are a mixture of oligosaccharides with a broad size distribution of 
chains, having different affinities towards protamine.  Our data suggest that protamine only 
neutralizes chains in LMWHs that are larger than decasaccharides. Smaller chains, 
pentasaccharide to decasaccharide, can exhibit anticoagulant activity[200], even though they are 
not protamine reversible.  Consequently, only partial neutralization for commercial LMWH can 
be achieved with protamine.  Synthetic 5 has a uniformly high affinity to protamine because it is 
a structurally homogeneous compound.  In addition, our results demonstrate that an extra 3-O-
sulfate group significantly increases the sensitivity for protamine neutralization, suggesting that 
the sulfation pattern plays a critical role in protamine binding.    
Additional efforts are necessary to further advance our findings to a LMWH drug 
candidate.  First, replacement of pNP aglycone should eliminate concerns that it might be 
converted to p-nitrophenol in vivo, leading to a potentially harmful metabolite.  Second, a 
comprehensive structure-activity relationship study will be required to understand the 
contribution of sulfation pattern to the pharmacological effects.   
LMWHs are critical for the practice of modern medicine yet their production still 
depends on a long supply chain, which is vulnerable to contamination and adulteration.  After the 
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contamination crisis, the US FDA and EMA implemented a series of new approaches to monitor 
the purity of heparin drugs.  Although these efforts have stopped the influx of contaminated 
heparin into the market, a long term solution should be to manufacture synthetic heparin under 
highly regulated processes, eliminating the need for animal-sourced heparin[182, 193].  
Chemoenzymatic synthesis offers a promising approach towards this goal.  A homogeneous 
product reduces the complexity for the quality control during the manufacturing process, and is 
compatible with standard approval processes by regulatory agencies[201].  While the structures 
produced through chemoenzymatic synthesis are limited by the substrate specificities of the 
enzymes, their synthetic capability can be expanded through better understanding of enzyme 
properties.  As demonstrated in the present study, a firm understanding of C5-epi specificity 
resulted in the design of a modification sequence leading to the synthesis of the critical -IdoA2S-
GlcNS- repeating domain.  The next challenge will be to determine whether a large-scale 
synthesis of homogeneous LMWH can be accomplished to meet the needs of the anticoagulant 
drug market.  The synthesis of 5 requires 22 synthetic steps with the yield around 7%, but it is 
significantly more efficient than the synthesis of fondaparinux that requires 50 steps with 0.1% 
yield [202].  Fondaparinux is now synthesized in kg-scale, and has been a profitable drug for ten 
years.  The success of fondaparinux suggests that further development of the chemoenzymatic 
approach will result in cost-effective products, accelerating the modernization of LMWH 
therapeutics.  
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Synthesis of Less Abundant Heparan Sulfate Oligosaccharide Library 
Introduction 
Proteoglycans mediate many protein functions and physiological processes ranging from 
cell development, differentiation, inflammation, viral or parasite infection, metastasis to cancer 
[2]. Proteoglycans comprise a core protein and various glycosaminoglycans (GAG) side chains.  
Although the amino acid sequence of the core protein is encoded by a specific gene, the GAG 
side chains are generated by a non-template enzymatic process [35, 203, 204]. Heparin and 
heparan sulfate (HS) are members of this polysulfated GAG family.  
Heparin, a widely used clinical anticoagulant since the 1930’s, was the first biopolymeric 
drug and is one of the few carbohydrate based drugs [11, 12]. Because of the heterogeneity of 
heparin sequences, understanding the contribution of a specific sulfated carbohydrate sequence 
for a given biological activity remains challenging.  Heparin is a mixture of polysaccharides and 
has high polydispersity and polyheterogeneity [12] as well as flexible structural characteristics 
[11]. In addition, heparin is a highly sulfated polysaccharide with an average molecular weight of 
~17 kDa [13] and with a range of chain lengths from 5,000 to 50,000 Da [14].  Heparin has 
repeating disaccharide units consisting of uronic acid (90% L-iduronic acid, IdoA, and 10% D-
glucuronic acid, GlcA) linked 1 → 4 to D-glucosamine (GlcN) [15], where the glucosamine 
residues can be either N-acetylated (GlcNAc) or sulfated (GlcNS). The GlcN monosaccharide 
can also contain O-sulfo groups, including 6-O- and 3-O-sulfation, while the GlcA and IdoA 
residues can be 2-O-sulfated.  Heparan sulfate (HS) is structurally analogous to heparin.  HS has 
a similar disaccharide repeating structure to heparin with some noticeable differences.  
Generally, the size of the HS chains is longer with an average MW of 30 kDa [16], and HS 
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contains a higher GlcA content and less sulfation than heparin [12]. In addition, HS has more 
diverse sulfated saccharide sequences and domain structures compared with heparin. 
Reliable structural characterization techniques are critically important to safeguard the 
quality of heparin drugs. In 2008, batches of contaminated heparin were discovered in US, which 
drew significant public attention because the contaminated drug killed 94 patients in US [68]. 
Nuclear Magnetic Resonance (NMR) techniques were employed, and rapidly identified the 
nature of the contaminant to be over sulfated chondroitin sulfate, demonstrating the important 
role of NMR measurements in heparin quality control [11]. NMR data provides structural 
information that cannot be obtained by other methods, specifically; epimer recognition, anomeric 
configuration identification, sulfated position determination, and conformation and secondary 
structure determination. One limitation in utilizing NMR to analyze the structure of heparin or 
HS is that these species are a mixture of compounds and pure oligosaccharide standards have not 
been available.  Although certain oligosaccharides have been isolated from partially 
depolymerized heparin or HS, obtaining sufficient amounts of those highly purified 
oligosaccharides is a difficult and time consuming process.  
Recently, a new method using recombinant HS biosynthetic enzymes to prepare 
structurally homogeneous HS oligosaccharides was developed [1]. This method allows the 
synthesis of a series of structurally homogeneous heparin or HS oligosaccharides at the scale of 
tens to hundreds of milligram with high yield. Access to highly purified HS oligosaccharides 
allows for full-scale analyses of these complex molecules by NMR. Notably these synthetic 
compounds enable the analysis of structurally “rare” oligosaccharides which are difficult to 
isolate in sufficient quantity for NMR analysis. For example, the -GlcA2S- residue represents 
only 1-5% of total uronic acid in heparin isolated from natural sources [77].  
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Here, to address this knowledge gap of the structure characteristics of these potentially 
important oligosaccharide species, we report the NMR analysis of a series of GlcA2S-containing 
hexasaccharides with different sulfation patterns. The GlcA2S oligosaccharides were prepared 
by a chemoenzymatic approach.  The GlcA2S NMR data was compared with the data obtained 
from IdoA2S-containing oligosaccharides synthesized by the same method. The data confirm 
previous assignments for the NMR signals of GlcA2S saccharides [77]. 
 
Chemoenzymatic Synthesis of GlcA2S- and IdoA2S-Containing Hexasaccharides 
 
Total of eight hexasaccharide constructs 1 to 8 were synthesized in this study using a 
chemoenzymatic approach (Figure 28). The synthesis was initiated from a commercially 
available monosaccharide, 1-O-(para-nitrophenyl) glucuronide (GlcA-pnp), requiring elongation 
steps, sulfation and epimerization steps (Figure 29) [1].  
Figure 28.  The synthetic hexasaccharide constructs 1 to 8.  A total of eight synthetic hexasaccharides were 
prepared in this study. 
68 
 
 
 
In the synthesis, a hexasaccharide with a structure of GlcNTFA-GlcA-GlcNS-GlcA-
GlcNS-GlcA-pnp is a crucial intermediate. The N-trifluoroacetyl group of this hexasaccharide 
intermediate was hydrolyzed to yield construct 1 by treatment with lithium hydroxide. Then this 
hexasaccharide intermediate was treated with a mixture of C5-epi and 2-OST to yield a mixture 
of GlcA2S- and IdoA2S-intermediate.  An anion-exchange HPLC method was used to isolate 
and purify those two products with a ratio of 1:9 (Figure 30A).   
Figure 29.  Chemoenzymatic synthesis of GlcA2S- and IdoA2S-containing hexasaccharides.  The 
chemoenzymatic synthetic scheme for hexasaccharides includes the backbone elongation and saccharide 
modification steps. The synthesis was initiated from a commercially available monosaccharide, 1-O-(para-
nitrophenyl) glucuronide (GlcA-pnp), requiring elongation steps, sulfation and epimerization steps to synthesize 
hexasaccharide intermediate and construct 1 to 8. The modification site is highlighted in blue color.  
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After the purification, a GlcA2S- intermediate was obtained with the purity greater than 
93% as determined by anion-exchange HPLC (Figure 30B).  Similarly, an IdoA2S-intermediate 
was obtained with the purity greater than 96% (Figure 30C).  The GlcA2S-intermediate was 
further converted to construct 2 by detriflouroacetylation under an alkaline condition.  Additional 
modifications were made, including N-sulfation and 6-O-sulfation, yielded to construct 3 and 4, 
Figure 30.  Two major products of epimerization and 2-O-sulfation.  Panel A shows the anion-exchange 
HPLC chromatogram after epimerization/2-O-sulfation of hexasaccharide intermediate. The product contains 
10% GlcA2S-intermediate and 90% IdoA2S-intermediate. Panel B and C show the anion-exchange HPLC 
chromatogram of GlcA2S-intermediate and IdoA2S-intermediate after purification. The purity is greater than 
93% and 96%, respectively. The chemical structure of GlcA2S-intermediate and IdoA2S-intermediate are 
shown on right of Panel B and C. 
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respectively. Similarly, the IdoA2S-intermediate was transformed to construct 5, 6 and 7. 3-O-
sulfation was carried out on construct 7 to form construct 8. The purity analysis of each 
synthesized oligosaccharide and mass spectrometric analyses are shown in the Supplementary 
data (Figure 31-32).  
 
 
Figure 31.  Mass and HPLC analysis of construct 1 to 4.  Panel A, B, C and D show the ESI-MS 
spectrometry and anion-exchange HPLC chromatogram of construct 1, 2, 3 and 4, respectively. The chemical 
structure is shown on top of each Panel. Monoisotopic peak mass and charge ratio (m/z) values are shown for 
different charge states in negative electrospray ionization (ESI) mode. 
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The GlcA2S residue is present in low abundance in heparin, and thus, very limited 
information about the role of such rare saccharide residues has been obtained.  In this work, we 
demonstrate the synthesis and structural characterization of highly pure oligosaccharides 
containing GlcA2S. The synthesis of three GlcA2S containing hexasaccharides was completed 
through a chemoenzymatic approach. The substrate specificity of 2-OST modifies only one of 
the two GlcA in the hexasaccharides, allowing us to position the GlcA2S residue at the desired 
site (Figure 29). Although the synthesis of a number of HS hexasaccharides using a chemical and 
Figure 32.  Mass and HPLC analysis of construct 5 to 8.  Panel A, B, C and D show the ESI-MS 
spectrometry and anion-exchange HPLC chromatogram of construct 5, 6, 7 and 8. The chemical structure is 
shown on top of each Panel. Monoisotopic peak mass and charge ratio (m/z) values are shown for different 
charge states in negative electrospray ionization (ESI) mode. 
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chemoenzymatic approach has been reported [163, 205], the synthesis of GlcA2S-containing 
hexasaccharide variants described in this research is novel.  
 
Structural Characterization of 2-O-Sulfated Glucuronic Acid (GlcA2S)- and Iduronic Acid 
(IdoA2S)- Containing Oligosaccharides 
NMR Analysis of Hexasaccharides 
The availability of high purity structurally defined hexasaccharides provided us sufficient 
quantities for NMR analyses.  The 
1
H-NMR spectra of GlcA-containing hexasaccharide 
(construct 1) and GlcA2S-containing hexasaccharides, including construct 2, 3 and 4, are shown 
in Figure 33; the 
1
H-NMR spectra of IdoA2S-containing hexasaccharides, including construct 5 
to 8, are shown in Figure 34.  The clustered proton signals from the saccharide residues made the 
assignments difficult.  Therefore, 2D-homonuclear and -heteronuclear correlation spectroscopy 
analyses (
1
H-
1
H COSY, TOCSY,
 1
H-
13
C HSQC, and HMBC) were conducted; however the 
analyses only partially resolved the overlapped signals.  Thus, 2D 
1
H-
13
C HSQC-TOCSY NMR 
experiments (Figure 35) was employed to resolve these signals.  The fully assigned signals for 
constructs 1-8 are listed in Table 4 and 5. 
 
Characterization of GlcA2S-Containing Oligosaccharides 
 Construct 3 (with the structure of GlcNS-GlcA-GlcNS-GlcA2S-GlcNS-GlcA-pnp) was 
used to demonstrate how the signals of GlcA2S were identified in the synthesized 
oligosaccharides. In the 
1
H-NMR spectrum of construct 3, the signals from anomeric protons of 
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the three GlcNS units are located around 5.6 ppm, and the signals from GlcA/GlcA2S are located 
around 4.6 ppm (Figure 33-34). The ~5.3 ppm shift of I-1 is attributed to the effect of the nearby 
electron withdrawing group, para-nitrophenyl (pnp). The 
3
JHH coupling constants of I-1, III-1, 
and V-1 were ~8 Hz (consistent with β linkages), and II-1, IV-1, and VI-1 were ~4 Hz 
(consistent with α linkages). Other saccharide ring proton signals were highly overlapped and 
resonated between 3.2 and 4.1 ppm. 
 
 
Figure 33.  
1
H-NMR spectra of construct 1, 2, 3 and 4.  Panel A, B, C and D show the 
1
H-NMR spectrum of 
construct 1, 2, 3 and 4, respectively.  The signals of anomeric protons and some non-overlapping protons are 
indicated.  The chemical structure of construct is shown on top of each panel. The 
1
H-NMR spectra represent 
the range between 3.1 and 5.7 ppm. 
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The increased shift dispersion in 2D 
1
H-
13
C HSQC-TOCSY NMR, fully resolved these 
signals so that assignments could be made (Figure 35).  In addition, 
1
H-
1
H COSY and 
1
H-
13
C 
HSQC analysis were run with better digital resolution to allow more accurate identification of 
the proton and carbon assignments (Table 4-5). The assignments for other GlcA2S-containing 
hexasaccharides were conducted in a similar manner. 
 
Figure 34.  
1
H-NMR spectra of construct 5, 6, 7 and 8.  Panel A, B, C and D show the 
1
H-NMR spectrum of 
construct 5, 6, 7 and 8, respectively.  The signals of anomeric protons and some non-overlapping protons are 
indicated.  The chemical structure of construct is shown on top of each panel. The 
1
H-NMR spectra represent 
the range between 3.1 and 5.7 ppm. 
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Figure 35.  2D 
1
H-
13
C HSQC-TOCSY NMR spectrum of construct 3.  2D 
1
H-
13
C HSQC-TOCSY NMR 
experiment was employed to characterize the structure of construct 3. The signals of protons are indicated. The 
signals are connected with lines identifying correlated protons on each saccharide residue.  The chemical 
structure of construct 3 is shown on top of the Figure. 
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Table 4.  
1
H–13C NMR chemical shift assignments (in ppm) of Constructs 1–4 (25°C, D2O, pD 7.0). 
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The 2D-
1
H-
13
C HMBC experiment confirmed the glycosidic linkages between each 
saccharide unit through 
3
J correlations between the anomeric II-1, III-1, IV-1, V-1 or VI-1 
protons show connectivity to the I-4, II-4, III-4, IV-4 or V-4 carbons, respectively (Figure 36). 
These connectivities allowed sequencing of the hexasaccharides. In addition, the anomeric I-1 
proton shows a 
3
JCH-correlation with the quaternary carbon of the pnp tag. Furthermore, the II-6, 
IV-6 or VI-6 protons shows through-bond connectivity to II-4, IV-4 or VI-4 carbons, 
respectively, supporting the assignments of glucosamine residues. The other GlcA2S-containing 
hexasaccharides were characterized by following the same approach. In addition to 
1
H-
1
H COSY 
and 
1
H-
13
C HSQC experiments, we focused on using 2D 
1
H-
13
C HSQC-TOCSY NMR to 
identify the residue spin systems and 2D 
1
H-
13
C HMBC NMR to confirm the linkages. 
Table 5.  
1
H–13C NMR chemical shift assignments (in ppm) of Constructs 5–8 (25°C, D2O, pD 7.0). 
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Comparing the NMR spectra of construct 1 with construct 2 provides evidence of the 
influence of 2-O-sulfation on the neighboring residues (Figure 33). The signals of III-1, III-2 and 
III-3 from construct 2 are shifted +0.17, +0.73 and +0.17 ppm (to 4.70, 4.11, and 4.02 ppm), 
respectively, due to the attached 2-O-sulfo group. Notably, the shift of proton II-1 (-0.12 ppm), 
II-6b (+0.11 ppm), and VI-2 (-0.15 ppm) are also sensitive to 2-O-sulfation even though they are 
Figure 36.  
1
H-
13
C HMBC key correlations of construct 3.  2D 
1
H-
13
C HMBC NMR experiment was 
employed to confirm the glycosidic linkages between each saccharide unit of construct 3. The signals of 
anomeric protons are indicated. The peaks are connected with lines identifying correlated carbon and proton.  
The chemical structure of construct 3 is shown on top of Figure. Some other key 
3
JCH-correlations are shown as 
dashed lines on the chemical structure.  
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distant from the site of substitution. The chemical shift changes of II residue are attributed to 
inter-residue influences between this additional 2-O-sulfo group. The effect on VI-2 may be due 
to charge-to-charge interaction between the positively charged unsubstituted amino group and 
the negatively charged 2-O-sulfo group. The ~8 Hz axial-axial proton coupling constants of the 
III residue remains unchanged indicating that the GlcA2S conformation remains predominately 
in the 
4
C1 form in Construct 2 and is the same as GlcA in Construct 1 [206].  
To reveal the structural flexibility of GlcA2S and IdoA2S residues, we compared the 
proton spectra of GlcA2S-containing hexasaccharides with IdoA2S-containing hexasaccharides, 
focusing on the signals of the Residue III. The measurements of 
3
JHH coupling constant reflect 
the change of saccharide conformation. The coupling constant (doublet, 8.0 Hz) of III-1 signal of 
GlcA2S in construct 2 remains same as that in construct 3 and 4, suggesting that the 
conformation of GlcA2S is relatively unaffected by the extra sulfo groups (Figure 33). This 
result is consistent with that GlcA2S predominately maintain the 
4
C1 conformation as GlcA in 
construct 1 [206]. We observed that broad signals for IdoA2S (residue III) (Figure 34).  The 
addition of EDTA significantly sharpened the IdoA2S signals. Similarly, the coupling constants 
of III-5 signals are also sensitive to different sulfation patterns, suggesting that conformational 
distribution of IdoA2S is affected by different sulfation pattern. For example, the 
3
JHH coupling 
constants of III-1 (2.2 Hz) and III-5 (2.2 Hz) signal in construct 5 are increased to (3.7 Hz) and 
(3.1 Hz) in construct 8 due to the presence of additional sulfo groups. These changes are 
attributed to greater structural flexibility of IdoA2S residue compared to GlcA2S in these 
constructs. This result is consistent with the previously reported that IdoA2S equilibrates 
between 
2
S0 (skew boat) and 
1
C4 (chair) conformers [82, 206].  
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The presence of GlcA2S or IdoA2S also impacted the chemical environment of 
neighboring saccharide residues. We compared the signals from each proton of GlcA2S- and 
IdoA2S-containing hexasaccharides (Table 6). As expected, signals from Residue III displayed 
the largest difference in chemical shifts.  Outside Residue III, significant differences in the 
chemical shifts were observed for the protons of Residue II (II-1, II-3, II-6), and protons of 
Residue IV (IV-1 and IV-5) (Table 3).  For example, comparing the IV-1 proton in construct 2 
and 5, the signals are shifted by 0.34 ppm.  Similarly, between construct 3 and 6 the IV-1 proton 
was shifted by 0.32 ppm and 0.22 ppm between construct 4 and 7, respectively. These data 
suggest the presence of GlcA2S or IdoA2S has different effects on the chemical environment of 
neighboring residues. Beyond Residue II and IV, chemical shift differences between GlcA2S- 
and IdoA2S-hexasaccharides diminished significantly. Some differences in chemical shifts were 
observed from Residue VI, an N-unsubstituted glucosamine residue in construct 2 and 5, 
suggesting that the presence of a primary amino group (-NH2) of this end residue is sensitive to 
GlcA2S vs IdoA2S residues. 
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Intramolecular Effects by N-sulfation, 6-O-sulfation, and 3-O-sulfation 
Comparing the chemical shifts of the signals from hexasaccharides bearing N-
unsubstituted versus N-sulfated Residue VI suggests the intramolecular interaction between the 
N-sulfo groups and the GlcA residue at its reducing end.  The chemical shifts of the V-3 signals 
in construct 2 and 3 are differed by +0.08 ppm; similarly, the signals of V-3 proton in construct 5 
and 6 are different by +0.10 ppm (Table 4 and 5). These effects may attribute to the function of 
acidic sulfo group masking the basic amino group on VI residue and altering the chemical 
Table 6.  
1H NMR chemical shift difference (Δδ) by subtracting GlcA2S- from IdoA2S-containing 
hexasaccharides.  Listed values represent chemical shift difference ≥0.05 ppm.  
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environment around the V residue. These observations also support by the molecular dynamics 
simulation result that an interaction exits between the N-sulfo group of Residue VI and the V-3 
position of Residue V as proposed by Langeslay and colleagues through the analysis of the 
structure of fondaparinux [207].  Another interesting observation is the impact of N-sulfation on 
the chemical shift of VI-2 signals. In GlcA2S-containing hexasaccharides, N-sulfation shifts the 
VI-2 signal to higher ppm (+0.06 ppm) probably due to the effects of de-shielding (less local 
electron density). By contrast, in IdoA2S-containg hexasaccharides, the N-sulfation shifts the VI-
2 signal to lower ppm (-0.07 ppm) due to increased shielding (more electron density).  Such 
different effects suggest more complicated through space interactions between the saccharide 
residues, which could involve in the participation of IdoA2S or GlcA2S residue; however, the 
available techniques do not permit us to dissect these interactions. 
As expected, 6-O-sulfation clearly shifts the proton resonances of Residues II, IV and VI 
in both GlcA2S-containg and IdoA2S-containing hexasaccharides (Table 4 and 5). The presence 
of 6-O-sulfation also affects the chemical environments of the neighboring residues.  For 
instance, Residue V in construct 4 is flanked by two GlcNS6S resides (Residue IV and VI), the 
signal of V-1 is shifted by +0.08 ppm in comparison with the signal of construct 3.  Similarly, a 
chemical shift difference for the V-1 proton was also observed (+0.07 ppm) between construct 6 
and 7 (Table 1 and 2).  These data suggest that the impact of 6-O-sulfation on the neighboring 
residues can be observed in both GlcA2S-containing and IdoA2S-containing hexasaccharides.   
The availability of 3-O-sulfated construct 8 and non-3-O-sulfated construct 7 
differentiates the impact of 3-O-sulfation on the distribution of IdoA2S residue conformers.  The 
3-O-sulfation on Residue IV alters the conformation of its reducing-end IdoA2S residue 
(Residue III) as demonstrated by changes in the coupling constant of IdoA2S signals. For 
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example, the 
3
JHH coupling constants of III-1 and III-5 are larger in construct 8 (3.7 Hz, 3.1 Hz) 
than in construct 7 (3.0 Hz, 2.7 Hz) (Supplementary Fig S5), suggesting an increased proportion 
of 
2
S0 conformation for Residue III in construct 8.  Indeed, Guerrini and colleagues demonstrated 
that 3-O-sulfated glucosamine residue influences the IdoA2S residue conformational equilibrium 
between 
1
C4 and 
2
S0 [208].  
   
Antithrombin Binding and Anti-Xa Activity of Less Abundant Heparan Sulfate   
 Contribution of GlcA2S and IdoA2S to the Binding Affinity to Antithrombin 
Heparin binds antithrombin to exert its anticoagulant activity.  Within heparin a unique 
pentasaccharide sequence, -GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-, has been shown to 
display high binding affinity. Previous work has suggested that IdoA2S in this pentasaccharide 
domain contributes to the binding to antithrombin [209]. To confirm this conclusion, the binding 
affinity to antithrombin of the IdoA2S versus GlcA2S constructs was determined. Both 3-O-
[
35
S]sulfated GlcA2S-containing hexasaccharide and IdoA2S-containing hexasaccharide were 
prepared for the analysis. The result showed that IdoA2S-containing hexasaccharide binds to 
antithrombin with a dissociation constant (Kd) of 12 ± 3 nM, whereas no binding affinity was 
measurable for GlcA2S-containing hexasaccharide.  Our result confirmed the essential role of 
IdoA2S in antithrombin binding.    
The chemoenzymatic approach allows the construction of diverse hexasaccharide analogs 
containing antithrombin-binding domain to confirm the contribution of IdoA2S and GlcA2S 
residue to the binding affinity to antithrombin.  Our data suggest that GlcA2S-containing 
hexasaccharide does not bind to antithrombin despite the fact it carries 3-O- and 6-O-sulfo 
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groups, confirming the previously reported essential role of IdoA2S for high affinity binding to 
antithrombin [10, 210, 211]. 
The NMR structural analysis data are consistent with the hypothesis that GlcA2S is a 
relatively structural rigid unit in heparin and HS compared to IdoA2S.  Compared with the 
signals of the IdoA2S residue, the 
3
JHH coupling constants are unchanged for the GlcA2S 
residue.  The 
3
JHH coupling constants of GlcA ring protons in all constructs are about 8.0 Hz as 
reported previously as 
4
C1 form [206]. In our studies, the coupling constant of GlcA2S ring 
protons in the synthesized hexasaccharide show equal values, supporting the conformation of 
GlcA2S remains predominately in the 
4
C1 form as well.  In contrast, the protons of IdoA2S 
display smaller and various coupling constants in the constructs, consistent with the fact that the 
conformations of the IdoA2S residue are in the equilibrium between 
2
S0 and 
1
C4 forms.   
The 
2
S0 conformation of IdoA2S is known to contribute to antithrombin binding affinity 
[210-212]. Indeed, IdoA2S-containing hexasaccharide displayed high affinity with a Kd value of 
12 nM, while no detectable antithrombin-binding affinity for GlcA2S-containing hexasaccharide 
was observed.  Importantly, the conformation of the IdoA2S residue can be affected by the 
protein that interacts with it as well as the neighboring sulfated saccharide residues. For example, 
binding of fibroblast growth factor 1 (FGF1) requires 
1
C4 form of IdoA2S that is flanked by 
GlcNS6S residues [213-215]; however, in the absence of nearby GlcNS6S residue, IdoA2S could 
rearrange its conformation from 
2
S0 to 
1
C4 form which binds FGF2 [216, 217]. Possibly, the 
IdoA2S conformation flexibility plays a role in orienting the oligosaccharide to increase its 
binding affinity to a specific protein. 
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Discussion 
Using highly purified GlcA2S- and IdoA2S-containing hexasaccharides synthesized by 
the chemoenzymatic approach, we successful fully assign all the proton and carbon chemical 
shifts of GlcA2S and IdoA2S-containing oligosaccharides through 1D and 2D NMR 
experiments. We compared the assignments obtained from our study with the previously 
reported values.  The proton assignments of GlcA2S signals in this study are similar to the 
previous reports, where the GlcA2S residue is flanked by GlcNS6S and GlcNS residue in a 
tetrasaccharide [208, 218-220]. The anomeric carbon assignment of GlcA2S was also reported 
[77], and our result is consistent with the reported values.  In the reports, only partial 
assignments were achieved for GlcA2S residues. Here, we provide the full assignments for the 
GlcA2S residue within different sulfated saccharide contexts. The assignments for IdoA2S are 
consistent with previous reports; however an IdoA2S residue flanked by two GlcNS3S6S 
residues show significant difference on proton and carbon assignments [208]. The GlcNS3S6S 
residues may participate in the change of chemical environment and conformation equilibrium of 
neighboring IdoA2S residue, causing significant changes in chemical shifts.  
Taking advantage of these chemical shift assignments, the presence of GlcA2S can be 
easily distinguished from mixture of GlcA2S- and IdoA2S-containing oligosaccharides within 
NMR spectra. 2D 
1
H-
13
C HSQC NMR is a powerful tool for fingerprint the GlcA2S residue, and 
the 
1
H-
13
C correlation of III-1 and III-2 position signals from this residue is easily observable 
(Figure 37). The cross peak of GlcA2S anomeric signal is also consistent to the signal observed 
in enoxaparin [77] or porcine intestinal heparin [221], demonstrating the capability of using the 
2D-NMR fingerprint method to confirm the authenticity of heparin drugs.  Very interestingly, 
the anomeric signals of GlcA2S were reportedly difficult to identify in unfractionated heparin 
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and low-molecular weight heparins; however, such signals are visible in enoxaparin, a low-
molecular weight heparin manufactured by depolymerized unfractionated heparin under basic 
conditions [77, 222].  
 
 
Since the 2008 contaminated heparin crisis, NMR analysis of heparin drug has become 
part of the heparin sodium US Pharmacopeia monograph. Because heparin is a heterogeneous 
polysaccharide mixture, the assignment of all of the signals is difficult. To this end, acquiring the 
NMR spectra of highly purified heparin oligosaccharide standards provides a map for assigning 
Figure 37.  2D 
1
H-
13
C HSQC NMR spectrum of GlcA2S- and IdoA2S-containing oligosaccharide mixture.  
2D 1H-13C HSQC NMR experiment was employed to distinguish the presence of GlcA2S and IdoA2S residue 
from mixture of GlcA2S- and IdoA2S-containing oligosaccharides. The chemical structure of oligosaccharide 
mixture is shown on top of the Figure. The distinguishable signals of GlcA2S and IdoA2S residue are 
highlighted in different colors. The GlcA2S residue and its signals are highlighted in blue color. The IdoA2S 
residue and its signals are highlighted in green color. 
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highly complex heparin spectra, especially those signals from rare components.  Our study 
should assist NMR analysis of heparin to safeguard the heparin drug. 
 
Conclusions 
Low molecular weight heparins (LMWHs) are carbohydrate-based anticoagulants 
clinically used to treat thrombotic disorders, but impurities, structural heterogeneity or functional 
irreversibility can limit treatment options.  We report a series of synthetic LMWHs prepared by 
cost-effective chemoenzymatic methods.  The high anti-FXa activity of structural defined 
synthetic LMWH was reversible in vitro and in vivo using protamine, demonstrating 
synthetically accessible constructs can play a critical role in the next generation of LMWHs. 
Heparan sulfate and heparin are highly sulfated polysaccharides that consist of a 
repeating disaccharide unit of glucosamine and glucuronic or iduronic acid.  The 2-O-sulfated 
iduronic acid (IdoA2S) residue is commonly found in heparan sulfate and heparin; however, 2-
O-sulfated glucuronic acid (GlcA2S) and non-sulfated iduronic acid (IdoA) are less abundant 
monosaccharides (~<5% of total saccharides).  Here, we report the synthesis these less abundant 
HS component molecules including GlcA2S-containing (Chapter III) and IdoA-containing 
hexasaccharides (Chapter V) using a chemoenzymatic approach. For comparison purposes, 
additional IdoA2S-containing hexasaccharides were synthesized.  NMR analyses were 
performed to obtain full chemical shift assignments for the GlcA2S-, IdoA- and IdoA2S-
hexasaccharides.  These data show that GlcA2S is a more structurally rigid saccharide residue 
than IdoA and IdoA2S.  The antithrombin binding affinities of synthetic oligosaccharides were 
determined by affinity co-electrophoresis. In contrast to IdoA- and IdoA2S-hexasaccharides, the 
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GlcA2S-hexasaccharide does not bind to antithrombin, confirming that the presence of IdoA or 
IdoA2S is critically important for the anticoagulant activity. The availability of pure synthetic 
common and less abundant HS oligosaccharides can not only serve as referencing standards to 
secure the drug components, but also allow the investigation of the structure and activity 
relationship of individual molecules of heparin or heparan sulfate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
_____________________________ 
1Part of this chapter previously appeared as two articles in the Journal of Biological Chemistry and Chemical Communications.  The original 
citations are as follows: C. Liu, J. Sheng, J. Krahn, L. Perera, Y. Xu, P. H. Hsieh, J. Liu, L. Pedersen, “Molecular mechanism of substrate 
specificity for heparan sulfate 2-O-sulfotransferase, Journal of Biological Chemistry,” 2014, 13407–13418;  W. Zhou‡, P. H. Hsieh‡, Y. Xu, T. 
R. O’Leary, X. Huang, J. Liu, “Design and synthesis of active heparan sulfate-based probes,” Chemical Communications, 51, 2015, 11019-11021 
(‡contributed equally) 
 
 
Chapter IV 
Utilize Heparan Sulfate Based Probe to Investigate Interaction with Proteins
1
 
 
Substrate Specificity Revealed by Crystal Structure of 2-O-Sulfotransferase 
Introduction 
The heparan sulfate 2-O-sulfotransferase (2-OST) is a key enzyme in the HS biosynthetic 
pathway.  2OST is responsible for the transfers of a sulfo group to the 2-OH position of 
preferentially IdoA, and to a limited extent GlcA, within HS polysaccharides to form 2-O-
sulfated iduronic acid (IdoA2S) or 2-O-sulfated glucuronic acid (GlcA2S).  The IdoA2S unit is a 
common structural motif found in cellular HS, and is required for binding several growth factors 
and is essential for triggering growth factor–mediated signal transduction pathways [223, 224].  
The critical physiological functions of IdoA2S residues have been revealed through numerous 
studies. 
Better understanding of the enzymes used in the chemoenzymatic approach should aid in 
the production of heparin-based therapeutics tailored for specific disease targets.  However, the 
cellular mechanism regulating HS biosynthesis is largely unknown.  Understanding the substrate 
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specificities and mechanisms of HS biosynthetic enzymes is crucial for dissecting this 
fundamental process.  In this article, we report a crystal structure of a ternary complex of 2OST 
with 3’-phosphoadenosine 5’-phosphate (PAP) and a heptasaccharide acceptor substrate (Figure 
38). 
 
 
NMR Analysis of Heptasaccharide Substrate 
The structure of oligosaccharides constructs and intermediates were analyzed by NMR 
experiments, including 1D- (
1
H and 
13
C), 2D- (
1
H-
1
H COSY, TOCSY,
 1
H-
13
C HSQC) NMR.  
NMR experiments were performed at 298 K with a Varian Inova 500 MHz spectrometer 
Figure 38.  Crystal structure of the 2-OST trimer.  A) Chemical structure of the heptasaccharide substrate  
used in the ternary complex.  B) Crystal structure of the 2OST trimer with each monomer (colored dark blue, 
slate, light blue) bound to a molecule of PAP (pink) and heptasaccharide substrate (green) (monomers D,E and 
F). The C-terminus of each subunit (circled in magenta) extends into the active site of the neighboring molecule.  
C) Figure 1B rotated 90° with respect to the horizontal axis in the plane of the paper. 
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equipped with 5mm triple resonance XYZ or broadband PFG probe and processed by VnmrJ 
2.2D software.  Samples (2 mg) were each dissolved in 0.5 mL D2O (99.994%, Sigma, Co.) and 
lyophilized three times to remove the exchangeable protons. The samples were re-dissolved in 
0.5 mL D2O and transferred to NMR microtubes (OD 5 mm, Norrell). 1D 
1
H-NMR experiments 
were performed with 256 scans and an acquisition time of 768 msec. 1D 
13
C-NMR experiments 
were performed with 40000 scans, 1.0 sec relaxation delay, and an acquisition time of 1000 msec. 
2D (
1
H-
1
H COSY, TOCSY,
 1
H-
13
C HSQC) spectra were recorded with carbon decoupling, 1.5 
sec relaxation delay, during 204 msec acquisition time with 500 increments for 48 scans.  
Taking advantage of 1D and 2D NMR experiments, we are able to assign anomeric 
protons and chemical shifts of saccharide E with GlcA or IdoA in the heptasaccharides.  Series 
of IdoA proton signals are E1 (4.94 ppm, very broad), E5 (4.76 ppm, very broad), E3 (4.09 ppm, 
broad), E4 (4.04 ppm, broad), and E2 (3.72 ppm, broad) from downfield to upfield.  HSQC 
spectra of compound confirmed the presence of IdoA residue in compound. In the 
1
H NMR 
spectrum of compound, the proton peaks of IdoA also showed as smaller coupling constants or 
broad shape, not typically larger axial-axial coupling constants in GlcA, supporting the existence 
of IdoA and possibly fast conformational equilibrium among chair (
4
C1 and 
1
C4) and skew-boat 
(
2
S0) conformers.  
 
Crystal Structure of 2OST with Bound Heptasaccharide 
Here, we report the crystal structure of the ternary complex of 2OST, 3’-
phosphoadenosine 5’-phosphate, and a heptasaccharide substrate.  Utilizing site-directed 
mutagenesis and specific oligosaccharide substrate sequences, we probed the molecular basis of 
specificity and 2OST’s position in the ordered HS biosynthesis pathway.   
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Based on the best fit to the electron density, the acceptor saccharide was modeled as an 
IdoA in the 
4
C1 conformation (Figure 39).  Because the resolution (3.45 Å) does not allow for 
unambiguous identification of the sugar or ring conformation at the acceptor site, molecular 
dynamic simulations were carried out on all four sugar conformations for 25ns.  The 
conformations 
1
C4 and 
2
S0  have been previously reported as preferred conformations for HS 
structures[187, 225]. Among the three possible conformations for IdoA, the 
4
C1 conformation 
displayed the strongest binding energy (E) (Table 2), supporting the crystallographic 
assignment of saccharide E as an IdoA in the 
4
C1 conformation while binding 2OST.  However, 
given the relatively small range for the binding energies of the IdoA conformations, coupled with 
the inherent errors in the calculation of binding energy for this system, it is difficult to rule out 
any of the three IdoA conformations. 
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This study indicates that a pentasaccharide is the minimum size required for sulfation by 
2OST.  The crystal structure suggests saccharides C-G of the heptasaccharide form all of the 
observed specific interactions with the protein.  These studies revealed that Arg80, Lys350, and 
Arg190 of 2OST interact with the N-sulfo groups near the modification site, consistent with the 
dependence of 2OST on N-sulfation.  Within the required pentasaccharide 2OST recognizes a 
Figure 39.  Refinement of different conformations of the acceptor saccharide.  A) Refinement of saccharide 
E as Ido A in the 
4
C1 conformation (green).  B,C,D) Refinement of saccharide E as either GlcA in the 
4
C1 
conformation, IdoA 
2
S0, or IdoA 
1
C4 respectively ( yellow) superimposed with the IdoA 
4
C1 structure (green).  
The simulated annealing omit Fo-Fc map contoured at 4.0  is displayed in black. Positive Fo-Fc density from 
each respective refinement is shown in green (3.0 )  and negative density (3.0 )  is shown in red.  In figure B 
the black dashed line represents a salt bridge (2.9 Å) between the IdoA and Arg189.  For GlcA this distance is 
4.0 Å (red dashed line) and thus likely does not form a salt bridge. 
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trisaccharide motif with the structure of –GlcNS-GlcA-GlcNS- or –GlcNS-IdoA-GlcNS-.  The 
acceptor IdoA or GlcA residue must be flanked by two N-sulfo glucosamine residues.     
In contrast, 6-O-sulfation on the flanking GlcNS residues of the acceptor site abolishes 
the reactivity to 2OST modification.  Based on the crystal structure, 6-O-sulfation on saccharide 
F, on the reducing side of the acceptor saccharide, would create steric clashes with Pro82 and/or 
Tyr173, interfering with its ability to bind within the substrate binding cleft (Figure 40A).  6-O-
sulfation is also likely selected against on the nonreducing adjacent glucosamine due to charge 
repulsion with Glu349 from the neighboring monomer (Figure 40B).  6-O-sulfo groups on HS 
are likely excluded by steric and electrostatic repulsion within the active site supporting the 
hypothesis that 2-O-sulfation occurs prior to 6-O-sulfation.   
 
 
Figure 40.  Modeling of 6-O-sulfates on the substrate heptasaccharide.  Modeling of 6-O-sulfates on the 
substrate heptasaccharide. A) A 6-O-sulfate on saccharide F would result in steric clashes with Y173 (2.2 Å) 
and P82 (2.4 Å). B) 6-O-sulfate on saccharide D would likely create electrostatic repulsion with E349 (3.0 Å). 
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Our conclusion is consistent with the current sequential model for the HS biosynthetic 
pathway with N-sulfation occurring first, followed by C5-epimerization/2-O-sulfation, 6-O-
sulfation and 3-O-sulfation respectively.  This study provides the structural evidence for 
understanding the sequence of enzymatic events in this pathway.   
 
Synthesis of Heparan Sulfate Oligosaccharides Carrying Diazoacetyl Group 
Introduction 
Heparan sulfate (HS) is a highly sulfated polysaccharide abundantly present on the cell 
surface and in the extracellular matrix.  It participates in a wide range of physiological and 
pathophysiological functions, including embryonic development,[226] inflammatory 
responses,[227] blood coagulation,[228] and viral/bacterial infections.[229]  HS consists of a 
disaccharide repeating unit with glucuronic acid (GlcA) or iduronic acid (IdoA) and 
glucosamine, each of which is capable of carrying sulfo groups.  HS achieves its functions by 
interacting with a variety of proteins.[230]  The positions of sulfo groups and the locations of the 
IdoA residues are critically important for their binding specificities.[231]  There is strong 
demand for methods to decipher the interactions of specific HS structures with their protein 
targets. 
Here, we report a new approach for synthesizing active heparan sulfate based probes 
(AHSBP).  The probe consists of an HS oligosaccharide functionalized with an N-diazoacetyl 
moiety (Figure 41).  It utilizes the saccharide motif as a guiding system to find the protein target 
site. The diazoacetyl group,[232] while stable under neutral pH, upon binding and acidification, 
could be activated to covalently couple the oligosaccharide with the protein and inhibit protein 
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activity.  The effects of AHSBP on two HS biosynthetic enzymes, including 2-O-sulfotransferase 
(2-OST) and 3-O-sulfotransferase (3-OST), were examined to demonstrate the utility of these 
compounds. 
 
 
 
Synthesis and Characterization of Heparan Sulfate Based Probe and Hydrolysis Product 
Figure 41.  Structures of the synthesized AHSBP.  1 and 2 are the substrates for 2-OST and 3-OST 
respectively.  The hydroxyl groups that can be modified by 2-OST and 3-OST are indicated.   
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Synthesis of AHSBP started from the preparation of diazo acylating agent p-nitrophenyl 
diazoacetate 4, which was obtained from the N-hydroxysuccinimide diazoacetate 5[233] in 81% 
yield (Figure 42a).[233]  The oligosaccharides bearing diazoacetyl functionalized glucosamine 
(GlcNDaz) residues were synthesized through a chemoenzymatic approach (Figure 42).  The 
optimized condition was to maintain the molar ratio of compound 4 and the HS oligosaccharide 
at a 10:1 ratio in a mixture of 1,4-dioxane/H2O (2:1) using trimethylamine as the base.  An 
attempt to use compound 5 to directly react with the N-unsubstituted glucosamine (8) failed 
under various conditions.  This is probably due to the higher hydrolytic instability of 5 compared 
Figure 42.  Synthesis scheme of active heparan sulfate based probes (AHSBP).   
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to the p-nitrophenyl ester 4.  HS octasaccharide 2 was synthesized from 7 that was prepared from 
3 through four enzymatic steps (Figure 42c and 42d). A control compound, hexasaccharide 3, 
was also synthesized (Figure 42c).  3 has the identical number of saccharide residue and sulfo 
groups as 1, except that a GlcNAc residue was used to substitute the GlcNDaz at the non-
reducing end (Appendix Supplementary Figure 31-33). 
 While diazo compounds can be activated by light, we explored the alternative of their 
activation by acid. After 1 was incubated in water at pH 5.5 for one hour, one major product was 
obtained from the solution.  Electrospray ionization mass spectrometry (ESI-MS) analysis 
demonstrated the product had the molar mass of 1369.3 indicating addition of a water molecule 
and the loss of nitrogen gas (Appendix Supplementary Figure 34-35).  There are two possible 
mechanisms for product formation. The first is that the diazoacetamide underwent Wolff 
rearrangement with subsequent hydrolysis of the isocyanate leading to a carboxylic acid 10 
(Figure 43a).[234, 235]  The other pathway is that protonation of the diazoacetamide triggers the 
release of nitrogen, which is followed by nucleophilic attack by water generating the 
glycolamide 11 (Figure 43b), which is an isomer of 10.  
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To establish the product structure, two disaccharide standards (12 and 13) were 
synthesized (Appendix Supplementary Figure 36-41).  12 has the N-carboxymethyl glucosamine 
residue as in 10, while 13 bears the N-glycolyl glucosamine residue, mimicking the structure of 
11.  From 
1
H-
13
C-HMBC (homonuclear multiple bond correlation) spectra, key correlations were 
observed from these disaccharides (Appendix Supplementary Figure 39).  The signals from cross 
peak I-2 (3.97 ppm)/I-7(177.9 ppm) from 13 were similar to that observed from product of 1 (I-
2(3.93 ppm)/I-7(177.8 ppm)), hinting that 11 rather than 10 was the structure of main product 
from 1 (Figure 44).  To finally confirm the structure, hexasaccharide 14 was synthesized from 8 
(Appendix Supplementary Figure 42-45) and glycolic acid.  
1
H-NMR spectrum of 14 matched 
well with that from acid treated 1 (Figure 44).  Taken together, these results suggest that the 
major pathway for acid catalyzed conversion of 1 is through pathway 2 (Figure 43b) rather than 
Wolff rearrangement. 
Figure 43.  Two potential pathways for activation of the GlcNDaz residue.   
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Figure 44.  
1
H–13C HMBC key correlations of compound 11. The signals of featured groups are indicated. 
The cross peaks are connected with arrowed lines identifying correlated carbon and proton. The corresponding 
chemical structure is shown on top of each spectrum. The anticipated correlations are indicated in the structures 
by curved arrows.  
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Using GlcNDaz-Containing Oligosaccharides as Active HS Based Probes (AHSBP) 
 The abilities of compounds 1 and 2 to function as AHSBPs (Appendix Supplementary 
Figure 46-53) were investigated next using two HS biosynthesis enzymes, i.e., 2-OST and 3-
OST.[236]  2-OST is an enzyme that transfers sulfo group to the 2-OH position of a glucuronic 
acid residue that is flanked by two N-sulfated glucosamine residues (Figure 41).  1 was incubated 
with 2-OST at pH 5.5.  The reaction was monitored with gel-permeation chromatography HPLC 
(GPC-HPLC) at two wavelength, 280 nm and 310 nm, characteristic for the protein and p-
nitrophenyl chromophore, respectively.   2-OST (MW at around 70 KDa) was eluted at 39.3 min 
(Figure 45A), and 1 (MW = 1379.4 Da) was eluted at 56.3 min (Figure 45B).  The reaction 
mixture yielded a major new peak at 28.6 min, earlier than 2-OST alone (Figure 45C).  
Compared to 2-OST, the new peak has significantly higher absorbance in 310 nm, suggesting 
that the coupling of 2-OST and 1 occurred.  In a control experiment, incubation of 2-OST with 
compound 3 bearing no GlcNDaz, did not change the elution time for 2-OST (Figure 45D). 
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 Additional evidence suggesting the cross-linking between 2-OST and 1 was demonstrated 
by the effect on the enzymatic activity.  The protein peaks resolved from GPC-HPLC were 
collected for the activity measurement.  The presence of the desired protein in collected fractions 
from GPC-HPLC was confirmed by SDS-PAGE (Figure 45E).  Both the protein alone and the 
Figure 45.  Analysis of the conjugate product of 2-OST and compound 1.  Panel A shows the GPC-HPLC 
chromatogram of 2-OST protein only in the absence of compound 1.  Panel B shows the GPC-HPLC 
chromatogram of compound 1 only.  Panel C shows the GPC-HPLC chromatogram after incubating 2-OST with 
compound 1.  Panel D shows the chromatogram of 2-OST and compound 3 after coupling reaction.  Panel E 
shows the picture of PAGE analysis of three proteins samples from GPC-HPLC analysis.  Panel F shows the 
results of the sulfotransferase activity measurement of three protein samples.  The activity was determined 
based on the amount 
35
S-labeled sulfo group transferred to a polysaccharide substrate. 
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protein incubated with 3 displayed excellent sulfotransferase activities, while the sample 
incubated with 1 lost the enzymatic activity completely (Figure 45F).  In contrast, incubation of 
2-OST with 3 did not change the sulfotransferase activity.  The reason for the lost activity of 2-
OST/1 conjugate is presumably because the hexasaccharide was covalently attached to or near 
the active site of the enzyme, preventing the substrate binding. 
 
Inhibitory Effect on 2-O-Sulfotransferase and 3-O-Sulfotransferase 
 We next demonstrate that enzyme inhibition is based on the saccharide structures.  3-OST 
transfers a sulfo group to the 3-OH position of a glucosamine residue that is linked to a GlcA at 
the nonreducing end.  3-OST (3-OST-1) recognizes very different saccharide sequence from 1, 
preferring substrates with high level of sulfations.[187]  Based on the substrate specificity studies 
and crystal structures, only 2-OST can bind to the hexasaccharide 1,[237] but not to 2.[187]  In 
contrast, 3-OST (3-OST-1) should bind to 2, but not to 1.[187]  In this experiment, 1 or 2 was 
incubated with 2-OST and 3-OST separately under an acidic condition to allow the compound to 
react with the enzymes.  The activity measurement for each enzyme was then performed to 
assess the impact of the AHSBP (Figure 46).  1 displayed much higher potency toward the 
inhibition of 2-OST (IC50 = 13 nM) than that for 3-OST (IC50 = 334 nM).  In contrast, 2 potently 
inhibited the activity of 3-OST (IC50 = 2 nM), but not against 2-OST (IC50 > 50 nM).  Our data 
suggest that 1 and 2 selectively inhibit their respective target enzymes.  This is the first time that 
small molecule inhibitors display selective inhibition effects towards different HS biosynthetic 
enzymes. 
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Figure 46.  Inhibitory effects of compounds 1 and 2 on 2-OST and 3-OST.  2-OST, or 3-OST, was 
incubated with different concentrations of compound 1 or 2 in an acidic buffer at 4
o
C for 1h to allow the cross-
linking between the compound and proteins.   
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Synthesis of 
13
C-Isotope Labeled Heparan Sulfate Oligosaccharides 
Introduction 
 The goal of this application is to develop a NMR-based method to study the conformation 
of heparan sulfate (HS) and the interaction of HS with proteins.  HS exerts its biological 
functions by interacting with proteins; however, the mechanism used by HS to display the 
selectivity during these interactions is only partially understood.  It has been proposed that the 
conformation of HS plays a critical role in binding affinity and selectivity toward proteins [238]; 
but this hypothesis remains to be unproven due to the lack of a tool that is able to analyze the 
conformation of HS accurately. 
 Although nuclear magnetic resonance (NMR) is a widely used method for studying 
molecular conformations, including carbohydrates[239], several factors limit its application to 
study the conformation of HS.  First, the NMR signals from HS highly overlap because HS is 
composed of structurally similar repeating units.  Second, sufficient amount of structurally 
defined oligosaccharides for comprehensive NMR analysis are difficult to obtain [240].  Here, 
we propose a new method to study the conformation of HS.  The crucial innovation is to 
strategically introduce a 
13
C-labeled residue in an oligosaccharide.  The 
13
C-labeled 
oligosaccharides were synthesized using a chemoenzymatic approach in adequate amounts. The 
13
C-labeled saccharide residue improves the detection sensitivity by 100-fold using NMR.  This 
method also simplifies the 
13
C-signals from the oligosaccharide, provided that only the labeled 
saccharide residues are detectable by NMR.  Computational simulations are employed to relate 
the NMR parameters to 3D structural properties.  This advance will provide an essential tool to 
study HS and the interaction with proteins utilizing sophisticated NMR methods.   
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Chemoenzymatic Synthesis of 
13
C-labeled Cofactor and Oligosaccharide 
 Two key reagents for preparing 
13
C-labeled oligosaccharides are UDP-[
13
C]GlcA and 
UDP-[
13
C]GlcNTFA.  The synthesis of both sugar nucleotides was completed using enzymatic 
methods following previous publications [241, 242].  The preparation of UDP-[
13
C]GlcNTFA 
was started from uniformly-
13
C-labeled glucosamine (Omicron, Inc.) followed by the protocol 
described previously in Chapter II.  UDP-GlcNTA is made by chemoenzymatic approach (Figure 
47).  The preparation of UDP-[
13
C]GlcA was started from 
13
C-labeled glucose (Cambridge 
Isotope Laboratories, Inc.). The 
13
C-labeled glucose was firstly converted to [
13
C]Glucose-6-
phosphate using hexokinase. The expression of the enzyme was carried out in E. coli.  The 
[
13
C]Glucose-6-phosphate was secondly converted to [
13
C]Glucose-1-phosphate using 
phosphoglucomutase.  Thirdly, the UDP-[
13
C]Glucose synthesis was obtained by transforming 
[
13
C]Glucose-1-phosphate using UDP-glucose pyrophosphorylase (GalU).  Finally, the UDP-
[
13
C]Glucose was converted to UDP-[
13
C]GlcA by using UDP-glucose dehydrogenase.  The 
resultant UDP-[
13
C]GlcA as well as UDP-[
13
C]GlcNTFA were ready for the elongation reaction.  
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 The pilot synthesis of two hexasaccharides was completed following the scheme shown 
in Figure 48.  Hexasaccharide A has the 
13
C-labeled residue at the IdoA2S position; and 
hexasaccharide B has the 
13
C-labeled saccharide residues at both GlcNS3S6S and IdoA2S 
positions.  About 6.7 mg of hexasaccharide A and 3.5 mg of hexasaccharide B were obtained by 
far.    
 
 
MS and NMR analysis confirmed the structures of both hexasaccharide A and 
hexasaccharide B (Figure 49-50).  In NMR spectrum the 
13
C-labeled carbons show 100 times 
stronger intensity of signal than the unlabeled ones.  As expected, HSQC analysis showed that 
Figure 47.  Synthesis of [
13
C]-UDP-Glucuronic Acid.  
Figure 48.  Synthesis of 
13
C-labeled oligosaccharide.  The synthesis was initiated from a monosaccharide 
GlcA-pNP.  The introduction of 
13
C-saccharide residue was completed by using KfiA and pmHS2 during the 
backbone synthesis.  Introducing UDP-[
13
C]saccharide at specific steps lead to synthesis of 
13
C-labeled 
constructs labeled at desired saccharide residues.  After the hexasaccharide intermediates syntheses were 
completed, both intermediate were subjected to sulfation/epimerization modification steps to form the final 
hexasaccharide products 
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hexasaccharide A has only five cross peaks from IdoA2S residue (Figure 49), while 
hexasaccharide B has only 12 cross peaks from both GlcNS3S6S and IdoA2S residues (Figure 
50).  Only 150 ug was enough used for HSQC and 1D 
13
C-NMR analysis for the hexasaccharide, 
suggesting that our method is able to synthesize sufficient amount of the hexasaccharides for the 
studies. 
 
 
Figure 49.  HPLC and heteronuclear single quantum coherence (HSQC) spectra of hexasaccharide A.  
Hexasaccharide A (0.17 mM) were dissolved in 10 mM phosphate buffer containing 150 mM NaCl. The 
13
C-
labeling sites in hexasaccharide A is colored in red (IdoA2S).  The spectra were recorded at 35
o
C on Bruker 850 
MHz instrument. 
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In addition to hexasaccharide A and B, a series of 
13
C-labeled hexasaccharides with 
different sulfation levels were also obtained from the pilot synthesis (Table 7).  Among these 
oligosaccharides, only hexasaccharide A and B bind to AT. 
compounds Abbreviated structures Measured MW Calculated  MW 
Hexa-1A GlcNH2-GlcA-GlcNS-[
13C]IdoA2S-GlcNS-GlcA-pNP 1397.5 ± 0.5 1397.1 
Hexa-2A GlcNS-GlcA-GlcNS-[13C]IdoA2S-GlcNS-GlcA-pNP 1477.7 ± 0.7 1477.2 
Hexa-3A GlcNS6S-GlcA-GlcNS6S-[13C]IdoA2S-GlcNS6S-GlcA-pNP 1717.4 ± 0.6 1717.4 
Hexasaccharide A  GlcNS6S-GlcA-GlcNS3S6S-[13C]IdoA2S-GlcNS6S-GlcA-pNP 1797.8 ± 1.5 1797.4 
Hexa-1B GlcNH2-GlcA-[
13C]GlcNS-[13C]IdoA2S-GlcNS-GlcA-pNP 1403.4 ± 0.3 1403.1 
Hexa-2B GlcNS-GlcA-[13C]GlcNS-[13C]IdoA2S-GlcNS-GlcA-pNP 1483.1 ± 0.5 1483.2 
Hexa-3B GlcNS6S-GlcA-[13C]GlcNS6S-[13C]IdoA2S-GlcNS6S-GlcA-pNP 1723.4 ± 0.6 1723.6 
Figure 50.  HPLC and heteronuclear single quantum coherence (HSQC) spectra of hexasaccharide B.  
Hexasaccharide B (0.17 mM) were dissolved in 10 mM phosphate buffer containing 150 mM NaCl. The 
13
C-
labeling sites in hexasaccharide B is colored in blue (GlcNS3S6S) and in red (IdoA2S).  The spectra were 
recorded at 35
o
C on Bruker 850 MHz instrument. 
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Hexasaccharide B  GlcNS6S-GlcA-[13C]GlcNS3S6S-[13C]IdoA2S-GlcNS6S-GlcA-pNP 1803.3 ± 1.2 1803.4 
 
 
Determination of the Binding of Labeled Hexasaccharide to AT 
 AT interacts in high affinity with a specific pentasaccharide domain in heparin [200], 
both hexasaccharide A and B contain this domain.  We used of 
13
C-labeled hexasaccharide A to 
probe the binding to AT.  Firstly, we performed 2D-HSQC experiments using NMR.  Under the 
same concentration of AT and hexasaccharide A (0.17 mM), only signals of AT are visible, 
signals of hexasaccharide A are not distinguishable (Figure 51A).  The invisible signals of 
hexasaccharide A is due to being tightly bound by AT with molecular weight around 60kDa.  To 
confirm the tight binding of 
13
C-labeled hexasaccharide A and AT, an additional one equivalent 
amount of hexasaccharide A was added to observe the expected free-form of hexasaccharide A.  
At this concentration, the amount of hexasaccharide A is two-folds that of AT (0.34 mM). At this 
concentration, the signals of free-form hexasaccharide A become visible (Figure 51B).  The 
cross peaks of free-form hexasaccharide A are the same as in Figure 49.  The results support the 
labeled oligosaccharide can tightly bind AT and the binding is detectable using this optimized 
condition.   
Table 7.  List of 
13
C-labeled hexasaccharides prepared in the pilot synthesis.  The labeled saccharides are 
marked in blue or red color. 
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Secondly, three individual proton-decoupled 
13
C-NMR experiments were performed 
using the same concentration (0.17 mM) of AT only, hexasaccharide A only, or both AT and 
hexasaccharide A, respectively (Figure 52).  In the experiment containing both AT and 
hexasaccharide A, the signals of bound-form hexasaccharide are visible because of 
13
C-isotope 
labeling (indicated by arrow).  The labeled saccharide has 100-fold higher sensitivity leading to 
the signals being visible even when bound to a much larger protein - 60kDa AT here.  The 
signals of bound hexasaccharide A are broad due to high AT affinity with shorter T2.  The 
significant different chemical shifts between bound and free form of hexasaccharide A are 
highlighted in red.  The signals of C2 and C5 show different chemical shifts indicating that the 
Figure 51.  2D-HSQC NMR spectrum of HS/hexasaccharide A mixture.  A) Under the same concentration 
of AT and hexasaccharide A (0.17 mM), only signals of AT are visible, signals of hexasaccharide A are not 
distinguishable.  B) Under the concentration of hexasaccharide A is two-folds of AT (0.34 mM), the signals of 
free-form hexasaccharide A becomes visible. The cross peaks from labeled IdoA2S are indicated. 
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sulfate and carboxylate at these two positions are tightly involved in interaction with AT, which 
is consistent to previous literature reported crystal structures [243, 244].  These results 
demonstrate a direct way to find the binding epitope of HS, and show the promising potential of 
isotope-labeled reagents in NMR-related applications. 
 
 
 
Another goal is to develop 2D-saturation transfer different (STD) experiments to study 
the interaction of proteins and oligosaccharides.  Unlike traditional 1-D STD, the 2D-STD will 
Figure 52.  The proton-decoupled 
13
C-NMR.  Three individual proton-decoupled 
13
C-NMR experiments were 
performed using the same concentration of AT only, hexasaccharide A only, or both AT and hexasaccharide A.  
The signals of bound-form hexasacchairde are visible because of 
13
C-isotope labeling (indicated by arrow).  The 
significant different chemical shifts between bound and free form of hexasaccharide are highlighted in red. 
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provide the option to measure the changes in HSQC spectrum, significantly improving the 
accuracy and sensitivity for monitoring protein/HS oligosaccharide interactions.  The 2D-STD 
has never been performed on HS/protein complexes, and thus, a careful validation experiment is 
needed.  This part of experiment is still in progress, and will be completed in the near future.  
Because the co-crystal and solution structures of AT/pentasacccharides are available[243, 244], 
the results from our studies will validate our approach.  Results of 2D-STD analysis will greatly 
help obtain a high resolution picture for the interaction of AT/oligosaccharide in solution. The 
same strategy can also extend to the studies of other HS-bound proteins. 
 
Investigation of the Conformation of Heparan Sulfate 
 The conformations of a given hexasaccharide include the conformation of individual 
saccharide residue (i.e., chair, skew boat or boat conformations) as well as the two dihedral 
angles, ϕ and φ, for the glycosidic linkages.  Here, we will focus on determining the 
conformation of the dihedral angles of glycosidic linkages, at the reducing and nonreducing end 
of 
13
C-labeled saccharide residue, under the influences of different sulfation patterns.  
Measurements of proton-carbon long-range coupling constants combined with molecular 
simulation, will achieve these goals.  Introduction of 
13
C-labeling technique is essential to 
complete the measurement due to the increased sensitivity of 
13
C-NMR signals.  
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To demonstrate the feasibility, we conducted the J-HMBC and HSQC analysis on 
hexasaccharide A.  The anticipated long range 
1
H-
13
C coupling effects measured by 
heteronuclear multiple-bond correlation (HMBC) are indicated in Figure 53.  In addition to those 
HSQC signals (signals colored in red in Figure 54), two signals were observed in HMBC 
resulting from reducing end glycosidic linkage of IdoA2S residue (the C1 of IdoA2S and H4 
from GlcNS6S residue), as well as the nonreducing end glycosidic linkage of IdoA2S residue 
(the C4 of IdoA2S and H1 from GlcNS3S6S residue).  As shown in the enlarged portion 
showing H4 GlcNS6S/C1 IdoA2S signal (Figure 54a), both one bond C-C coupling (
1
JC-C) and 
three bond C-H (
3
JC-H) coupling can be detected.  Using frequency-selective pulse, we can 
suppress the one bond C-C bond coupling [245], allowing us to obtain accurate three bond 
coupling constant (
3
JC-H) (Figure 54b).     
Figure 53.  The anticipated inter-residue glycosidic 
3
JC-H coupling detected by HMBC.   
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The coupling constant values determined by NMR can be translated into glycosidic 
angles according to established computational protocols employed previously by the Woods’ lab 
[246-250] .  Briefly, quantum mechanical calculations can be employed to compute the relevant 
heteronuclear 
3
J-values for conformations derived from independent molecular dynamics (MD) 
simulations of the oligosaccharide structures.  The experimental 
3
J-values can then be 
deconvoluted into a linear combination of the populations of the theoretical conformational states 
[249].  In the event that MD simulations fail to identify appropriate states, the experimental J-
values can be employed as constraints during the MD simulations to obtain a single 
experimentally-consistent average conformation.  This part of experiment is still in progress.  We 
Figure 54.  HSQC (red) and J-HMBC (green) spectra of hexasaccharide A.  The region related to 
3
J
C1-H4′ 
without (a) and with (b) frequency-selective pulse for suppression of homonuclear carbon–carbon coupling 
constants. 
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plan to carry out similar analysis on some of the seven additional oligosaccharides as shown in 
Table 7, depending on the results from the analysis of hexasaccharide A.  The results should 
provide the desired information on the conformation of glycosidic linkages under different 
sulfation patterns.  We suspect the results will confirm that the sulfation patterns dictate the 
conformation of HS oligosaccharides. 
 
Conclusions 
 HS is composed of sulfated saccharides that are biosynthesized through a complex 
pathway involving multiple enzymes.  HS 2-O-sulfotransferase (2OST) is a key enzyme in this 
pathway.  Here, we report the crystal structure of the ternary complex of 2OST, 3’-
phosphoadenosine 5’-phosphate, and a heptasaccharide substrate.  We successfully probed the 
molecular basis of specificity and 2OST’s position in the ordered of the HS biosynthesis 
pathway.  These studies revealed that 2OST interacts with the N-sulfo groups near the 
modification site, consistent with the dependence of 2OST on N-sulfation.  In contrast, 6-O-sulfo 
groups on HS are likely excluded by steric and electrostatic repulsion within the active site 
supporting the hypothesis that 2-O-sulfation occurs prior to 6-O-sulfation.  Our results provide 
the structural evidence for understanding the sequence of enzymatic events in this pathway.  In 
addition, for 2-OST the acceptor IdoA residue in the heptasaccharide appears to be in the 
4
C1 
conformation.   This conformation contradicts previous data that suggests IdoA assumes either 
the 
1
C4 or 
2
S0 conformation within the context of HS.   
The saccharide sequences of HS determine the selectivity/specificity of their functions.  
Traditionally, the efforts for the identification of the contribution of specific saccharide structure 
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to HS biological function have been hindered due to the lack of an effective method.  A 
chemoenzymatic approach for synthesizing active heparan sulfate based probes (AHSBP) with a 
reactive diazoacetyl saccharide residue is reported.  The AHSBP approach takes advantage of the 
understanding of structural selectivity of HS receptors.  Although using diazo group that is 
conjugated with peptide substrates has been used to study the biochemistry of proteases, 
utilization of this chemistry in HS oligosaccharides has not been previously reported. The 
covalent linkage formed between the probe and the target protein enables irreversible inhibition 
of the activities in a sequence selective manner.  The resultant oligosaccharides were 
demonstrated to serve as specific inhibitors for heparan sulfate sulfotransferases 2-OST or 3-
OST, offering a new set of tools to probe the structural selectivity for heparan sulfate-binding 
proteins.  This is the first time that small molecule inhibitors display selective inhibition effects 
towards different HS biosynthetic enzymes.  This approach can be potentially applied to any HS 
binding proteins or enzymes.  Conversely, a specific AHSBP molecule can be utilized to identify 
previously unknown binding partners of HS.  With further development, the AHSBP method can 
become a powerful method to aid in the study of HS biology.  
We also developed an innovative method to directly analyze the binding between HS and 
target proteins.  The crucial innovation of this method is capable of introducing 13C-labeled 
saccharide at the desired site based on a newly developed and state-of-the-art chemoenzymatic 
method.  Our site-specific labeled oligosaccharides will overcome the NMR signal overlapping 
issue caused from other repeating saccharides and protein residues, allowing us to analyze the 
specific saccharide/protein interaction directly.  Furthermore, making multiple 13C-labeled 
saccharides at different sites of single oligosaccharide is accessible as well.  The access of these 
oligosaccharides will open the possibility for the conformational analysis of HS using NMR.  
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The conformational analysis of glycosidic linkages can take advantages of these labeled 
saccharides via computing dihedral angles from NMR measured 3JC-H coupling values.  This 
method is particularly valuable given the fact attempts to crystalize a free HS oligosaccharide for 
X-ray analysis failed due to extremely high water solubility of HS oligosaccharides.  This 
approach will also allow us to systematically investigate the contributions of the size and 
sulfation patterns on the conformation of HS.  In the near future we will study the effect of 
protein binding on the conformation of HS oligosaccharides. 
The success from these three studies will advance the fundamental understanding for the 
interaction between HS and proteins.  In addition, these strategies may be used for the analysis of 
other biological important glycosaminoglycans, such as dermatan sulfates and chondroitin 
sulfates. 
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Chapter V 
Investigate the Effect of Different Sulfation on Heparan Sulfate Conformation 
 
Synthesis of Heparan Sulfate with Different Sulfation Pattern 
Introduction 
HS and heparin are negatively charged polysaccharides consisting of repeating 
disaccharide unit of α-D-(1,4)-glucosamine and β-D-(1,4)-glucuronic or α-L-(1,4)-iduronic acid 
with different sulfations.[9]  Except antithrombin, heparan sulfates were reported to bind to 
several other proteins, including fibroblast growth factors and corresponding receptors, 
chemokines, selectins, platelet factor 4, etc.[6]  In addition to the length of saccharide chain, 
diversity of sulfation patterns and plasticity of iduronic acid (IdoA) are known to be correlated to 
the biological importance.[8, 82]  The flexible glycosidic linkages and IdoA could facilitate 
heparan sulfate conformational rearrangement to allow diverse proteins binding.  The same 
structure of HS oligosaccharide may dynamically populate at several stable conformations, but 
only certain conformation binds to protein.[43, 83]  The preference of conformation could 
attribute to comparable energy states established by local environment.  Highly heterogeneous 
sulfation patterns of heparan sulfate provide the local environment diversity.  We hypothesize the 
combining of specific sulfation pattern with certain sequenced oligosaccharide may allow us to 
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build pre-defined conformations with spatially tuned flexibility for specific protein binding.  
Larger sizes of oligosaccharide could allow for more defined conformation by more 
intramolecular constraints including hydrogen bonds and electrostatic interactions.[8]  Therefore, 
the sufficient length of oligosaccharide or multi-flexible-domain may increase the specificity and 
selectivity for carbohydrate-protein interactions. 
Crystallography and NMR are the best ways to accurately identify the molecular structure 
of HS.  Unfortunately due to highly flexible character, carbohydrates are difficult to crystalized 
and analyzed by NMR. [84]  The rapid dynamically exchange between conformations makes 
NMR only observe the signals averaged from individual conformations.[85]  Alternatively, 
molecular dynamics (MD) simulation could identify the list of possible low energy 
conformations; however, simulations are unable to accurately calculate the equilibrium 
population of each conformation[86].  Taking the advantage of both NMR and MD simulation 
analysis, the best manner to calculate the realistic equilibrium population of conformations is to 
deconvolute the NMR measured parameters into simulated parameters for each conformation 
with corresponding populations.  The measurement of spin-spin coupling constant (
3
JH-H) and 
intensity of nuclear overhauser effects (NOE) are the appropriate parameters representing 
saccharide conformation.[82]  The change of conformation altering the dihedral between vicinal 
protons as well as the spatial distance between ring protons which are reflected in a shift of the 
3
JH-H coupling constant and NOE, respectively.  The 
3
JH-H coupling constants are obtained by 
direct 
1
H-NMR experiment or calculated from simulated dihedral using the Karplus equation 
(Figure 55).[87, 88]  Intensity of NOE signals are acquired from 2D-NOESY NMR experiment 
or calculated from simulated proton distance.  Both 
3
JH-H coupling constant and NOE are used as 
constraints to monitor the conformational change and corresponding population in this study.  
121 
 
Parallel usage of both NMR and simulation approach enable us to capture the structural and 
dynamic properties of carbohydrate conformation ensembles.[85]   
 
 
This study is to investigate the relation between the various sulfations and the saccharide 
conformations among heparan sulfate.  A total of 8 HS oligosaccharides were synthesized with 
different sulfation pattern (Figure 56).  The size of hexa-saccharide was considered containing 
sufficient constrains to make molecule at more defined conformation comparing to di-, tri- or 
tetra-saccharide.  The saccharide of interest, IdoA, was designed at the central site of the 
oligosaccharides (Figure 56).  The construct 1 to 4 were used to understand the effect of N-
sulfation, 6-O-sulfation and 3-O-sulfation on the conformation of IdoA.  In addition, the effect of 
2-O-sulfation was investigated.  The construct 5 to 8, which lack the 2-O-sulfo group on iduronic 
Figure 55.  Transition of simulated dihedral angle to coupling constant by Karplus equation. The 
exemplified dihedral angle of H2-H3 was translated to 
3
JH2-H3  coupling constant for 
1
C4, 
2
So and 
4
C1 
conformation, respectively, highlighted by arrows. The reparameterized Haasnoot Karplus equations: 
3
JH-H = 
14.63*cos2(φ)-0.78*cos(φ)+0.60+∑λi[0.34-2.31cos2[sin(φ)+18.4|λi|]]  
. 
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acid, were used to identify the effect of 2-O-sulfation on saccharide conformation with different 
sulfation level.  Our results suggest that the sulfation affects heparan sulfate conformation. 
 
 
 
Chemoenzymatic Synthesis of Oligosaccharide 
A series of constructs were designed to determine impact of the surrounding saccharide 
sequences on the conformation of IdoA.  The chemoenzymatic synthesis approach was utilized 
to synthesize a total of 8 oligosaccharides.[1]  The structures are a set of 2-O-sulfated 
oligosaccharide construct 1 to 4 with 4 different sulfation patterns, and another set of 
oligosaccharides construct 5 to 8 with comparable sulfation patterns but lack 2-O-sulfation 
(Figure 56).  Constructs 5 to 8 are new structures that have never been reported synthesized.  
Starting from commercial monosaccharide, backbone elongation and saccharide modification 
were carried out in sequential steps (Figure 57).  Construct 1-4 were made in the order of 
Figure 56.  Chemoenzymatic synthesized oligosaccharide constructs 1 to 8. 
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epimerization/2-O-sulfation, N-sulfation, 6-O-sulfation and 3-O-sulfation.  Similarly, without 
using 2-O-sulfotransferase, constructs 5-8 were obtained.   
 
 
Purification of synthetic oligosaccharides was performed using C18 and anion-exchange 
column chromatography for elongation and modification steps, respectively.  Separation of 
epimerized construct 5 from epimer precursor demands high performance liquid chromatograph 
(HPLC) system with semi-preparative polyamine column and optimized buffer gradient (Figure 
58).  The purity of synthesized oligosaccharides was analyzed using HPLC and Mass 
spectrometry (Appendix Supplementary Figure 54) 
Figure 57.  Schematic synthesis of IdoA- and IdoA2S-containing oligosaccharides. 
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Structural Characterization 
 The chemoenzymatic approach makes the synthesis of sufficient amount of constructs 
possible.  Structural characterization by NMR experiments becomes much easier by virtue of 
better signal intensity.  
1
H NMR was used to test the purity of constructs as well as to measure 
the 
3
JH-H coupling constants (Figure 59-60).   
Figure 58.  The anion-exchange HPLC chromatogram of the epimerization reaction mixture. The products 
contain non-reacted precursor (~60 %) and epimerized construct 5 (~40 %) with only 1 min retention time 
difference in 40 min gradient buffer system.  The chemical structure of precursor and construct 5 is shown on top 
of figure. 
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Figure 59.  
1
H-NMR spectra of construct 1, 2, 3 and 4 
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To fully assign the chemical shifts of all the proton and carbon signals, multidimensional 
homonuclear (COSY, NOESY) and heteronuclear (HSQC, HMBC, HSQC-TOCSY) NMR 
experiments were used to resolve the overlapped signals.  The chemical shift assignments of 
constructs were acquired by dissecting the individual residue coupling system, one-bond and 
three-bond correlation based on NMR spectra.   
Construct 6 (hexasaccharide with the structure of GlcNS-GlcA-GlcNS-IdoA-GlcNS-
GlcA-pnp) was exemplified for structural characterization due to highly overlapped spectrum.  In 
1
H-NMR spectrum, the anomeric protons are located in the range between 4.5 and 5.6 ppm 
(Figure 60).  Proton II-1, IV-1, and VI-1 were identified resonating between 5.3 and 5.7 ppm 
with 
3
JH-H coupling constants at 3.7 Hz because of α-(1, 4) linkage of glucosamine (GlcNS) 
residue.  Proton I-1 and V-1 of GlcA residue were assigned at 5.28 and 4.52 ppm due to β-(1, 4) 
linkage with larger 
3
JH-H coupling constants at 7.9 Hz. The electron withdrawing group, para-
nitrophenyl (pnp), makes proton I-1 resonates at downfield comparing to V-1.   The remaining 
protons at chemical shift 4.94 and 4.76 ppm were assigned as III-1 and III-5 from IdoA residue 
with 
3
JH-H at 3.1 and 2.7 Hz, respectively.  
The multidimensional NMR experiments were then utilized to assign the overlapped 
proton signals between 3.2 and 4.1 ppm.  2D 
1
H-
13
C HSQC-TOCSY was used to identify 
coupling network of each residue.  This heteronuclear NMR experiment provide better chemical 
shift dispersion at indirect carbon dimension and resolved the signals.  The spectrum analysis 
starting from anomeric protons, the six saccharide residue coupling networks were identified 
Figure 60.  
1
H-NMR spectra of construct 5, 6, 7 and 8. 
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(Figure 61).  Within each residue coupling network, the proton and carbon signals belonging to 
the same saccharide were connected by lines (Figure 61).   
 
 
Afterwards, 
1
H-
1
H COSY was used to assign coupled protons from one proton to the 
adjacent one within the same saccharide residue (Figure 62).  For example, anomeric protons (I-
1, II-1, III-1, IV-1, V-1, VI-1) have cross peaks with nearby protons (I-2, II-2, III-2, IV-2, V-2, 
VI-2), respectively. 
Figure 61.   2D 
1
H-
13
C HSQC-TOCSY NMR spectrum of construct 6. 
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1
H-
13
C HSQC acquires the signals of proton with correlated attached carbon (Figure 
63).  The proton and carbon chemical shift assignment of each individual saccharide residue 
were obtained.   
Figure 62.   2D 
1
H-
1
H COSY NMR spectrum of construct 6. 
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1
H-
13
C HMBC was finally used to designate the glycosidic linkages through three-bond 
correlation (Figure 64). The signals of anomeric protons (II-1, III-1, IV-1, V-1, VI-1) have cross 
peaks with the carbons at reducing end residue (I-4, II-4, III-4, IV-4, V-4).  The anomeric proton 
I-1 was correlated to the quaternary carbon of pnp group.  These correlations were confirmed 
from anomeric carbons to the respective protons at reducing end residue.  The glucosamine 
protons II-6, IV-6 and VI-6 also showed the connectivity with correlated carbons II-4, IV-4 and 
Figure 63.   2D 
1
H-
13
C HSQC NMR spectrum of construct 6. 
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VI-4, respectively.  These multiple bond correlations observed by HMBC enable the sequencing 
of the residues within the oligosaccharides.   
 
 
The full chemical shift assignments of construct 6 were made by analysis and cross-
validation of these sequential NMR experiments. The structures of other constructs were 
characterized by similar approaches (Table 8-9).  The HSQC-TOCSY, COSY and HSQC 
experiments were run to assign coupling network of each residue, HMBC were then used to 
Figure 64.   2D 
1
H-
13
C HMBC key correlations of construct 6. 
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connect the residues through the glycosidic linkages.  Structural characterization of the 
oligosaccharides using this approach greatly enhances the accuracy and facilitates full chemical 
shift assignments. 
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Table 8.  
1
H-
13
C NMR chemical shift assignments (in ppm) of construct 1 – 4 (25°C, D2O, pD 7.4, 3mM 
EDTA). 
Table 9.  
1
H-
13
C NMR chemical shift assignments (in ppm) of construct 5 – 8 (25°C, D2O, pD 7.4, 3mM 
EDTA). 
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Conformation Analysis and Molecular Dynamic Simulation 
The best approach to accurately identify the saccharide conformations is to observe the 
three-bond proton-proton coupling constants (
3
JH-H) of the sugar residue using NMR.  Each 
three-bond coupling constant corresponds to a dihedral angle of two vicinal protons on the 
saccharide (Figure 55).  The pyranose saccharide ring contains four proton-proton dihedrals with 
corresponding coupling constants 
3
JH1-H2, 
3
JH2-H3, 
3
JH3-H4 and 
3
JH4-H5, respectively. The integrated 
information combining series of these four corresponding proton-proton dihedrals with 
corresponding 
3
JH-H coupling constants designate the specific ring conformation.  Except 
iduronic acid, the glucosamine and glucuronic acid residues are relatively structural rigid in all 
the 8 constructs in spite of sulfation patterns.  The 
3
JH1-H2 value for anomeric proton of 
glucosamine and glucuronic acid are similar with α and β linkage as 3.7 and 7.9 Hz, respectively.  
Comparing to the glucosamine and glucuronic acid, iduronic acid flips among different 
conformations, including the major stable 
1
C4, 
2
So and 
4
C1 conformers (Figure 55).[251]  The 
energy barrier between conformations is relatively low, which allows iduronic acid to populate 
among these three major states.[206]  The conformation exchanges on the microsecond time 
scale.[206] This fast exchange leads real-time NMR to merely measure the averaged 
3
JH-H 
coupling constant over the three populated conformations.  Accordingly, all the NMR measured 
coupling constants, 
3
JH1-H2, 
3
JH2-H3, 
3
JH3-H4 and 
3
JH4-H5, are averaged by the relative population of 
three conformations.  The best manner to calculate the equilibrium population of conformations 
is to deconvolute the NMR measured 
3
JH-H values into theoretical 
3
JH-H values of each 
conformation with corresponding populations.  The IdoA theoretical 
3
JH-H values for 
1
C4, 
2
So and 
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4
C1 conformation were acquired by molecular dynamics (MD) simulation.  
1
H-NMR was used to 
measure 
3
JH-H values of IdoA for each construct. 
 
3
JH-H Coupling Constant Measurement 
To simplify NMR analysis, only a single IdoA or IdoA2S residue is present in these 
oligosaccharides.  The proton chemical shifts of IdoA and IdoA2S can be recognized on 
1
H-
NMR spectrum after fully assignment of all the signals (Table 8-9).  The splitting patterns of 
coupled protons were able to be identified on 
1
H-NMR spectrum (Figure 59-60).  For example in 
construct 6, all the five IdoA ring protons, 4.94, 3.72, 4.09, 4.04 and 4.76 ppm marginally belong 
to AX pattern at the high magnetic field of 700 MHz.  The doublet proton III-1 and III-5 were 
measured with 
3
JH1-H2 and 
3
JH4-H5 at 3.1 and 2.7 Hz.  The proton III-2, III-3 and III-4 were 
recognized as doublet of doublets with 
3
JH2-H3 and 
3
JH3-H4 at 5.3 and 3.5 Hz.  For all the synthetic 
constructs, the experimental 
3
JH-H values of iduronic acid were acquired using the similar 
approach (Table 10).  The 
3
JH1-H2 and 
3
JH4-H5 were firstly measured from proton III-1 and III-5 
due to the signals away from overlapped proton region; secondly, the 
3
JH2-H3 and 
3
JH3-H4 were 
identified by the other protons III-2, III-3 or III-4.  In the case of leaning effect happened among 
coupled protons, the program 1D DAISY in Topspin was used to simulate the splitting pattern to 
assist the analysis of coupling constants.   
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The theoretical 
3
JH-H values of iduronic acid for each conformation were calculated from 
the results of molecular dynamics (MD) simulation.  The molecular dynamics simulation of 
synthetic constructs were performed by AMBER14 with GLYCAM06 parameter sets 
specifically designed for carbohydrate.  Total of 8 microsecond simulation were independently 
performed for iduronic acid at 
1
C4, 
2
So and 
4
C1 conformation.  The simulation was performed 
with extended microsecond timescale to secure the representative conformation of HS 
oligosaccharides.  The simulated proton dihedral angles H1-H2, H2-H3, H3-H4 and H4-H5 of 
iduronic acid for the three different conformations were collected separately.  A simulated 
dihedral angle was transformed into a corresponding 
3
JH-H value via the reparameterized 
Haasnoot Karplus equation which properly considers the electronegative substituent effects.[174, 
175]  For example, the simulated H2-H3 dihedral angle of the 
1
C4 conformation is -73°, can be 
transformed to a 
3
JH2-H3 equal to 2.04 Hz (Figure 55, Table 11).  Each transformed 
3
JH-H values 
were then averaged over 8 microseconds to obtain the theoretical 
3
JH1-H2, 
3
JH2-H3, 
3
JH3-H4 and 
3
JH4-
Table 10.  Experimental and theoretical 
3
JH-H couplings of IdoA/2S among synthetic constructs. 
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H5 values for one IdoA conformation.   All the three major IdoA conformation, 
1
C4, 
2
So and 
4
C1 
separately acquired their own corresponding theoretical 
3
JH-H values (Table 11).   
 
 
Instead of maintaining a single conformation state, IdoA can populate three major 
conformation states during the timescale of an NMR experimental measurement.  Percentage 
fitting of the theoretical 
3
JH-H values from three individual IdoA conformations into the 
experimental 
3
JH-H values can allow one to obtain the population of each IdoA conformation 
(Figure 65).  Different populations of three IdoA conformations were acquired using different 
construct’s experimental 3JH-H values to fit (Figure 65).  Based on the populations of three 
conformations, in order to refer the timescale of NMR experiments, the averaged theoretical 
IdoA 
3
JH-H values of each construct were calculated (Table 10).  For each construct, the statistic 
Table 11.  Averaged theoretical dihedral angle and 
3
JH-H value for each conformation of IdoA. The 
reparameterized Haasnoot Karplus equation was used: 
3
JH-H = 14.63*cos2(φ)-0.78*cos(φ)+0.60+∑λi{0.34-
2.31cos2[sin(φ)+18.4|λi|]}. 
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program R was used to calculate the best fitting with minimum sum of square differences 
between theoretical and the corresponding experimental 
3
JH-H values (Table 10).  The smaller 
sum of square difference means the better fitting.  The results show that theoretical and 
experimental 
3
JH-H values have good consistency comparing to literature reported values.  
Among all the eight constructs, the maximum 
3
JH-H value difference is only 0.8 Hz supporting 
that the MD simulations were performed properly resulting in confident calculation of 
conformation populations. 
 
 
Shift of IdoA Conformation Population 
Figure 65.  Hexuronic acid (GlcA, IdoA/2S) as pivot of conformation equilibrium to response sulfations. 
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 The shift of IdoA conformation population reflects the effect of different sulfation pattern 
on heparan sulfate oligosaccharide (Figure 65).  The glucuronic acid (GlcA) was observed as 
4
C1 
conformation presented in the precursor HS backbone.  Epimerization of GlcA to IdoA renders 
the accessibility of multi-conformation at desired location of the oligosaccharide.  The 
chemoenzymatic approach introduces the sequential sulfation mimicking the biosynthesis of 
heparan sulfate, including 2-O-sulfation, N-sulfation, 6-O-sulfation and 3-O-sulfation (Figure 
65).  Along the synthetic steps, the epimerization and 2-O-sulfation dramatically change the 
destiny of iduronic acid conformation equilibrium.  For example in construct 1, the 2-O-sulfated 
IdoA populate at major 
1
C4 conformation (68.4 %) and minor 
2
So conformation (31.6 %).  In 
construct 5, lacking a 2-O-sulfo group, the IdoA is able to populate at three conformations with 
comparable population of 
1
C4 (52.8 %) and 
2
So (46.8 %) as well as a rare 
4
C1 conformer.  
However, the following stepwise 6-O-sulfation and 3-O-sulfation lead IdoA2S toward 
2
So 
conformer in construct 4; oppositely, lead IdoA to majorly populate at 
1
C4 conformation in 
construct 8.  The effect of 6-O-sulfation and 3-O-sulfation shift 
2
So population of IdoA2S from 
31.8 % in construct 2, to 53.3 % and 75.1 % in construct 3 and 4, respectively. In contrast, these 
two sulfations shift 
2
So population of IdoA from 48.8 % in construct 6, to 29.2 % and 18.8 % in 
construct 7 and 8.  These added 6-O- and 3-O-sulfo groups also gradually increase the 
4
C1 
population of non-sulfated IdoA to 3.3 % and 8.4 % in construct 7 and 8, respectively, but not for 
4
C1 population of IdoA2S in construct 3 and 4.  On the other hand, as expected, the N-sulfation 
of residue VI has no effects on the conformation population of IdoA2S or IdoA at III residue in 
construct 2 and 6 comparing to construct 1 and 5.  These results support iduronic acid with, or 
without, 2-O-sulfation may result in different free energy state or different energy barrier 
between conformations. Furthermore, IdoA and IdoA2S could display different conformation 
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equilibrium based on respective surrounding environment in the constructs.  The biosynthetic 
downstream sequential 6-O- and 3-O-sulfations generate different environments to further divide 
IdoA and IdoA2S containing oligosaccharides toward different stable conformations (Figure 65).  
Comparing to relatively rigid glucuronic acid, iduronic acid containing heparan sulfate could 
show different conformational preference in response to different neighboring sulfation patterns.  
 
NOE Intensity Measurement 
Proton-proton nuclear overhauser effect (NOE) is another approach that can be used to 
confirm the shift of IdoA conformation equilibrium observed using the 
3
JH-H value measurements 
[208, 211]. For each 
1
C4, 
2
So or 
4
C1 conformation, the spacial distance between the ring protons 
represents different intensity of NOE.  The change of NOE intensity on indicative protons 
reflects the shift of saccharide conformation.  Based on simulation result, in iduronic acid the 
distance between proton H2 and H5 is significantly shorter for 
2
So (2.6 Å) than for 
1
C4 (4.0 Å) or 
4
C1 (4.2 Å) conformation (Figure 66).  The distance between proton H4 and H5 are relatively 
similar among these three conformations (2.4, 2.3, 2.4 Å) (Figure 66).    
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NOE intensity is inversely proportional to the sixth power of distance, therefore, the NOE 
intensity ratio of H2-H5/H4-H5 of iduronic acid could be used as an indicator of relative 
population of 
2
So to the other 
1
C4 and 
4
C1 conformation.  The higher population of 
2
So 
conformation carry higher NOE ratio of H2-H5/H4-H5 due to larger intensity of NOE of H2-H5.  
The theoretical NOE ratio of H2-H5/H4-H5 was separately calculated for 
1
C4, 
2
So and 
4
C1 
conformation as 4.53 %, 52.73 % and 3.11 %, respectively (Table 12).  Since IdoA rapidly 
populates among these three conformations, multiplication of population of each conformation 
acquired the averaged theoretical NOE ratio values for each construct (Table 12).  The trend of 
increased theoretical NOE ratio values through construct 1 to 4 shows the increased population 
of 
2
So conformation by additional 6-O- and 3-O-sulfation.  In contrast, the decreased theoretical 
NOE ratio values through construct 5 to 8 displays the reduction of 
2
So population.  On the other 
hand, NMR 2D-NOESY experiments were performed for each construct.  The NOE cross peaks 
of iduronic acid H2-H5 and H4-H5 were integrated for intensity ratio calculation.  Through 
Figure 66.  The simulated proton distance for three major conformations of Iduronic acid. The distance 
between H2 and H5, H4 and H5 is labelled. The featured difference is highlighted in red color. 
141 
 
construct 1 to 4 as well as construct 5 to 8, the opposite trends of experimental NOE ratio of H2-
H5/H4-H5 are nicely consistent with the theoretical NOE ratio of H2-H5/H4-H5.  The NOE 
analysis further supports different sulfation pattern could shift conformation equilibrium of 
heparan sulfate as observed in previous analysis of 
3
JH-H values. 
 
 
 
Possible Mechanism for Shift of Conformation Equilibrium 
Table 12.  Experimental and theoretical NOE H2-H5/H4-H5 ratio of IdoA/2S among synthetic constructs.  
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The possible mechanism for the shift of conformation equilibrium among constructs is 
attributed to hydrogen bond and electrostatic repulsion using MD simulations.  For individual 
1
C4, 
2
So and 
4
C1 conformation of iduronic acid in each construct, the simulation was performed 
separately for all 8 constructs.  A total of 24 independent simulations were finished with the 
extended 1 microsecond to acquire the proper averaged low energy conformation.  Based on the 
low energy conformation of construct 4, the 2-O-sulfated IdoA prefers 
2
So conformation rather 
than 
1
C4 conformation possibly due to two main reasons: hydrogen bond and electrostatic 
repulsion (Figure 67).  Firstly, the 2-O-sulfo group is capable to form an intra-residue hydrogen 
bond with 3-O-hydroxyl group in the 
2
So conformation of IdoA2S, but not at 
1
C4 conformation 
(Figure 67).  The hydrogen bond occurs frequently among all IdoA2S-containing constructs with 
occupancy higher than 30 % (Table 13).  The orientated 3-O-hydroxy group of IdoA2S in the 
Figure 67.  Superimposition of low energy conformations of construct 4 with iduronic acid as major 
2
So 
conformation (bold bond) and minor 
1
C4 conformation (thin line).  The featured possible hydrogen bond and 
electrostatic repulsion is highlighted by dashes with occupancy and double arrows, respectively.  The hydrogen 
bond is based on atom distance cutoff of 3.5 Å and angle of 120°. 
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2
So conformation is able to from an inter-residue hydrogen bond with N-sulfate at residue IV as 
well (Figure 67).  Secondly, the spacial adjacent 3-O- and N-sulfo groups at residue IV as well as 
6-O-sulfo at residue II could contribute repulsion to the 2-O-sulfo group of IdoA2S in the 
1
C4 
conformation.  The electrostatic repulsion makes IdoA2S disfavor the 
1
C4 conformation and 
prefer the 
2
So conformation (Figure 67).  These hydrogen bond and electrostatic repulsion effects 
could synergistically lead IdoA2S conformation equilibrium toward the 
2
So conformation in 
construct 4.   
 
 
Table 13.  The occupancy of possible hydrogen bond during 1us MD simulation. 
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On the other hand, the IdoA in construct 8 lacks 2-O-sulfation and majorly populates the 
1
C4 instead of the 
2
So conformation (Figure 68).  The possible mechanism is the repulsion from 
the 3-O-sulfo group repulses the nearby N-sulfate (residue IV) closer to the 2-O-hydroxy group 
of IdoA (residue III).  Without the 2-O-sulfo group in construct 8, the 2-O-hydroxyl group of 
IdoA at 
1
C4 conformer, rather than 
2
So conformer, is openly spacial close to N-sulfate and 
capable to form an inter-residue hydrogen bond (Figure 68).  The occupancy of this inter-residue 
hydrogen bond is significantly increased in construct 8 (47.2 %) comparing to construct 7 (15.2 
%) further supports the role of added 3-O-sulfo group for shift of iduronic acid conformation 
equilibrium (Figure 69, Table 13).  Comparing the conformation population of iduronic acid in 
construct 4 and 8, given the 2-O-sulfation or not could shift the conformation equilibrium of 
IdoA-containing oligosaccharides toward opposite preference.   
Figure 68.  Superimposition of low energy conformations of construct 8 with iduronic acid as major 
1
C4 
conformation (bold bond) and minor 
2
So conformation (thin line). The featured possible hydrogen bond and 
electrostatic repulsion is highlighted by dashes with occupancy and double arrows, respectively. The hydrogen 
bond is based on atom distance cutoff of 3.5 Å and angle of 120°. 
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Synthesis of Large Heparan Sulfate with Multiple IdoA/2S Saccharides 
The presence of IdoA enhances the structural complexity for heparan sulfate.  Unlike 
GlcA and GlcNS which are stable as 
4
C1 conformation, IdoA was reported to adopt 
1
C4 
conformation and form a kink within linear structure of whole heparan sulfate molecules.[9]  
Furthermore, we found different sulfation patterns could change the conformational preference 
of IdoA, and accordingly shifts the substituent and ring position of the IdoA (Figure 70).  
Comparing to the rest of the residues, the orientation of 3-O-hydroxyl and 2-O-sulfo group is 
shifted while IdoA taking either 
1
C4 or 
2
So conformation.  The relatively ring position of the 
IdoA is altered as well, which associated with some degree difference of glycosidic dihedral 
angle (Figure 70).   
Figure 69.  Superimposition of low energy conformations of construct 8 with IdoA as 
1
C4 conformation 
(bold bond) and construct 7 with IdoA as 
1
C4 conformation (thin blue line). The featured possible hydrogen 
bond is highlighted by dashes with occupancy. Without 3-O-sulfaiton, 3-O-hydorxy group and N-sulfate at 
residue IV could have intra-residue hydrogen bond with occupancy 41.2 %. The hydrogen bond is based on atom 
distance cutoff of 3.5 Å and angle of 120°. 
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These structural heterogeneities are gradually accumulated in longer or multiple IdoA 
containing heparan sulfate.  The conformational change of IdoA based on sulfation pattern even 
further enlarges the structural diversity.  However, there may be only certain low energy heparan 
sulfate conformations that are relatively stable.  The intramolecular constraint such as hydrogen 
bond or electrostatic repulsion could possibly establish some defined conformations.  The 
widespread strong electronegative sulfo and polar hydroxyl groups of saccharide may be the 
Figure 70.  Superimposition of low energy conformations of construct 4 with IdoA2S as 
2
So conformation 
(bold bond) and construct 8 with IdoA as 
1
C4 conformation (thin line).  Construct 4 and construct 8 are 
similar molecules except IdoA2S in construct 4 and IdoA in construct 8 at residue III.  The bottom panel was 
made by rotate 90° of upper panel.  The featured differences between two constructs are highlighted by arrow. 
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determining factors in the environmental influence on the conformation of IdoA/2S.  Protein and 
nucleic acid are known to have secondary or tertiary structure due to intramolecular interactions 
with the extended size of these molecules.  To understand the presence of any higher level of 
stable heparan sulfate conformation, an array of large size of IdoA/2S-containing 
oligosaccharides is urgently required for future study.   In a pilot synthesis study, a series of 
oligosaccharide larger than hexasaccharide were or are to be synthesized consisting of multiple 
IdoA2S saccharides (Table 14).  The isotope labeled saccharide can make the target saccharide 
signals distinguishable from other repeated saccharides.  The conformation of IdoA2S and 
glycosidic linkage located at different desired sites of HS molecule, such as at reducing- or 
nonreducing-end, will be analyzed and compared.       
 
 
 
 
 
Table 14.  List of multi-IdoA-containing oligosaccharide prepared in the pilot synthesis.  The IdoA2S 
saccharides are marked as bold font.  The 
13
C-labeled saccharides are indicated in red color. 
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Discussion 
In addition to heparan sulfate, IdoA is also present in dermatan sulfate (DS) 
glycosaminoglycans.  The structural differences leads dermatan sulfate to have distinct biological 
roles.[252]  Dermatan sulfate uses β-D-galactosamine and -(1,3)- linkage instead of α-D-
glucosamine and -(1,4)- linkage as in heparan sulfate.  Additionally, the galactosamine can be 4-
O-sulfated instead of 3-O-sulfation on glucosamine.  Here we assert that 3-O-sulfation is an 
important factor in the conformation of the adjacent IdoA via intramolecular interaction.  Similar 
sulfation effect may also impact the conformational preference of dermatan sulfate and even 
other type of glycosaminoglycans.  Similar to the 3-O-sulfated pentasaccharide fondaparinux 
binding to AT for anticoagulation effect, special sulfation pattern may drive glycosaminoglycan 
conformation for other specific protein binding and biological activity.  The carbohydrate 
microarray made by structure defined oligosaccharides may serve as useful tool for protein 
binding screening as well as investigating the conformation-activity relationship. 
 
Conclusions 
Diversity of sulfation patterns and plasticity of iduronic acid (IdoA) are known to be 
associated with the protein binding; however, the understanding of the relationship between 
sulfations and saccharide conformations is not well understood.  Here, we developed a method to 
accurately analyze the saccharide conformation of HS.  This study systematically investigates the 
relation between the various sulfations and the saccharide conformations among heparan sulfate.  
The chemoenzymatic approach was used to synthesize a total of eight IdoA/2S-containing 
hexasaccharides with different sulfation patterns.  To calculate the realistic equilibrium 
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population of IdoA/2S conformations, we deconvoluted the NMR measured parameters into 
simulated parameters for each conformation with corresponding populations.  Both spin-spin 
coupling constant (
3
JH-H) and intensity of nuclear overhauser effects (NOE) are used to monitor 
the conformational change and corresponding population in this study.   
Our results directly suggest that different sulfation influences the heparan sulfate 
conformation.  2-O-sulfation is capable to shift the conformation equilibrium of IdoA.  The 
biosynthetic downstream 6-O- and 3-O-sulfations provide different environment shifting IdoA2S 
toward increased 
2
So conformation, which shifting IdoA population to 
1
C4 conformation.  
Comparing to relatively rigid glucuronic acid, IdoA/2S-containing oligosaccharide could show 
diverse conformational preference in response to different sulfation patterns.  This is the first 
demonstration that 2-O-sulfation cooperates with other sulfation to regulate conformational 
equilibrium of IdoA.  The sequential N-, 6-O- and 3-O-sulfation are involved in settling local 
environment for different conformational preference of heparan sulfates.   
The combination of the specific sulfation pattern and certain sequenced oligosaccharide 
can build pre-defined conformation.  The buildup of conformation appears due to hydrogen 
bonds and electrostatic interactions.  Therefore, the larger size and multi-IdoA/2S 
oligosaccharides are synthesized to investigate the conformation of individual saccharide at 
different locations of oligosaccharide.  The labeled saccharides are introduced to facilitate NMR 
analysis by enhancing the signals of interested saccharide by 100-folds.  Assembling the 
conformational analysis results from each labeled piece will provide a complete conformation for 
the oligosaccharide.  In our opinion, our method will provide an unique, and the most effective 
by far, solution to analyze the conformation of HS oligosaccharides.  It may be existed the 
specific oligosaccharide conformation for desired biological function.  The understanding of the 
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sulfation-conformation relationship will assist the design of next generation heparin-based 
therapeutics.   
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APPENDIX I 
SUPPLEMENTARY HPLC, MASS, AND NMR DATA 
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Supplementary Fig 1. Purity and structural analysis of hexasaccharide 6. (a) Silica-based polyamine(PAMN)-HPLC chromatogram. (b) 
High resolution MS spectrum. Monoisotopic peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic 
distribution analysis was performed as shown in insets. Inset a is experimental data, and inset b, c and d is simulated theoretical data for H 
adduct, one Na adduct and two Na adduct. Accurate MS and isotope distribution matched very well (within 5 ppm mass accuracy) with the 
empirical formulae. (c) 1H-NMR spectrum. The signals of anomeric protons are indicated. The signal from H-5 of Residue D is also indicated, 
demonstrating the presence of an IdoA2S residue. The chemical structure of hexasaccharide 6 is shown on top of (c). 
1
5
2
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Supplementary Fig 2. NMR analysis of hexasaccharide 6. (a) 13C-NMR spectrum of hexasaccharide 6. Signals from six anomeric carbons 
are identified. (b) 2D 1H-1H COSY spectrum of hexasaccharide 6. The corresponding peak assignments of the anomeric protons resonate as 
doublets or singlets at δ 5.52 (d, J = 3.2 Hz, 1H), 5.43 (d, J = 4.0 Hz, 1H), 5.24 (d, J = 3.2 Hz, 1H), 5.22 (d, J = 8.0 Hz, 1H), 5.18 (broad singlet, 
1H), and 4.41 (d, J = 8.0 Hz, 1H) ppm. The chemical shift of D1 on IdoA is 5.18 ppm (broad singlet, 1H). (c) 2D 1H-13C HMQC spectrum of 
hexasaccharide 6. 
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Supplementary Fig 3. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of hexasaccharide 6. The structure of hexasaccharide 
6 is shown. The protons and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of 
carbohydrate protons and carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are 
not listed in the table. 
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Supplementary Fig 4. Purity and structural analysis of octasaccharide 7. (a) PAMN-HPLC chromatogram. (b) High resolution MS 
spectrum. Monoisotopic peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was 
performed as shown in insets. Inset a is experimental data, and inset b and c is simulated theoretical data for H adduct and one Na adduct for the 
empirical formulae C56H80F3N5O59S5 and C56H79F3N5O59S5Na, respectively. Accurate MS and isotope distribution matched very well 
(within 5 ppm mass accuracy) with the empirical formulae. (c) 1H-NMR spectrum. The signals of anomeric protons are indicated. The signals 
from H-5 of Residue D and F are also indicated, demonstrating the presence of two IdoA2S residues. The chemical structure of octasaccharide 
7 is shown on top of (c). 
1
5
5
 
156 
 
 
Supplementary Fig 5. NMR analysis of octasaccharide 7. (a)13C-NMR spectrum of octasaccharide 7. Signals from eight anomeric carbons 
are identified. (b) 2D 1H-1H COSY spectrum of octasaccharide 7. The corresponding peak assignments of the anomeric protons resonate as 
doublets or singlets at δ 5.51 (d, J = 3.2 Hz, 1H), 5.43 (d, J = 4.0 Hz, 1H), 5.24 (s, 1H), 5.23 (s, 1H), 5.22 (d, J = 8.0 Hz, 1H), 5.18 (broad 
singlets, 2H), and 4.42 (d, J = 8.0 Hz, 1H) ppm. (c) 2D 1H-13C HMQC spectrum of octasaccharide 7. 
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Supplementary Fig 6. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of octasaccharide 7. The structure of octasaccharide 7 
is shown. The protons and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of 
carbohydrate protons and carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are 
not listed in the table. 
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Supplementary Fig 7. Purity and structural analysis of decasaccharide 8. (a) PAMN-HPLC chromatogram. A small peak eluted before the 
major peak is a detrifluoroacetylated decasaccharide 8. (b) High resolution MS spectrum. Monoisotopic peak mass and charge ratio (m/z) 
values are shown for different charge states. An isotopic distribution analysis was performed as shown in insets. Inset a is experimental data, 
and inset b is simulated theoretical data. Accurate MS and isotope distribution matched very well (within 5 ppm mass accuracy) with the 
empirical formula (C68H99F3N6O75S7). (c) 1H-NMR spectrum. The signals of anomeric protons are indicated. The chemical structure of 
decasaccharide 8 is shown on top of (c). 
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Supplementary Fig 8. NMR analysis of decasaccharide 8. (a) 13C-NMR spectrum of decasaccharide 8. Signals from ten anomeric carbons 
are identified. (b) 2D 1H-1H COSY spectrum of decasaccharide 8. The corresponding peak assignments of the anomeric protons resonate as 
doublets or singlets at δ 5.51 (d, J = 3.2 Hz, 1H), 5.43 (d, J = 4.0 Hz, 1H), 5.24 (s, 3H), 5.22 (d, 1H), 5.18 (broad singlets, 3H), and 4.42 (d, J = 
7.2 Hz, 1H) ppm. The intensity of the signal at 5.18 ppm is consistent with three protons, suggesting that three IdoA2S residues are present in 
decasaccharide 8. (c) 2D 1H-13C HMQC spectrum of decasaccharide 8. 
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Supplementary Fig 9. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of decasaccharide 8. The structure of decasaccharide 
8 is shown. The protons and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of 
carbohydrate protons and carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are 
not listed in the table. 
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Supplementary Fig 10. Purity and structural analysis of dodecasaccharide 9. (a) PAMN-HPLC chromatogram. (b) High resolution MS 
spectrum. Monoisotopic peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was 
performed as shown in insets. Inset a is experimental data, and inset b is simulated theoretical data. Accurate MS and isotope distribution 
matched very well (within 5 ppm mass accuracy) with the empirical formula (C80H121N7O91S9). (c) 1H-NMR spectrum. The signals of 
anomeric protons are indicated. The chemical structure of dodecasaccharide 9 is shown on top of (c). 
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Supplementary Fig 11. NMR analysis of dodecasaccharide 9. (a) 13C-NMR spectrum of dodecasaccharide 9. Signals from twelve anomeric 
carbons are identified. (b) 2D 1H-1H COSY spectrum of dodecasaccharide 9. The corresponding peak assignments of the anomeric protons 
resonate as doublets or singlets at δ 5.51 (d, J = 3.2 Hz, 1H), 5.34 (d, J = 4.0 Hz, 1H), 5.24-5.20 (m, 5H), 5.18 (broad singlets, 4H), and 4.42 (d, 
J = 7.2 Hz, 1H) ppm. The intensity of the signal at 5.18 ppm is consistent with four protons, suggesting that four IdoA2S residues are present in 
dodecasaccharide 9. (c) 2D 1H-13C HMQC spectrum of dodecasaccharide 9. 
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Supplementary Fig 12. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of dodecasaccharide 9. The structure of 
dodecasaccharide 9 is shown. The protons and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical 
shifts of carbohydrate protons and carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of 
pNP are not listed in the table. 
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Supplementary Fig 13. Purity and structural analysis of 1. (a) DEAE-HPLC chromatogram. (b) High resolution MS spectrum. Monoisotopic 
peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was performed as shown in 
insets. Inset a is experimental data for 1, and inset b is simulated theoretical data accurate MS data for 1 at charge 3 in negative electrospray 
ionization (ESI) mode. Isotope distribution analysis by high resolution MS matched (within 5 ppm mass accuracy) with the empirical formula 
(C42H62N4O57S8). “-SO3” indicates the signal of the molecule ion losing a sulfate group. (c) 1H-NMR spectrum. The signals of anomeric 
protons are indicated. The chemical structure of 1 is shown on top of (c). 
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Supplementary Fig 14. NMR analysis of 1. (a) 13C-NMR spectrum of 1. Signals from six anomeric carbons are labeled. (b) 2D 1H-1H 
Correlation Spectroscopy (COSY) spectrum of 1. The corresponding peak assignments of the anomeric protons resonate as doublets or singlets 
at δ 5.55 (d, J = 3.4 Hz, 1H), 5.53 (d, J = 3.3 Hz, 1H), 5.44 (d, J = 2.5 Hz, 1H), 5.23 (d, J = 7.8 Hz, 1H), 5.18 (broad singlet, 1H), and 4.55 (d, J 
= 7.8 Hz, 1H) ppm. The small coupling constants (<4 Hz) of the anomeric protons indicate an α linkage, and the large coupling constants (~8 
Hz) indicate a β linkage. (c) 2D 1H-13C Heteronuclear Multiple-Quantum Correlation (HMQC) spectrum of 1. 
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Supplementary Fig 15. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of 1. The structure of 1 is also shown. The protons 
and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of carbohydrate protons and 
carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are not listed in the table. 
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Supplementary Fig 16. Purity and structural analysis of 2. (a) DEAE-HPLC chromatogram. (b) High resolution MS spectrum. Monoisotopic 
peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was performed as shown in 
insets. Inset a is experimental data for 2, and inset b is simulated theoretical data accurate MS data for 2 at charge 4 in negative ESI mode. 
Accurate MS and isotope distribution matched very well (within 5 ppm mass accuracy) with the empirical formula (C54H81N5O76S11). (c) 
1H-NMR spectrum. The signals of anomeric protons are indicated. The chemical structure of 2 is shown on top of (c). 
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Supplementary Fig 17. NMR analysis of 2. (a) 13C-NMR spectrum of 2. Signals from eight anomeric carbons are clearly identified. (b) 2D 
1H-1H COSY spectrum of 2. The corresponding peak assignments of the anomeric protons resonate as doublets or singlets at δ 5.55 (d, J = 3.6 
Hz, 1H), 5.53 (d, J = 3.5 Hz, 1H), 5.44 (d, J = 2.8 Hz, 1H), 5.33 (d, J = 2.8 Hz, 1H), 5.23 (d, J = 7.8 Hz, 1H), 5.18, 5.13 (broad singlet, 2H), and 
4.55 (d, J = 7.6 Hz, 1H) ppm. (c) 2D 1H-13C HMQC spectrum of 2 
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Supplementary Fig 18. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of 2. The structure of 2 is shown. The protons and 
carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of carbohydrate protons and carbons. 
The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are not listed in the table. 
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Supplementary Fig 19. Purity and structural analysis of 3. (a) DEAE-HPLC chromatogram. (b) High resolution MS spectrum. Monoisotopic 
peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was performed as shown in 
insets. Inset a is experimental data for 3, and inset b is simulated theoretical data accurate MS data for 3 at charge 5 in negative ESI mode. 
Accurate MS and isotope distribution matched very well (within 5 ppm mass accuracy) with the empirical formula (C66H100N6O95S14). (c) 
1H-NMR spectrum. The signals of anomeric protons are indicated. The chemical structure of 3 is shown on top of (c). 
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Supplementary Fig 20. NMR analysis of 3. (a) 13C-NMR spectrum of 3. Signals from ten anomeric carbons are identified. (b) 2D 1H-1H 
COSY spectrum of 3. The corresponding peak assignments of the anomeric protons resonate as doublets or singlets at δ 5.55 (s, 1H), 5.53 (s, 
1H), 5.44 (s, 1H), 5.33 (s, 2H), 5.26 (broad singlets, 2H), 5.23 (d, J = 7.8 Hz, 1H), 5.18 (broad singlet, 1H), and 4.55 (d, J = 7.6 Hz, 1H) ppm. 
(c) 2D 1H-13C HMQC spectrum of 3. 
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Supplementary Fig 21. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of 3. The structure of 3 is shown. The protons and 
carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of carbohydrate protons and carbons. 
The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are not listed in the table. 
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Supplementary Fig 22. Purity and structural analysis of 4. (a) DEAE-HPLC chromatogram. (b) High resolution MS spectrum. Monoisotopic 
peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was performed as shown in 
insets. Inset a is experimental data for 4, and inset b is simulated theoretical data accurate MS data for 4 at charge 6 in negative ESI mode. 
Accurate MS and isotope distribution matched very well (within 5 ppm mass accuracy) with the empirical formula (C80H121N7O112S16). (c) 
1H-NMR spectrum. The signals of anomeric protons are indicated. The chemical structure of 4 is shown on top of (c). 
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Supplementary Fig 23. NMR analysis of 4. (a) 13C-NMR spectrum of 4. Signals from twelve anomeric carbons are identified. (b) 2D 1H-1H 
COSY spectrum of 4. The corresponding peak assignments of the anomeric protons resonate as doublets or singlets at δ 5.53 (s, 1H), 5.45 (s, 
1H), 5.35 (d, J = 3.0 Hz, 1H), 5.31 (s, 3H), 5.26-5.10 (broad singlets, 4H), 5.23 (d, J = 7.8 Hz, 1H) and 4.53 (d, J = 7.6 Hz, 1H) ppm. (c) 2D 1H-
13C HMQC spectrum of 4. 
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Supplementary Fig 24. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of 4. The structure of 4 is shown. The protons and 
carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical shifts of carbohydrate protons and carbons. 
The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of pNP are not listed in the table. 
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Supplementary Fig 25. Purity and structural analysis of 5. (a) DEAE-HPLC chromatogram. (b) High resolution MS spectrum. Monoisotopic 
peak mass and charge ratio (m/z) values are shown for different charge states. An isotopic distribution analysis was performed as shown in 
insets. Inset a is experimental data for 5, and inset b is the simulated isotopic distribution for 5 at charge -5. Accurate MS and isotope 
distribution matched very well (within 5 ppm mass accuracy) with the empirical formula (C80H116N7O115S17). (c) 1H-NMR spectrum. The 
signals of anomeric protons are indicated. The chemical structure of 5 is shown on top of (c). 
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Supplementary Fig 26. NMR analysis of 5. (a) 13C-NMR spectrum of 5. Signals from twelve anomeric carbons are identified. (b) 2D 1H-1H 
COSY spectrum of 5. The corresponding peak assignments of the anomeric protons resonate as doublets or singlets at δ 5.53 (s, 1H), 5.44 (s, 
2H), 5.36 (d, J = 3.1 Hz, 1H), 5.31 (s, 2H), 5.26-5.10 (broad singlets, 4H), 5.23 (d, J = 7.8 Hz, 1H) and 4.54 (d, J = 7.4 Hz, 1H) ppm. The small 
coupling constants (< 4 Hz) of the anomeric protons indicate a α linkage, and the large coupling constants (~8 Hz) indicate a β linkage. Through 
the 2D 1H-1H COSY, we can identify that one hydroxyl group at the 3-position on GlcNS of E or G or I was sulfated. One of the anomeric 
protons at 5.31 ppm correlates to the proton at one of the 2-postions of E or G or I resonated at 3.42 ppm (the other two signals for the 2-
positions were at 3.20 ppm). The proton at 3-position coupled to the proton at 3.42 ppm resonated at 4.39 ppm (instead of the 3.59 ppm seen for 
the other two 3-position protons) consistent of its substitution with a 3-O-sulfate group. (c) 2D 1H-13C HMQC spectrum of 5. Two questions 
remain. The first question is why the residue with the new 3-O-sulfate group (inserted using 3-OST-5) has an anomeric proton resonating 
upfield from the other 3-O-sulfate group (inserted using 3-OST-1) and with a GlcNS6S residue not having a 3-O-sulfate group (this will be 
addressed in Supplementary Fig 27). The second question is which residue (E, G or I) contains the 3-O-sulfate group (this will be addressed in 
Supplementary Figs 29-30). 
1
7
7
 
178 
 
 
Supplementary Fig 27. 1H-NMR spectra of 5 under different temperatures (298 K to 318 K). The GlcNS3S6S residues (C and I) should 
show similar shift values for their anomeric protons (as should the GlcNS6S residues of E and G), because of the similar chemical 
environments for these residues. Since they do not, we hypothesize that the observed differences in shift are due to conformational effects. To 
test this hypothesis and to resolve these signals, 1D 1H NMR was conducted at temperatures ranging from 298K to 318K. With increasing 
temperature, the two anomeric resonances for the GlcNS3S6S residues shifted downfield relative to the two GlcNS6S anomeric resonances. In 
addition, the two anomeric resonances for the GlcNS3S6S residues moved closer to each other as did the two anomeric resonances for the 
GlcNS6S residues. Finally, all four of these anomeric protons were resolved. This is consistent with the unusual chemical shifts for these 
anomeric protons being caused by a conformational effect that can be overcome on heating. The assignment of which residue (E,G, or I) 
contains the 3-O-sulfate group is addressed in Supplementary Figs 29-30. 
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Supplementary Fig 28. 1H-NMR and 13C-NMR chemical shift assignments (in ppm) of 5. The structure of 5 is shown. The proton 
assignments for Residue I are colored in red to demonstrate that an extra 3-O-sulfate glucosamine residue is present in 5. The location of the 
additional 3-O-sulfate glucosamine residue was determined by a MS-assisted oligosaccharide sequencing technique as described in 
Supplementary Fig 29. The protons and carbons of pNP group are clearly identifiable because they are outside the ranges of the chemical 
shifts of carbohydrate protons and carbons. The protons (doublet 7.28 ppm and doublet 8.28 ppm) and carbons (116.4 ppm and 126.1 ppm) of 
pNP are not listed in the table. 
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Supplementary Fig 29. MS-assisted sequencing analysis of 5. Due to the complex structure of 5, NMR and MS analyses were only able to 
locate one 3-O-sulfate group within Residue C. Therefore, MS-assisted sequence analysis was carried out 6. In this experiment, 5 was partially 
degraded with heparin lyase II. (a) Signals of the degraded products. (b) MS spectra of each signal, proving the structure of the degraded 
products. MS and LC/MS analyses were then performed to determine the structures of the resulting products, from which the structure of 5 
could be definitively established. The signals of products, ranging from disaccharide to pentasaccharide, were observed and their structures 
were established by MS. The presence of a 3-O-sulfate group at Residue I, prevented the heparin lyase II cleavage of the linkage between 
Residue G and H 7. Consequently, a tetrasaccharide product, representing FGHI, was detected, clearly pinpointing the location of the second 3-
O-sulfate group at Residue I. The MS-assisted sequencing analysis was also conducted on 4 (missing the 3-O-sulfate group on Residue I) and 
the tetrasaccharide fragment (FGHI) was absent in the products (Supplementary Fig 30). 
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Supplementary Fig 30. MS-assisted sequencing analysis of 4. 4 was partially degraded with heparin lyase II. MS and LC/MS analyses were 
then performed to determine the structures of the degraded product. Knowing the structures of the degraded products, one can piece together the 
structure of 4. (a) Signals of the degraded products. (b) MS spectra of each signal, proving the structure of the degraded products. A 
representative shorthanded representation and the structure of 4 are shown above (a) and (b). Comparing with the digestion pattern for 5 (shown 
in Supplementary Fig 29), more complete digestion by heparin lyase II was observed. Namely, no tetrasaccharide product, representing 
Residue FGHI, was observed. 
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Supplementary Fig 31. 1H-NMR of compound 3 (700 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ 5.63, 5.60, 5.39, 5.27, 4.51, and 4.47 ppm. Chemical structure of compound 3 is shown on top of figure.  
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Supplementary Fig 32. 13C-NMR of compound 3 (175 MHz, D2O). The signals of anomeric carbons are indicated. The anomeric carbons 
resonate at δ 105.0, 104.9, 102.0, 99.9, 99.8, and 99.6 ppm. Chemical structure of compound 3 is shown on top of figure. 
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Supplementary Fig 33. Purity and MS analysis of compound 3.  Left panel shows the PAMN-HPLC chromatogram of compound 3.  
The compound was eluted as a single symmetric peak on PAMN-HPLC, suggesting that compound 3 was pure. Right panel shows the 
MS spectrum.  The measured molecular mass was 1353.6, which is very close to the calculated molecular weight (1353.1).  [M-2H-
PNP]2- refers to the molecular ion that lost PNP (p-nitrophenyl) moiety.
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HPLC of compound 11
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Supplementary Fig 34. Purity and structural analysis of compound 11.  Left panel shows the PMAN-HPLC chromatogram of  compound 11. 
The compound was eluted as a single symmetric peak on PMAN-HPLC, suggesting that 11 was pure.  Right panel shows the MS spectrum.  The 
measured molecular mass was 1369.3, which is very close to the calculated molecular weight (1369.1).  [M-3H-PNP]3- refers to the molecular 
ion of compound 11 that lost PNP moiety.
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Supplementary Fig 35. 1H-13C HSQC NMR spectra of 1 and 11.  Compound 11 is the product after 1 being exposed to water under 
an acidic condition.  Spectra were recorded in D2O containing 10 mM phosphate buffer at pD7.4 and 25°C.  Under this condition, 
signals of compound 1 were detectable before the diazoacetyl group underwent decomposition reactions. The distinct signals are 
indicated in spectra.   
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Supplementary Fig 36. Synthetic scheme for compound 12 and 13
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Supplementary Fig 37. Purity and MS analysis of compound 12.   Left panel shows the PMAN-HPLC chromatogram of compound 
12.  The compound was eluted as a single symmetric peak on PMAN-HPLC, suggesting that compound 12 was pure.  Right panel 
shows the MS spectrum.  The measured molecular mass was 534.1, which is very close to the calculated molecular weight (534.4).  
1
8
8
 
189 
 
 
HPLC of  compound 13
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Supplementary Fig 38. Purity and MS analysis of 13.  Left panel shows the PMAN-HPLC chromatogram of compound 13.  The 
compound was eluted as a single symmetric peak on PMAN-HPLC, suggesting that compound 13 was pure.  Right panel shows the MS 
spectrum.  The measured molecular mass was 534.1, which is very close to the calculated molecular weight (534.4).  [M-H+TFA]-
refers to the molecular ion of compound 13 and trifluoroacetic acid adduct.  
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Supplementary Fig 39. 1H-13C HMBC key correlations of 12 and 13.  The signals of featured groups are indicated.  The cross peaks are 
connected with arrowed lines identifying correlated carbon and proton.  The corresponding chemical structure is shown on top of each spectrum.  
The anticipated correlations are indicated in the structures by curved arrows.
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Supplementary Fig 40. 1H-NMR of compound 12(850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ5.83 and 5.26 ppm. The chemical structure of compound 12is shown on top of figure. 
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Supplementary Fig 41. 1H-NMR of compound 13(850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ5.41 and 5.30 ppm. The anomeric proton signals from 13were similar to the comparable ones observed from 14(I-1, 
5.41 ppm/VI-1, 5.27 ppm).The chemical structure of compound 13is shown on top of figure. 
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Supplementary Fig. 42.  The scheme for the synthesis compound 14.  The starting hexasaccharide was an intermediate from the 
synthesis of compound 1. 
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Supplementary Fig 43. 1H-NMR of compound 14 (850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ 5.63, 5.60, 5.41, 5.27, 4.51, and 4.47 ppm. Chemical structure of compound 14 is shown on top of figure.  
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Supplementary Fig 44. 13C-NMR of compound 14 (212.5 MHz, D2O). The signals of anomeric carbons are indicated. The anomeric 
carbons resonate at δ 105.0, 104.9, 102.0, 99.9, 99.8, and 99.6 ppm. Chemical structure of compound 14 is shown on top of figure. 
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Supplementary Fig. 45. Purity and MS analysis of compound 14.  Left panel shows the PMAN-HPLC chromatogram of compound 14.  
The compound was eluted as a single symmetric peak on PMAN-HPLC, suggesting that compound 14 was pure.  Right panel shows the MS 
spectrum.  The measured molecular mass was 1368.9, which is very close to the calculated molecular weight (1369.1).  [M-3H-PNP]3- refers 
to the molecular ion of compound 14 that lost PNP moiety.
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Supplementary Fig 46. 1H-NMR of compound 1 (850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ 5.63, 5.60, 5.41, 5.27, 4.51, and 4.47 ppm. Chemical structure of compound 1 is shown on top of figure. 
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Supplementary Fig 47. 13C-NMR of compound 1 (212.5 MHz, D2O). The signals of anomeric carbons are indicated. The anomeric carbons 
resonate at δ 105.0, 104.9, 102.0, 99.8, 99.8, and 99.8 ppm. Chemical structure of compound 1 is shown on top of figure. 
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Supplementary Fig 48. Purity and MS analysis of compound 1.  Left panel shows the DEAE-HPLC chromatogram of compound 1.  The 
compound was eluted as a single symmetric peak on DEAE-HPLC, suggesting that compound 1 was pure. Right panel shows the MS spectrum.  
The measured molecular mass was 1379.4, which is very close to the calculated molecular weight (1379.1).  [M-3H-PNP]3- refers to the 
molecular ion that lost PNP (p-nitrophenyl) moiety.
1
9
9
 
200 
 
 
Supplementary Fig 49. 1H-NMR of compound 2 (850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate at δ 5.59, 5.41, 5.40, 5.39, 5.27, 5.21, 4.56, and 4.56 ppm. Chemical structure of compound 2 is shown on top of figure. The spectrum 
was acquired with 256 scans.
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Supplementary Fig 50. 13C-NMR of compound 2 (212.5 MHz, D2O). The signals of anomeric carbons are indicated. The anomeric carbons 
resonate at δ 104.6, 104.6, 102.0, 101.7, 100.3, 100.0, 99.5, and 99.2 ppm. The structure of compound 2 is shown on top of figure. The spectrum 
was acquired using distortionless enhancement by polarization transfer with pulse width for 1H at 45°.
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Supplementary Fig 51. Purity and structural analysis of compound 2.  Left panel shows the DEAE-HPLC chromatogram of 
compound 2.  The compound was eluted as a major single symmetric peak on DEAE-HPLC, suggesting that compound 2 was pure. 
Right panel shows the MS spectrum.  The measured molecular mass was 2159.0, which is very close to the calculated molecular weight 
(2158.7).  
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Supplementary Fig 52. 1H-NMR of compound 7 (850 MHz, D2O). The signals of anomeric protons are indicated. The anomeric protons 
resonate as doublet at δ 5.69, 5.58, 5.40, 5.39, 5.27, 5.21, 4.56, and 4.56 ppm. Chemical structure of compound 7 is shown on top of figure.  
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Supplementary Fig 53. 13C-NMR of compound 7 (212.5 MHz, D2O). The signals of anomeric carbons are indicated. The anomeric carbons 
resonate at δ 104.6, 104.6, 102.0, 101.8, 100.3, 99.5, 99.2, and 98.0 ppm. Chemical structure of compound 7 is shown on top of figure. 
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Supplementary Fig  54. Mass and HPLC analysis of constructs
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